#FORMAT=WebAnno TSV 3.3
#T_SP=webanno.custom.ConceptLayer|identifier


#Text=Multilocus genetic profile in dopaminergic pathway modulates the striatum and working memory
#Text=Dopamine is critical in pathophysiology and therapy of schizophrenia.
1-1	0-10	Multilocus	_	
1-2	11-18	genetic	_	
1-3	19-26	profile	_	
1-4	27-29	in	_	
1-5	30-42	dopaminergic	_	
1-6	43-50	pathway	_	
1-7	51-60	modulates	_	
1-8	61-64	the	_	
1-9	65-73	striatum	_	
1-10	74-77	and	_	
1-11	78-85	working	_	
1-12	86-92	memory	_	
1-13	93-101	Dopamine	_	
1-14	102-104	is	_	
1-15	105-113	critical	_	
1-16	114-116	in	_	
1-17	117-132	pathophysiology	_	
1-18	133-136	and	_	
1-19	137-144	therapy	_	
1-20	145-147	of	_	
1-21	148-161	schizophrenia	http://maven.renci.org/NeuroBridge/neurobridge#Schizophrenia	
1-22	161-162	.	_	

#Text=Many studies have reported altered dopaminergic activity in the dorsal but not ventral striatum in schizophrenia.
2-1	163-167	Many	_	
2-2	168-175	studies	_	
2-3	176-180	have	_	
2-4	181-189	reported	_	
2-5	190-197	altered	_	
2-6	198-210	dopaminergic	_	
2-7	211-219	activity	_	
2-8	220-222	in	_	
2-9	223-226	the	_	
2-10	227-233	dorsal	_	
2-11	234-237	but	_	
2-12	238-241	not	_	
2-13	242-249	ventral	_	
2-14	250-258	striatum	_	
2-15	259-261	in	_	
2-16	262-275	schizophrenia	http://maven.renci.org/NeuroBridge/neurobridge#Schizophrenia	
2-17	275-276	.	_	

#Text=Based on the largest genome-wide association study of schizophrenia to date, we calculated the polygenic risk score (PGRS) of each subject in a healthy general group, including all variations in the set of functionally related genes involved in dopamine neurotransmitter system.
3-1	277-282	Based	_	
3-2	283-285	on	_	
3-3	286-289	the	_	
3-4	290-297	largest	_	
3-5	298-309	genome-wide	_	
3-6	310-321	association	_	
3-7	322-327	study	_	
3-8	328-330	of	_	
3-9	331-344	schizophrenia	http://maven.renci.org/NeuroBridge/neurobridge#Schizophrenia	
3-10	345-347	to	_	
3-11	348-352	date	_	
3-12	352-353	,	_	
3-13	354-356	we	_	
3-14	357-367	calculated	_	
3-15	368-371	the	_	
3-16	372-381	polygenic	_	
3-17	382-386	risk	_	
3-18	387-392	score	_	
3-19	393-394	(	_	
3-20	394-398	PGRS	_	
3-21	398-399	)	_	
3-22	400-402	of	_	
3-23	403-407	each	_	
3-24	408-415	subject	_	
3-25	416-418	in	_	
3-26	419-420	a	_	
3-27	421-428	healthy	_	
3-28	429-436	general	_	
3-29	437-442	group	_	
3-30	442-443	,	_	
3-31	444-453	including	_	
3-32	454-457	all	_	
3-33	458-468	variations	_	
3-34	469-471	in	_	
3-35	472-475	the	_	
3-36	476-479	set	_	
3-37	480-482	of	_	
3-38	483-495	functionally	_	
3-39	496-503	related	_	
3-40	504-509	genes	_	
3-41	510-518	involved	_	
3-42	519-521	in	_	
3-43	522-530	dopamine	_	
3-44	531-547	neurotransmitter	_	
3-45	548-554	system	_	
3-46	554-555	.	_	

#Text=We aimed to test whether the genetic variations in the dopaminergic pathway that have been identified as associated with schizophrenia are related to the function of the striatum and to working memory.
4-1	556-558	We	_	
4-2	559-564	aimed	_	
4-3	565-567	to	_	
4-4	568-572	test	_	
4-5	573-580	whether	_	
4-6	581-584	the	_	
4-7	585-592	genetic	_	
4-8	593-603	variations	_	
4-9	604-606	in	_	
4-10	607-610	the	_	
4-11	611-623	dopaminergic	_	
4-12	624-631	pathway	_	
4-13	632-636	that	_	
4-14	637-641	have	_	
4-15	642-646	been	_	
4-16	647-657	identified	_	
4-17	658-660	as	_	
4-18	661-671	associated	_	
4-19	672-676	with	_	
4-20	677-690	schizophrenia	http://maven.renci.org/NeuroBridge/neurobridge#Schizophrenia	
4-21	691-694	are	_	
4-22	695-702	related	_	
4-23	703-705	to	_	
4-24	706-709	the	_	
4-25	710-718	function	_	
4-26	719-721	of	_	
4-27	722-725	the	_	
4-28	726-734	striatum	_	
4-29	735-738	and	_	
4-30	739-741	to	_	
4-31	742-749	working	_	
4-32	750-756	memory	_	
4-33	756-757	.	_	

#Text=We found that a higher PGRS was significantly associated with impairment in working memory.
5-1	758-760	We	_	
5-2	761-766	found	_	
5-3	767-771	that	_	
5-4	772-773	a	_	
5-5	774-780	higher	_	
5-6	781-785	PGRS	_	
5-7	786-789	was	_	
5-8	790-803	significantly	_	
5-9	804-814	associated	_	
5-10	815-819	with	_	
5-11	820-830	impairment	_	
5-12	831-833	in	_	
5-13	834-841	working	_	
5-14	842-848	memory	_	
5-15	848-849	.	_	

#Text=Moreover, resting-state functional connectivity analysis revealed that as the polygenic risk score increased, the connections between left putamen and caudate and the default mode network grew stronger, while the connections with the fronto-parietal network grew weaker.
6-1	850-858	Moreover	_	
6-2	858-859	,	_	
6-3	860-873	resting-state	_	
6-4	874-884	functional	_	
6-5	885-897	connectivity	_	
6-6	898-906	analysis	_	
6-7	907-915	revealed	_	
6-8	916-920	that	_	
6-9	921-923	as	_	
6-10	924-927	the	_	
6-11	928-937	polygenic	_	
6-12	938-942	risk	_	
6-13	943-948	score	_	
6-14	949-958	increased	_	
6-15	958-959	,	_	
6-16	960-963	the	_	
6-17	964-975	connections	_	
6-18	976-983	between	_	
6-19	984-988	left	_	
6-20	989-996	putamen	_	
6-21	997-1000	and	_	
6-22	1001-1008	caudate	_	
6-23	1009-1012	and	_	
6-24	1013-1016	the	_	
6-25	1017-1024	default	_	
6-26	1025-1029	mode	_	
6-27	1030-1037	network	_	
6-28	1038-1042	grew	_	
6-29	1043-1051	stronger	_	
6-30	1051-1052	,	_	
6-31	1053-1058	while	_	
6-32	1059-1062	the	_	
6-33	1063-1074	connections	_	
6-34	1075-1079	with	_	
6-35	1080-1083	the	_	
6-36	1084-1099	fronto-parietal	_	
6-37	1100-1107	network	_	
6-38	1108-1112	grew	_	
6-39	1113-1119	weaker	_	
6-40	1119-1120	.	_	

#Text=Our findings may shed light on the biological mechanism underlying the “dopamine hypothesis” of schizophrenia and provide some implications regarding the polygenic effects on the dopaminergic activity in the risk for schizophrenia.
7-1	1121-1124	Our	_	
7-2	1125-1133	findings	_	
7-3	1134-1137	may	_	
7-4	1138-1142	shed	_	
7-5	1143-1148	light	_	
7-6	1149-1151	on	_	
7-7	1152-1155	the	_	
7-8	1156-1166	biological	_	
7-9	1167-1176	mechanism	_	
7-10	1177-1187	underlying	_	
7-11	1188-1191	the	_	
7-12	1192-1193	“	_	
7-13	1193-1201	dopamine	_	
7-14	1202-1212	hypothesis	_	
7-15	1212-1213	”	_	
7-16	1214-1216	of	_	
7-17	1217-1230	schizophrenia	http://maven.renci.org/NeuroBridge/neurobridge#Schizophrenia	
7-18	1231-1234	and	_	
7-19	1235-1242	provide	_	
7-20	1243-1247	some	_	
7-21	1248-1260	implications	_	
7-22	1261-1270	regarding	_	
7-23	1271-1274	the	_	
7-24	1275-1284	polygenic	_	
7-25	1285-1292	effects	_	
7-26	1293-1295	on	_	
7-27	1296-1299	the	_	
7-28	1300-1312	dopaminergic	_	
7-29	1313-1321	activity	_	
7-30	1322-1324	in	_	
7-31	1325-1328	the	_	
7-32	1329-1333	risk	_	
7-33	1334-1337	for	_	
7-34	1338-1351	schizophrenia	http://maven.renci.org/NeuroBridge/neurobridge#Schizophrenia	
7-35	1351-1352	.	_	

#Text=Introduction
#Text=Understanding the dopamine neurotransmitter system is critical for research on the therapy and pathophysiology of schizophrenia.
8-1	1353-1365	Introduction	_	
8-2	1366-1379	Understanding	_	
8-3	1380-1383	the	_	
8-4	1384-1392	dopamine	_	
8-5	1393-1409	neurotransmitter	_	
8-6	1410-1416	system	_	
8-7	1417-1419	is	_	
8-8	1420-1428	critical	_	
8-9	1429-1432	for	_	
8-10	1433-1441	research	_	
8-11	1442-1444	on	_	
8-12	1445-1448	the	_	
8-13	1449-1456	therapy	_	
8-14	1457-1460	and	_	
8-15	1461-1476	pathophysiology	_	
8-16	1477-1479	of	_	
8-17	1480-1493	schizophrenia	_	
8-18	1493-1494	.	_	

#Text=Enhanced striatal dopamine neurotransmission and prefrontal cortex dysfunction are consist findings in schizophrenia that might correlated to functional impairments and cognitive deficits in schizophrenia, and the striatal dopamine D2 receptor is the therapeutic target of most antipsychotic drugs.
9-1	1495-1503	Enhanced	_	
9-2	1504-1512	striatal	_	
9-3	1513-1521	dopamine	_	
9-4	1522-1539	neurotransmission	_	
9-5	1540-1543	and	_	
9-6	1544-1554	prefrontal	_	
9-7	1555-1561	cortex	_	
9-8	1562-1573	dysfunction	_	
9-9	1574-1577	are	_	
9-10	1578-1585	consist	_	
9-11	1586-1594	findings	_	
9-12	1595-1597	in	_	
9-13	1598-1611	schizophrenia	_	
9-14	1612-1616	that	_	
9-15	1617-1622	might	_	
9-16	1623-1633	correlated	_	
9-17	1634-1636	to	_	
9-18	1637-1647	functional	_	
9-19	1648-1659	impairments	_	
9-20	1660-1663	and	_	
9-21	1664-1673	cognitive	_	
9-22	1674-1682	deficits	_	
9-23	1683-1685	in	_	
9-24	1686-1699	schizophrenia	_	
9-25	1699-1700	,	_	
9-26	1701-1704	and	_	
9-27	1705-1708	the	_	
9-28	1709-1717	striatal	_	
9-29	1718-1726	dopamine	_	
9-30	1727-1729	D2	_	
9-31	1730-1738	receptor	_	
9-32	1739-1741	is	_	
9-33	1742-1745	the	_	
9-34	1746-1757	therapeutic	_	
9-35	1758-1764	target	_	
9-36	1765-1767	of	_	
9-37	1768-1772	most	_	
9-38	1773-1786	antipsychotic	_	
9-39	1787-1792	drugs	_	
9-40	1792-1793	.	_	

#Text=Many pathophysiological models of mental illness ascribe a key role to the striatum (the caudate nucleus and putamen) because of its rich connectivity with other regions known to be dysfunctional in psychiatry, especially the prefrontal cortex.
10-1	1794-1798	Many	_	
10-2	1799-1817	pathophysiological	_	
10-3	1818-1824	models	_	
10-4	1825-1827	of	_	
10-5	1828-1834	mental	_	
10-6	1835-1842	illness	_	
10-7	1843-1850	ascribe	_	
10-8	1851-1852	a	_	
10-9	1853-1856	key	_	
10-10	1857-1861	role	_	
10-11	1862-1864	to	_	
10-12	1865-1868	the	_	
10-13	1869-1877	striatum	_	
10-14	1878-1879	(	_	
10-15	1879-1882	the	_	
10-16	1883-1890	caudate	_	
10-17	1891-1898	nucleus	_	
10-18	1899-1902	and	_	
10-19	1903-1910	putamen	_	
10-20	1910-1911	)	_	
10-21	1912-1919	because	_	
10-22	1920-1922	of	_	
10-23	1923-1926	its	_	
10-24	1927-1931	rich	_	
10-25	1932-1944	connectivity	_	
10-26	1945-1949	with	_	
10-27	1950-1955	other	_	
10-28	1956-1963	regions	_	
10-29	1964-1969	known	_	
10-30	1970-1972	to	_	
10-31	1973-1975	be	_	
10-32	1976-1989	dysfunctional	_	
10-33	1990-1992	in	_	
10-34	1993-2003	psychiatry	_	
10-35	2003-2004	,	_	
10-36	2005-2015	especially	_	
10-37	2016-2019	the	_	
10-38	2020-2030	prefrontal	_	
10-39	2031-2037	cortex	_	
10-40	2037-2038	.	_	

#Text=Early animal studies have emphasized dysfunction of the mesolimbic dopaminergic pathway, connecting ventral striatum (the nucleus accumbens) with medial prefrontal cortex.
11-1	2039-2044	Early	_	
11-2	2045-2051	animal	_	
11-3	2052-2059	studies	_	
11-4	2060-2064	have	_	
11-5	2065-2075	emphasized	_	
11-6	2076-2087	dysfunction	_	
11-7	2088-2090	of	_	
11-8	2091-2094	the	_	
11-9	2095-2105	mesolimbic	_	
11-10	2106-2118	dopaminergic	_	
11-11	2119-2126	pathway	_	
11-12	2126-2127	,	_	
11-13	2128-2138	connecting	_	
11-14	2139-2146	ventral	_	
11-15	2147-2155	striatum	_	
11-16	2156-2157	(	_	
11-17	2157-2160	the	_	
11-18	2161-2168	nucleus	_	
11-19	2169-2178	accumbens	_	
11-20	2178-2179	)	_	
11-21	2180-2184	with	_	
11-22	2185-2191	medial	_	
11-23	2192-2202	prefrontal	_	
11-24	2203-2209	cortex	_	
11-25	2209-2210	.	_	

#Text=However, subsequent in vivo PET research has indicated that patients with schizophrenia show up-regulation of dopaminergic activity in the dorsal but not ventral striatum.
12-1	2211-2218	However	_	
12-2	2218-2219	,	_	
12-3	2220-2230	subsequent	_	
12-4	2231-2233	in	_	
12-5	2234-2238	vivo	_	
12-6	2239-2242	PET	_	
12-7	2243-2251	research	_	
12-8	2252-2255	has	_	
12-9	2256-2265	indicated	_	
12-10	2266-2270	that	_	
12-11	2271-2279	patients	_	
12-12	2280-2284	with	_	
12-13	2285-2298	schizophrenia	_	
12-14	2299-2303	show	_	
12-15	2304-2317	up-regulation	_	
12-16	2318-2320	of	_	
12-17	2321-2333	dopaminergic	_	
12-18	2334-2342	activity	_	
12-19	2343-2345	in	_	
12-20	2346-2349	the	_	
12-21	2350-2356	dorsal	_	
12-22	2357-2360	but	_	
12-23	2361-2364	not	_	
12-24	2365-2372	ventral	_	
12-25	2373-2381	striatum	_	
12-26	2381-2382	.	_	

#Text=Working memory deficits area central feature of cognitive impairment in schizophrenia, and some functional magnetic resonance imaging studies have found that patients with schizophrenia showed not only alterations in prefrontal activity during working memory processing but also abnormalities in striatal function and dysfunction of dopamine signaling, which are both possible explanations for working memory deficits.
13-1	2383-2390	Working	_	
13-2	2391-2397	memory	_	
13-3	2398-2406	deficits	_	
13-4	2407-2411	area	_	
13-5	2412-2419	central	_	
13-6	2420-2427	feature	_	
13-7	2428-2430	of	_	
13-8	2431-2440	cognitive	_	
13-9	2441-2451	impairment	_	
13-10	2452-2454	in	_	
13-11	2455-2468	schizophrenia	_	
13-12	2468-2469	,	_	
13-13	2470-2473	and	_	
13-14	2474-2478	some	_	
13-15	2479-2489	functional	_	
13-16	2490-2498	magnetic	_	
13-17	2499-2508	resonance	_	
13-18	2509-2516	imaging	_	
13-19	2517-2524	studies	_	
13-20	2525-2529	have	_	
13-21	2530-2535	found	_	
13-22	2536-2540	that	_	
13-23	2541-2549	patients	_	
13-24	2550-2554	with	_	
13-25	2555-2568	schizophrenia	_	
13-26	2569-2575	showed	_	
13-27	2576-2579	not	_	
13-28	2580-2584	only	_	
13-29	2585-2596	alterations	_	
13-30	2597-2599	in	_	
13-31	2600-2610	prefrontal	_	
13-32	2611-2619	activity	_	
13-33	2620-2626	during	_	
13-34	2627-2634	working	_	
13-35	2635-2641	memory	_	
13-36	2642-2652	processing	_	
13-37	2653-2656	but	_	
13-38	2657-2661	also	_	
13-39	2662-2675	abnormalities	_	
13-40	2676-2678	in	_	
13-41	2679-2687	striatal	_	
13-42	2688-2696	function	_	
13-43	2697-2700	and	_	
13-44	2701-2712	dysfunction	_	
13-45	2713-2715	of	_	
13-46	2716-2724	dopamine	_	
13-47	2725-2734	signaling	_	
13-48	2734-2735	,	_	
13-49	2736-2741	which	_	
13-50	2742-2745	are	_	
13-51	2746-2750	both	_	
13-52	2751-2759	possible	_	
13-53	2760-2772	explanations	_	
13-54	2773-2776	for	_	
13-55	2777-2784	working	_	
13-56	2785-2791	memory	_	
13-57	2792-2800	deficits	_	
13-58	2800-2801	.	_	

#Text=In addition, schizophrenia is highly heritable, but the specific genetic variants identified have very minor effects.
14-1	2802-2804	In	_	
14-2	2805-2813	addition	_	
14-3	2813-2814	,	_	
14-4	2815-2828	schizophrenia	_	
14-5	2829-2831	is	_	
14-6	2832-2838	highly	_	
14-7	2839-2848	heritable	_	
14-8	2848-2849	,	_	
14-9	2850-2853	but	_	
14-10	2854-2857	the	_	
14-11	2858-2866	specific	_	
14-12	2867-2874	genetic	_	
14-13	2875-2883	variants	_	
14-14	2884-2894	identified	_	
14-15	2895-2899	have	_	
14-16	2900-2904	very	_	
14-17	2905-2910	minor	_	
14-18	2911-2918	effects	_	
14-19	2918-2919	.	_	

#Text=This implies that a large number of genetic variants may have additive effects on the complex phenotypes, i.e., that schizophrenia is also a polygenic inheritance disorder.
15-1	2920-2924	This	_	
15-2	2925-2932	implies	_	
15-3	2933-2937	that	_	
15-4	2938-2939	a	_	
15-5	2940-2945	large	_	
15-6	2946-2952	number	_	
15-7	2953-2955	of	_	
15-8	2956-2963	genetic	_	
15-9	2964-2972	variants	_	
15-10	2973-2976	may	_	
15-11	2977-2981	have	_	
15-12	2982-2990	additive	_	
15-13	2991-2998	effects	_	
15-14	2999-3001	on	_	
15-15	3002-3005	the	_	
15-16	3006-3013	complex	_	
15-17	3014-3024	phenotypes	_	
15-18	3024-3025	,	_	
15-19	3026-3029	i.e	_	
15-20	3029-3030	.	_	
15-21	3030-3031	,	_	
15-22	3032-3036	that	_	
15-23	3037-3050	schizophrenia	_	
15-24	3051-3053	is	_	
15-25	3054-3058	also	_	
15-26	3059-3060	a	_	
15-27	3061-3070	polygenic	_	
15-28	3071-3082	inheritance	_	
15-29	3083-3091	disorder	_	
15-30	3091-3092	.	_	

#Text=By using genome-wide association studies (GWAS), we can calculate a polygenic risk score (PGRS), which involves a few significant SNPs from GWAS and SNPs that meet nominal significance criteria but fail to reach the genome-wide significance level, for each individual associated with a particular disorder to capture its polygenic nature.
16-1	3093-3095	By	_	
16-2	3096-3101	using	_	
16-3	3102-3113	genome-wide	_	
16-4	3114-3125	association	_	
16-5	3126-3133	studies	_	
16-6	3134-3135	(	_	
16-7	3135-3139	GWAS	_	
16-8	3139-3140	)	_	
16-9	3140-3141	,	_	
16-10	3142-3144	we	_	
16-11	3145-3148	can	_	
16-12	3149-3158	calculate	_	
16-13	3159-3160	a	_	
16-14	3161-3170	polygenic	_	
16-15	3171-3175	risk	_	
16-16	3176-3181	score	_	
16-17	3182-3183	(	_	
16-18	3183-3187	PGRS	_	
16-19	3187-3188	)	_	
16-20	3188-3189	,	_	
16-21	3190-3195	which	_	
16-22	3196-3204	involves	_	
16-23	3205-3206	a	_	
16-24	3207-3210	few	_	
16-25	3211-3222	significant	_	
16-26	3223-3227	SNPs	_	
16-27	3228-3232	from	_	
16-28	3233-3237	GWAS	_	
16-29	3238-3241	and	_	
16-30	3242-3246	SNPs	_	
16-31	3247-3251	that	_	
16-32	3252-3256	meet	_	
16-33	3257-3264	nominal	_	
16-34	3265-3277	significance	_	
16-35	3278-3286	criteria	_	
16-36	3287-3290	but	_	
16-37	3291-3295	fail	_	
16-38	3296-3298	to	_	
16-39	3299-3304	reach	_	
16-40	3305-3308	the	_	
16-41	3309-3320	genome-wide	_	
16-42	3321-3333	significance	_	
16-43	3334-3339	level	_	
16-44	3339-3340	,	_	
16-45	3341-3344	for	_	
16-46	3345-3349	each	_	
16-47	3350-3360	individual	_	
16-48	3361-3371	associated	_	
16-49	3372-3376	with	_	
16-50	3377-3378	a	_	
16-51	3379-3389	particular	_	
16-52	3390-3398	disorder	_	
16-53	3399-3401	to	_	
16-54	3402-3409	capture	_	
16-55	3410-3413	its	_	
16-56	3414-3423	polygenic	_	
16-57	3424-3430	nature	_	
16-58	3430-3431	.	_	

#Text=The PGRS can also be used to estimate the cumulative genetic risk for the disease in diverse phenotypes.
17-1	3432-3435	The	_	
17-2	3436-3440	PGRS	_	
17-3	3441-3444	can	_	
17-4	3445-3449	also	_	
17-5	3450-3452	be	_	
17-6	3453-3457	used	_	
17-7	3458-3460	to	_	
17-8	3461-3469	estimate	_	
17-9	3470-3473	the	_	
17-10	3474-3484	cumulative	_	
17-11	3485-3492	genetic	_	
17-12	3493-3497	risk	_	
17-13	3498-3501	for	_	
17-14	3502-3505	the	_	
17-15	3506-3513	disease	_	
17-16	3514-3516	in	_	
17-17	3517-3524	diverse	_	
17-18	3525-3535	phenotypes	_	
17-19	3535-3536	.	_	

#Text=Resting-state functional connectivity is an effective method for detecting the coherent patterns of spontaneous neural activity fluctuations.
18-1	3537-3550	Resting-state	_	
18-2	3551-3561	functional	_	
18-3	3562-3574	connectivity	_	
18-4	3575-3577	is	_	
18-5	3578-3580	an	_	
18-6	3581-3590	effective	_	
18-7	3591-3597	method	_	
18-8	3598-3601	for	_	
18-9	3602-3611	detecting	_	
18-10	3612-3615	the	_	
18-11	3616-3624	coherent	_	
18-12	3625-3633	patterns	_	
18-13	3634-3636	of	_	
18-14	3637-3648	spontaneous	_	
18-15	3649-3655	neural	_	
18-16	3656-3664	activity	_	
18-17	3665-3677	fluctuations	_	
18-18	3677-3678	.	_	

#Text=It is under strong genetic control and reflects the basis of brain functional organization.
19-1	3679-3681	It	_	
19-2	3682-3684	is	_	
19-3	3685-3690	under	_	
19-4	3691-3697	strong	_	
19-5	3698-3705	genetic	_	
19-6	3706-3713	control	_	
19-7	3714-3717	and	_	
19-8	3718-3726	reflects	_	
19-9	3727-3730	the	_	
19-10	3731-3736	basis	_	
19-11	3737-3739	of	_	
19-12	3740-3745	brain	_	
19-13	3746-3756	functional	_	
19-14	3757-3769	organization	_	
19-15	3769-3770	.	_	

#Text=Thus, imaging genetics could help us to investigate the additive effects of genetic risk variants on brain function.
20-1	3771-3775	Thus	_	
20-2	3775-3776	,	_	
20-3	3777-3784	imaging	_	
20-4	3785-3793	genetics	_	
20-5	3794-3799	could	_	
20-6	3800-3804	help	_	
20-7	3805-3807	us	_	
20-8	3808-3810	to	_	
20-9	3811-3822	investigate	_	
20-10	3823-3826	the	_	
20-11	3827-3835	additive	_	
20-12	3836-3843	effects	_	
20-13	3844-3846	of	_	
20-14	3847-3854	genetic	_	
20-15	3855-3859	risk	_	
20-16	3860-3868	variants	_	
20-17	3869-3871	on	_	
20-18	3872-3877	brain	_	
20-19	3878-3886	function	_	
20-20	3886-3887	.	_	

#Text=In this study, the PGRS of schizophrenia was derived from the largest GWAS study in schizophrenia, and we only included all variations in the set of functionally related genes involved in dopamine functioning.
21-1	3888-3890	In	_	
21-2	3891-3895	this	_	
21-3	3896-3901	study	_	
21-4	3901-3902	,	_	
21-5	3903-3906	the	_	
21-6	3907-3911	PGRS	_	
21-7	3912-3914	of	_	
21-8	3915-3928	schizophrenia	_	
21-9	3929-3932	was	_	
21-10	3933-3940	derived	_	
21-11	3941-3945	from	_	
21-12	3946-3949	the	_	
21-13	3950-3957	largest	_	
21-14	3958-3962	GWAS	_	
21-15	3963-3968	study	_	
21-16	3969-3971	in	_	
21-17	3972-3985	schizophrenia	_	
21-18	3985-3986	,	_	
21-19	3987-3990	and	_	
21-20	3991-3993	we	_	
21-21	3994-3998	only	_	
21-22	3999-4007	included	_	
21-23	4008-4011	all	_	
21-24	4012-4022	variations	_	
21-25	4023-4025	in	_	
21-26	4026-4029	the	_	
21-27	4030-4033	set	_	
21-28	4034-4036	of	_	
21-29	4037-4049	functionally	_	
21-30	4050-4057	related	_	
21-31	4058-4063	genes	_	
21-32	4064-4072	involved	_	
21-33	4073-4075	in	_	
21-34	4076-4084	dopamine	_	
21-35	4085-4096	functioning	_	
21-36	4096-4097	.	_	

#Text=We aimed to dive deeper into the relationships between the PGRS related to dopamine genes and the structure and function of the dorsal striatum as well as working memory performance.
22-1	4098-4100	We	_	
22-2	4101-4106	aimed	_	
22-3	4107-4109	to	_	
22-4	4110-4114	dive	_	
22-5	4115-4121	deeper	_	
22-6	4122-4126	into	_	
22-7	4127-4130	the	_	
22-8	4131-4144	relationships	_	
22-9	4145-4152	between	_	
22-10	4153-4156	the	_	
22-11	4157-4161	PGRS	_	
22-12	4162-4169	related	_	
22-13	4170-4172	to	_	
22-14	4173-4181	dopamine	_	
22-15	4182-4187	genes	_	
22-16	4188-4191	and	_	
22-17	4192-4195	the	_	
22-18	4196-4205	structure	_	
22-19	4206-4209	and	_	
22-20	4210-4218	function	_	
22-21	4219-4221	of	_	
22-22	4222-4225	the	_	
22-23	4226-4232	dorsal	_	
22-24	4233-4241	striatum	_	
22-25	4242-4244	as	_	
22-26	4245-4249	well	_	
22-27	4250-4252	as	_	
22-28	4253-4260	working	_	
22-29	4261-4267	memory	_	
22-30	4268-4279	performance	_	
22-31	4279-4280	.	_	

#Text=We hypothesized that the dopamine gene-related polygenic risk would predict altered function in the dorsal dopaminergic pathway.
23-1	4281-4283	We	_	
23-2	4284-4296	hypothesized	_	
23-3	4297-4301	that	_	
23-4	4302-4305	the	_	
23-5	4306-4314	dopamine	_	
23-6	4315-4327	gene-related	_	
23-7	4328-4337	polygenic	_	
23-8	4338-4342	risk	_	
23-9	4343-4348	would	_	
23-10	4349-4356	predict	_	
23-11	4357-4364	altered	_	
23-12	4365-4373	function	_	
23-13	4374-4376	in	_	
23-14	4377-4380	the	_	
23-15	4381-4387	dorsal	_	
23-16	4388-4400	dopaminergic	_	
23-17	4401-4408	pathway	_	
23-18	4408-4409	.	_	

#Text=Results
#Text=The relationships of dopamine gene-related PGRS with working memory performance
#Text=The dopamine gene-related PGRS showed a significant negative correlation with the 3-back working memory correction rate (r = −0.122, p = 0.043), whereas the anti-correlation with 2-back working memory performance (r = −0.045, p = 0.462) did not reach statistical significance in the partial correlation analysis.
24-1	4410-4417	Results	_	
24-2	4418-4421	The	_	
24-3	4422-4435	relationships	_	
24-4	4436-4438	of	_	
24-5	4439-4447	dopamine	_	
24-6	4448-4460	gene-related	_	
24-7	4461-4465	PGRS	_	
24-8	4466-4470	with	_	
24-9	4471-4478	working	_	
24-10	4479-4485	memory	_	
24-11	4486-4497	performance	_	
24-12	4498-4501	The	_	
24-13	4502-4510	dopamine	_	
24-14	4511-4523	gene-related	_	
24-15	4524-4528	PGRS	_	
24-16	4529-4535	showed	_	
24-17	4536-4537	a	_	
24-18	4538-4549	significant	_	
24-19	4550-4558	negative	_	
24-20	4559-4570	correlation	_	
24-21	4571-4575	with	_	
24-22	4576-4579	the	_	
24-23	4580-4581	3	_	
24-24	4581-4582	-	_	
24-25	4582-4586	back	_	
24-26	4587-4594	working	_	
24-27	4595-4601	memory	_	
24-28	4602-4612	correction	_	
24-29	4613-4617	rate	_	
24-30	4618-4619	(	_	
24-31	4619-4620	r	_	
24-32	4621-4622	=	_	
24-33	4623-4624	−	_	
24-34	4624-4629	0.122	_	
24-35	4629-4630	,	_	
24-36	4631-4632	p	_	
24-37	4633-4634	=	_	
24-38	4635-4640	0.043	_	
24-39	4640-4641	)	_	
24-40	4641-4642	,	_	
24-41	4643-4650	whereas	_	
24-42	4651-4654	the	_	
24-43	4655-4671	anti-correlation	_	
24-44	4672-4676	with	_	
24-45	4677-4678	2	_	
24-46	4678-4679	-	_	
24-47	4679-4683	back	_	
24-48	4684-4691	working	_	
24-49	4692-4698	memory	_	
24-50	4699-4710	performance	_	
24-51	4711-4712	(	_	
24-52	4712-4713	r	_	
24-53	4714-4715	=	_	
24-54	4716-4717	−	_	
24-55	4717-4722	0.045	_	
24-56	4722-4723	,	_	
24-57	4724-4725	p	_	
24-58	4726-4727	=	_	
24-59	4728-4733	0.462	_	
24-60	4733-4734	)	_	
24-61	4735-4738	did	_	
24-62	4739-4742	not	_	
24-63	4743-4748	reach	_	
24-64	4749-4760	statistical	_	
24-65	4761-4773	significance	_	
24-66	4774-4776	in	_	
24-67	4777-4780	the	_	
24-68	4781-4788	partial	_	
24-69	4789-4800	correlation	_	
24-70	4801-4809	analysis	_	
24-71	4809-4810	.	_	

#Text=Thus, the PGRS is a reliable indicator of individual working memory performance.
25-1	4811-4815	Thus	_	
25-2	4815-4816	,	_	
25-3	4817-4820	the	_	
25-4	4821-4825	PGRS	_	
25-5	4826-4828	is	_	
25-6	4829-4830	a	_	
25-7	4831-4839	reliable	_	
25-8	4840-4849	indicator	_	
25-9	4850-4852	of	_	
25-10	4853-4863	individual	_	
25-11	4864-4871	working	_	
25-12	4872-4878	memory	_	
25-13	4879-4890	performance	_	
25-14	4890-4891	.	_	

#Text=The relationships of dopamine gene-related PGRS with functional connectivity of the striatum
#Text=Association of the dopamine gene-related PGRS and functional connectivity with the putamen.
26-1	4892-4895	The	_	
26-2	4896-4909	relationships	_	
26-3	4910-4912	of	_	
26-4	4913-4921	dopamine	_	
26-5	4922-4934	gene-related	_	
26-6	4935-4939	PGRS	_	
26-7	4940-4944	with	_	
26-8	4945-4955	functional	_	
26-9	4956-4968	connectivity	_	
26-10	4969-4971	of	_	
26-11	4972-4975	the	_	
26-12	4976-4984	striatum	_	
26-13	4985-4996	Association	_	
26-14	4997-4999	of	_	
26-15	5000-5003	the	_	
26-16	5004-5012	dopamine	_	
26-17	5013-5025	gene-related	_	
26-18	5026-5030	PGRS	_	
26-19	5031-5034	and	_	
26-20	5035-5045	functional	_	
26-21	5046-5058	connectivity	_	
26-22	5059-5063	with	_	
26-23	5064-5067	the	_	
26-24	5068-5075	putamen	_	
26-25	5075-5076	.	_	

#Text=(a) and (c) show that the functional connectivity between putamen (PUT) and medial prefrontal cortex (MPFG) increases with higher PGRS values (r = 0.214, p = 3.62 × 10−4); (b) and (d) show that connections between putamen (PUT) and inferior parietal lobule (IPL) are attenuated as the PGRS values increase (r = −0.219, p = 2.59 × 10−4) (Alphasim corrected p < 0.05, clusters > 60).
27-1	5077-5078	(	_	
27-2	5078-5079	a	_	
27-3	5079-5080	)	_	
27-4	5081-5084	and	_	
27-5	5085-5086	(	_	
27-6	5086-5087	c	_	
27-7	5087-5088	)	_	
27-8	5089-5093	show	_	
27-9	5094-5098	that	_	
27-10	5099-5102	the	_	
27-11	5103-5113	functional	_	
27-12	5114-5126	connectivity	_	
27-13	5127-5134	between	_	
27-14	5135-5142	putamen	_	
27-15	5143-5144	(	_	
27-16	5144-5147	PUT	_	
27-17	5147-5148	)	_	
27-18	5149-5152	and	_	
27-19	5153-5159	medial	_	
27-20	5160-5170	prefrontal	_	
27-21	5171-5177	cortex	_	
27-22	5178-5179	(	_	
27-23	5179-5183	MPFG	_	
27-24	5183-5184	)	_	
27-25	5185-5194	increases	_	
27-26	5195-5199	with	_	
27-27	5200-5206	higher	_	
27-28	5207-5211	PGRS	_	
27-29	5212-5218	values	_	
27-30	5219-5220	(	_	
27-31	5220-5221	r	_	
27-32	5222-5223	=	_	
27-33	5224-5229	0.214	_	
27-34	5229-5230	,	_	
27-35	5231-5232	p	_	
27-36	5233-5234	=	_	
27-37	5235-5239	3.62	_	
27-38	5240-5241	×	_	
27-39	5242-5244	10	_	
27-40	5244-5245	−	_	
27-41	5245-5246	4	_	
27-42	5246-5247	)	_	
27-43	5247-5248	;	_	
27-44	5249-5250	(	_	
27-45	5250-5251	b	_	
27-46	5251-5252	)	_	
27-47	5253-5256	and	_	
27-48	5257-5258	(	_	
27-49	5258-5259	d	_	
27-50	5259-5260	)	_	
27-51	5261-5265	show	_	
27-52	5266-5270	that	_	
27-53	5271-5282	connections	_	
27-54	5283-5290	between	_	
27-55	5291-5298	putamen	_	
27-56	5299-5300	(	_	
27-57	5300-5303	PUT	_	
27-58	5303-5304	)	_	
27-59	5305-5308	and	_	
27-60	5309-5317	inferior	_	
27-61	5318-5326	parietal	_	
27-62	5327-5333	lobule	_	
27-63	5334-5335	(	_	
27-64	5335-5338	IPL	_	
27-65	5338-5339	)	_	
27-66	5340-5343	are	_	
27-67	5344-5354	attenuated	_	
27-68	5355-5357	as	_	
27-69	5358-5361	the	_	
27-70	5362-5366	PGRS	_	
27-71	5367-5373	values	_	
27-72	5374-5382	increase	_	
27-73	5383-5384	(	_	
27-74	5384-5385	r	_	
27-75	5386-5387	=	_	
27-76	5388-5389	−	_	
27-77	5389-5394	0.219	_	
27-78	5394-5395	,	_	
27-79	5396-5397	p	_	
27-80	5398-5399	=	_	
27-81	5400-5404	2.59	_	
27-82	5405-5406	×	_	
27-83	5407-5409	10	_	
27-84	5409-5410	−	_	
27-85	5410-5411	4	_	
27-86	5411-5412	)	_	
27-87	5413-5414	(	_	
27-88	5414-5422	Alphasim	_	
27-89	5423-5432	corrected	_	
27-90	5433-5434	p	_	
27-91	5435-5436	<	_	
27-92	5437-5441	0.05	_	
27-93	5441-5442	,	_	
27-94	5443-5451	clusters	_	
27-95	5452-5453	>	_	
27-96	5454-5456	60	_	
27-97	5456-5457	)	_	
27-98	5457-5458	.	_	

#Text=Association of the dopamine gene-related PGRS and functional connectivity with the caudate nucleus.
28-1	5459-5470	Association	_	
28-2	5471-5473	of	_	
28-3	5474-5477	the	_	
28-4	5478-5486	dopamine	_	
28-5	5487-5499	gene-related	_	
28-6	5500-5504	PGRS	_	
28-7	5505-5508	and	_	
28-8	5509-5519	functional	_	
28-9	5520-5532	connectivity	_	
28-10	5533-5537	with	_	
28-11	5538-5541	the	_	
28-12	5542-5549	caudate	_	
28-13	5550-5557	nucleus	_	
28-14	5557-5558	.	_	

#Text=(a) and (c) show that functional connectivity between the caudate nucleus (CAU) and precuneus (PRE) increases with higher PGRS values (r = 0.188, p = 2 × 10−3); (b) and (d) show that the connection between the caudate and the middle frontal gyrus (MFG) is attenuated as the PGRS values increase (r = −0.205, p = 1 × 10−3) (Alphasim corrected p < 0.05, clusters > 79).
29-1	5559-5560	(	_	
29-2	5560-5561	a	_	
29-3	5561-5562	)	_	
29-4	5563-5566	and	_	
29-5	5567-5568	(	_	
29-6	5568-5569	c	_	
29-7	5569-5570	)	_	
29-8	5571-5575	show	_	
29-9	5576-5580	that	_	
29-10	5581-5591	functional	_	
29-11	5592-5604	connectivity	_	
29-12	5605-5612	between	_	
29-13	5613-5616	the	_	
29-14	5617-5624	caudate	_	
29-15	5625-5632	nucleus	_	
29-16	5633-5634	(	_	
29-17	5634-5637	CAU	_	
29-18	5637-5638	)	_	
29-19	5639-5642	and	_	
29-20	5643-5652	precuneus	_	
29-21	5653-5654	(	_	
29-22	5654-5657	PRE	_	
29-23	5657-5658	)	_	
29-24	5659-5668	increases	_	
29-25	5669-5673	with	_	
29-26	5674-5680	higher	_	
29-27	5681-5685	PGRS	_	
29-28	5686-5692	values	_	
29-29	5693-5694	(	_	
29-30	5694-5695	r	_	
29-31	5696-5697	=	_	
29-32	5698-5703	0.188	_	
29-33	5703-5704	,	_	
29-34	5705-5706	p	_	
29-35	5707-5708	=	_	
29-36	5709-5710	2	_	
29-37	5711-5712	×	_	
29-38	5713-5715	10	_	
29-39	5715-5716	−	_	
29-40	5716-5717	3	_	
29-41	5717-5718	)	_	
29-42	5718-5719	;	_	
29-43	5720-5721	(	_	
29-44	5721-5722	b	_	
29-45	5722-5723	)	_	
29-46	5724-5727	and	_	
29-47	5728-5729	(	_	
29-48	5729-5730	d	_	
29-49	5730-5731	)	_	
29-50	5732-5736	show	_	
29-51	5737-5741	that	_	
29-52	5742-5745	the	_	
29-53	5746-5756	connection	_	
29-54	5757-5764	between	_	
29-55	5765-5768	the	_	
29-56	5769-5776	caudate	_	
29-57	5777-5780	and	_	
29-58	5781-5784	the	_	
29-59	5785-5791	middle	_	
29-60	5792-5799	frontal	_	
29-61	5800-5805	gyrus	_	
29-62	5806-5807	(	_	
29-63	5807-5810	MFG	_	
29-64	5810-5811	)	_	
29-65	5812-5814	is	_	
29-66	5815-5825	attenuated	_	
29-67	5826-5828	as	_	
29-68	5829-5832	the	_	
29-69	5833-5837	PGRS	_	
29-70	5838-5844	values	_	
29-71	5845-5853	increase	_	
29-72	5854-5855	(	_	
29-73	5855-5856	r	_	
29-74	5857-5858	=	_	
29-75	5859-5860	−	_	
29-76	5860-5865	0.205	_	
29-77	5865-5866	,	_	
29-78	5867-5868	p	_	
29-79	5869-5870	=	_	
29-80	5871-5872	1	_	
29-81	5873-5874	×	_	
29-82	5875-5877	10	_	
29-83	5877-5878	−	_	
29-84	5878-5879	3	_	
29-85	5879-5880	)	_	
29-86	5881-5882	(	_	
29-87	5882-5890	Alphasim	_	
29-88	5891-5900	corrected	_	
29-89	5901-5902	p	_	
29-90	5903-5904	<	_	
29-91	5905-5909	0.05	_	
29-92	5909-5910	,	_	
29-93	5911-5919	clusters	_	
29-94	5920-5921	>	_	
29-95	5922-5924	79	_	
29-96	5924-5925	)	_	
29-97	5925-5926	.	_	

#Text=Overlaps of the significant clusters of the MPFG (a, green), the IPL (b, blue), the PRE (c, green), and the MFG (d, blue) with their corresponding functional network masks.
30-1	5927-5935	Overlaps	_	
30-2	5936-5938	of	_	
30-3	5939-5942	the	_	
30-4	5943-5954	significant	_	
30-5	5955-5963	clusters	_	
30-6	5964-5966	of	_	
30-7	5967-5970	the	_	
30-8	5971-5975	MPFG	_	
30-9	5976-5977	(	_	
30-10	5977-5978	a	_	
30-11	5978-5979	,	_	
30-12	5980-5985	green	_	
30-13	5985-5986	)	_	
30-14	5986-5987	,	_	
30-15	5988-5991	the	_	
30-16	5992-5995	IPL	_	
30-17	5996-5997	(	_	
30-18	5997-5998	b	_	
30-19	5998-5999	,	_	
30-20	6000-6004	blue	_	
30-21	6004-6005	)	_	
30-22	6005-6006	,	_	
30-23	6007-6010	the	_	
30-24	6011-6014	PRE	_	
30-25	6015-6016	(	_	
30-26	6016-6017	c	_	
30-27	6017-6018	,	_	
30-28	6019-6024	green	_	
30-29	6024-6025	)	_	
30-30	6025-6026	,	_	
30-31	6027-6030	and	_	
30-32	6031-6034	the	_	
30-33	6035-6038	MFG	_	
30-34	6039-6040	(	_	
30-35	6040-6041	d	_	
30-36	6041-6042	,	_	
30-37	6043-6047	blue	_	
30-38	6047-6048	)	_	
30-39	6049-6053	with	_	
30-40	6054-6059	their	_	
30-41	6060-6073	corresponding	_	
30-42	6074-6084	functional	_	
30-43	6085-6092	network	_	
30-44	6093-6098	masks	_	
30-45	6098-6099	.	_	

#Text=The red mask represents the default mode network (a,c); the violet mask represents the fronto-parietal network (b,d).
31-1	6100-6103	The	_	
31-2	6104-6107	red	_	
31-3	6108-6112	mask	_	
31-4	6113-6123	represents	_	
31-5	6124-6127	the	_	
31-6	6128-6135	default	_	
31-7	6136-6140	mode	_	
31-8	6141-6148	network	_	
31-9	6149-6150	(	_	
31-10	6150-6151	a	_	
31-11	6151-6152	,	_	
31-12	6152-6153	c	_	
31-13	6153-6154	)	_	
31-14	6154-6155	;	_	
31-15	6156-6159	the	_	
31-16	6160-6166	violet	_	
31-17	6167-6171	mask	_	
31-18	6172-6182	represents	_	
31-19	6183-6186	the	_	
31-20	6187-6202	fronto-parietal	_	
31-21	6203-6210	network	_	
31-22	6211-6212	(	_	
31-23	6212-6213	b	_	
31-24	6213-6214	,	_	
31-25	6214-6215	d	_	
31-26	6215-6216	)	_	
31-27	6216-6217	.	_	

#Text=In multiple regression analysis, we observed pronounced positive correlations between the PGRS and the functional connectivity between the left putamen and the medial prefrontal cortex (r = 0.214, p = 3.62 × 10−4, Fig. 1(a,c)); meanwhile, the functional connectivity with the inferior parietal lobule was anti-correlated with the PGRS (r = −0.219, p = 2.59 × 10−4, Fig. 1(b,d));.
32-1	6218-6220	In	_	
32-2	6221-6229	multiple	_	
32-3	6230-6240	regression	_	
32-4	6241-6249	analysis	_	
32-5	6249-6250	,	_	
32-6	6251-6253	we	_	
32-7	6254-6262	observed	_	
32-8	6263-6273	pronounced	_	
32-9	6274-6282	positive	_	
32-10	6283-6295	correlations	_	
32-11	6296-6303	between	_	
32-12	6304-6307	the	_	
32-13	6308-6312	PGRS	_	
32-14	6313-6316	and	_	
32-15	6317-6320	the	_	
32-16	6321-6331	functional	_	
32-17	6332-6344	connectivity	_	
32-18	6345-6352	between	_	
32-19	6353-6356	the	_	
32-20	6357-6361	left	_	
32-21	6362-6369	putamen	_	
32-22	6370-6373	and	_	
32-23	6374-6377	the	_	
32-24	6378-6384	medial	_	
32-25	6385-6395	prefrontal	_	
32-26	6396-6402	cortex	_	
32-27	6403-6404	(	_	
32-28	6404-6405	r	_	
32-29	6406-6407	=	_	
32-30	6408-6413	0.214	_	
32-31	6413-6414	,	_	
32-32	6415-6416	p	_	
32-33	6417-6418	=	_	
32-34	6419-6423	3.62	_	
32-35	6424-6425	×	_	
32-36	6426-6428	10	_	
32-37	6428-6429	−	_	
32-38	6429-6430	4	_	
32-39	6430-6431	,	_	
32-40	6432-6435	Fig	_	
32-41	6435-6436	.	_	
32-42	6436-6437	 	_	
32-43	6437-6438	1	_	
32-44	6438-6439	(	_	
32-45	6439-6440	a	_	
32-46	6440-6441	,	_	
32-47	6441-6442	c	_	
32-48	6442-6443	)	_	
32-49	6443-6444	)	_	
32-50	6444-6445	;	_	
32-51	6446-6455	meanwhile	_	
32-52	6455-6456	,	_	
32-53	6457-6460	the	_	
32-54	6461-6471	functional	_	
32-55	6472-6484	connectivity	_	
32-56	6485-6489	with	_	
32-57	6490-6493	the	_	
32-58	6494-6502	inferior	_	
32-59	6503-6511	parietal	_	
32-60	6512-6518	lobule	_	
32-61	6519-6522	was	_	
32-62	6523-6538	anti-correlated	_	
32-63	6539-6543	with	_	
32-64	6544-6547	the	_	
32-65	6548-6552	PGRS	_	
32-66	6553-6554	(	_	
32-67	6554-6555	r	_	
32-68	6556-6557	=	_	
32-69	6558-6559	−	_	
32-70	6559-6564	0.219	_	
32-71	6564-6565	,	_	
32-72	6566-6567	p	_	
32-73	6568-6569	=	_	
32-74	6570-6574	2.59	_	
32-75	6575-6576	×	_	
32-76	6577-6579	10	_	
32-77	6579-6580	−	_	
32-78	6580-6581	4	_	
32-79	6581-6582	,	_	
32-80	6583-6586	Fig	_	
32-81	6586-6587	.	_	
32-82	6587-6588	 	_	
32-83	6588-6589	1	_	
32-84	6589-6590	(	_	
32-85	6590-6591	b	_	
32-86	6591-6592	,	_	
32-87	6592-6593	d	_	
32-88	6593-6594	)	_	
32-89	6594-6595	)	_	
32-90	6595-6596	;	_	
32-91	6596-6597	.	_	

#Text=The PGRS showed a linear positive correlation with the functional connectivity between the left caudate nucleus and the precuneus (r = 0.188, p = 2 × 10−3, Fig. 2(a,c)), but it showed an inverse correlation with the functional connectivity between the left caudate and the middle frontal gyrus (r = −0.205, p = 1 × 10−3, Fig. 2(b,d)).
33-1	6598-6601	The	_	
33-2	6602-6606	PGRS	_	
33-3	6607-6613	showed	_	
33-4	6614-6615	a	_	
33-5	6616-6622	linear	_	
33-6	6623-6631	positive	_	
33-7	6632-6643	correlation	_	
33-8	6644-6648	with	_	
33-9	6649-6652	the	_	
33-10	6653-6663	functional	_	
33-11	6664-6676	connectivity	_	
33-12	6677-6684	between	_	
33-13	6685-6688	the	_	
33-14	6689-6693	left	_	
33-15	6694-6701	caudate	_	
33-16	6702-6709	nucleus	_	
33-17	6710-6713	and	_	
33-18	6714-6717	the	_	
33-19	6718-6727	precuneus	_	
33-20	6728-6729	(	_	
33-21	6729-6730	r	_	
33-22	6731-6732	=	_	
33-23	6733-6738	0.188	_	
33-24	6738-6739	,	_	
33-25	6740-6741	p	_	
33-26	6742-6743	=	_	
33-27	6744-6745	2	_	
33-28	6746-6747	×	_	
33-29	6748-6750	10	_	
33-30	6750-6751	−	_	
33-31	6751-6752	3	_	
33-32	6752-6753	,	_	
33-33	6754-6757	Fig	_	
33-34	6757-6758	.	_	
33-35	6758-6759	 	_	
33-36	6759-6760	2	_	
33-37	6760-6761	(	_	
33-38	6761-6762	a	_	
33-39	6762-6763	,	_	
33-40	6763-6764	c	_	
33-41	6764-6765	)	_	
33-42	6765-6766	)	_	
33-43	6766-6767	,	_	
33-44	6768-6771	but	_	
33-45	6772-6774	it	_	
33-46	6775-6781	showed	_	
33-47	6782-6784	an	_	
33-48	6785-6792	inverse	_	
33-49	6793-6804	correlation	_	
33-50	6805-6809	with	_	
33-51	6810-6813	the	_	
33-52	6814-6824	functional	_	
33-53	6825-6837	connectivity	_	
33-54	6838-6845	between	_	
33-55	6846-6849	the	_	
33-56	6850-6854	left	_	
33-57	6855-6862	caudate	_	
33-58	6863-6866	and	_	
33-59	6867-6870	the	_	
33-60	6871-6877	middle	_	
33-61	6878-6885	frontal	_	
33-62	6886-6891	gyrus	_	
33-63	6892-6893	(	_	
33-64	6893-6894	r	_	
33-65	6895-6896	=	_	
33-66	6897-6898	−	_	
33-67	6898-6903	0.205	_	
33-68	6903-6904	,	_	
33-69	6905-6906	p	_	
33-70	6907-6908	=	_	
33-71	6909-6910	1	_	
33-72	6911-6912	×	_	
33-73	6913-6915	10	_	
33-74	6915-6916	−	_	
33-75	6916-6917	3	_	
33-76	6917-6918	,	_	
33-77	6919-6922	Fig	_	
33-78	6922-6923	.	_	
33-79	6923-6924	 	_	
33-80	6924-6925	2	_	
33-81	6925-6926	(	_	
33-82	6926-6927	b	_	
33-83	6927-6928	,	_	
33-84	6928-6929	d	_	
33-85	6929-6930	)	_	
33-86	6930-6931	)	_	
33-87	6931-6932	.	_	

#Text=The overlap between each significant region and its corresponding resting-state functional network demonstrated that regions showing positive correlations were all components of the default mode network (Fig. 3(a,c)), and those that showed anti-correlation were parts of the fronto-parietal network (Fig. 3(b,d)).
34-1	6933-6936	The	_	
34-2	6937-6944	overlap	_	
34-3	6945-6952	between	_	
34-4	6953-6957	each	_	
34-5	6958-6969	significant	_	
34-6	6970-6976	region	_	
34-7	6977-6980	and	_	
34-8	6981-6984	its	_	
34-9	6985-6998	corresponding	_	
34-10	6999-7012	resting-state	_	
34-11	7013-7023	functional	_	
34-12	7024-7031	network	_	
34-13	7032-7044	demonstrated	_	
34-14	7045-7049	that	_	
34-15	7050-7057	regions	_	
34-16	7058-7065	showing	_	
34-17	7066-7074	positive	_	
34-18	7075-7087	correlations	_	
34-19	7088-7092	were	_	
34-20	7093-7096	all	_	
34-21	7097-7107	components	_	
34-22	7108-7110	of	_	
34-23	7111-7114	the	_	
34-24	7115-7122	default	_	
34-25	7123-7127	mode	_	
34-26	7128-7135	network	_	
34-27	7136-7137	(	_	
34-28	7137-7140	Fig	_	
34-29	7140-7141	.	_	
34-30	7141-7142	 	_	
34-31	7142-7143	3	_	
34-32	7143-7144	(	_	
34-33	7144-7145	a	_	
34-34	7145-7146	,	_	
34-35	7146-7147	c	_	
34-36	7147-7148	)	_	
34-37	7148-7149	)	_	
34-38	7149-7150	,	_	
34-39	7151-7154	and	_	
34-40	7155-7160	those	_	
34-41	7161-7165	that	_	
34-42	7166-7172	showed	_	
34-43	7173-7189	anti-correlation	_	
34-44	7190-7194	were	_	
34-45	7195-7200	parts	_	
34-46	7201-7203	of	_	
34-47	7204-7207	the	_	
34-48	7208-7223	fronto-parietal	_	
34-49	7224-7231	network	_	
34-50	7232-7233	(	_	
34-51	7233-7236	Fig	_	
34-52	7236-7237	.	_	
34-53	7237-7238	 	_	
34-54	7238-7239	3	_	
34-55	7239-7240	(	_	
34-56	7240-7241	b	_	
34-57	7241-7242	,	_	
34-58	7242-7243	d	_	
34-59	7243-7244	)	_	
34-60	7244-7245	)	_	
34-61	7245-7246	.	_	

#Text=We did not find any significant correlation between SNP and functional connectivity in the post-hoc tests (all p > 0.05).
35-1	7247-7249	We	_	
35-2	7250-7253	did	_	
35-3	7254-7257	not	_	
35-4	7258-7262	find	_	
35-5	7263-7266	any	_	
35-6	7267-7278	significant	_	
35-7	7279-7290	correlation	_	
35-8	7291-7298	between	_	
35-9	7299-7302	SNP	_	
35-10	7303-7306	and	_	
35-11	7307-7317	functional	_	
35-12	7318-7330	connectivity	_	
35-13	7331-7333	in	_	
35-14	7334-7337	the	_	
35-15	7338-7346	post-hoc	_	
35-16	7347-7352	tests	_	
35-17	7353-7354	(	_	
35-18	7354-7357	all	_	
35-19	7358-7359	p	_	
35-20	7360-7361	>	_	
35-21	7362-7366	0.05	_	
35-22	7366-7367	)	_	
35-23	7367-7368	.	_	

#Text=And we did not observe a polygenic effect of PGRS on the functional connectivity with the ventral striatum in our current sample.
36-1	7369-7372	And	_	
36-2	7373-7375	we	_	
36-3	7376-7379	did	_	
36-4	7380-7383	not	_	
36-5	7384-7391	observe	_	
36-6	7392-7393	a	_	
36-7	7394-7403	polygenic	_	
36-8	7404-7410	effect	_	
36-9	7411-7413	of	_	
36-10	7414-7418	PGRS	_	
36-11	7419-7421	on	_	
36-12	7422-7425	the	_	
36-13	7426-7436	functional	_	
36-14	7437-7449	connectivity	_	
36-15	7450-7454	with	_	
36-16	7455-7458	the	_	
36-17	7459-7466	ventral	_	
36-18	7467-7475	striatum	_	
36-19	7476-7478	in	_	
36-20	7479-7482	our	_	
36-21	7483-7490	current	_	
36-22	7491-7497	sample	_	
36-23	7497-7498	.	_	

#Text=Discussion
#Text=Based on all SNPs in the dopamine genetic pathway that confer risk for schizophrenia, our present study found that dopamine gene-related PGRS showed are markable correlation with the function of the dorsal striatum and with working memory performance.
37-1	7499-7509	Discussion	_	
37-2	7510-7515	Based	_	
37-3	7516-7518	on	_	
37-4	7519-7522	all	_	
37-5	7523-7527	SNPs	_	
37-6	7528-7530	in	_	
37-7	7531-7534	the	_	
37-8	7535-7543	dopamine	_	
37-9	7544-7551	genetic	_	
37-10	7552-7559	pathway	_	
37-11	7560-7564	that	_	
37-12	7565-7571	confer	_	
37-13	7572-7576	risk	_	
37-14	7577-7580	for	_	
37-15	7581-7594	schizophrenia	_	
37-16	7594-7595	,	_	
37-17	7596-7599	our	_	
37-18	7600-7607	present	_	
37-19	7608-7613	study	_	
37-20	7614-7619	found	_	
37-21	7620-7624	that	_	
37-22	7625-7633	dopamine	_	
37-23	7634-7646	gene-related	_	
37-24	7647-7651	PGRS	_	
37-25	7652-7658	showed	_	
37-26	7659-7662	are	_	
37-27	7663-7671	markable	_	
37-28	7672-7683	correlation	_	
37-29	7684-7688	with	_	
37-30	7689-7692	the	_	
37-31	7693-7701	function	_	
37-32	7702-7704	of	_	
37-33	7705-7708	the	_	
37-34	7709-7715	dorsal	_	
37-35	7716-7724	striatum	_	
37-36	7725-7728	and	_	
37-37	7729-7733	with	_	
37-38	7734-7741	working	_	
37-39	7742-7748	memory	_	
37-40	7749-7760	performance	_	
37-41	7760-7761	.	_	

#Text=Moreover, the PGRS was positively correlated with the functional connections between brain regions involved in the default mode network and the substructure of the dorsal striatum and was negatively correlated with the functional connections of regions within the fronto-parietal network.
38-1	7762-7770	Moreover	_	
38-2	7770-7771	,	_	
38-3	7772-7775	the	_	
38-4	7776-7780	PGRS	_	
38-5	7781-7784	was	_	
38-6	7785-7795	positively	_	
38-7	7796-7806	correlated	_	
38-8	7807-7811	with	_	
38-9	7812-7815	the	_	
38-10	7816-7826	functional	_	
38-11	7827-7838	connections	_	
38-12	7839-7846	between	_	
38-13	7847-7852	brain	_	
38-14	7853-7860	regions	_	
38-15	7861-7869	involved	_	
38-16	7870-7872	in	_	
38-17	7873-7876	the	_	
38-18	7877-7884	default	_	
38-19	7885-7889	mode	_	
38-20	7890-7897	network	_	
38-21	7898-7901	and	_	
38-22	7902-7905	the	_	
38-23	7906-7918	substructure	_	
38-24	7919-7921	of	_	
38-25	7922-7925	the	_	
38-26	7926-7932	dorsal	_	
38-27	7933-7941	striatum	_	
38-28	7942-7945	and	_	
38-29	7946-7949	was	_	
38-30	7950-7960	negatively	_	
38-31	7961-7971	correlated	_	
38-32	7972-7976	with	_	
38-33	7977-7980	the	_	
38-34	7981-7991	functional	_	
38-35	7992-8003	connections	_	
38-36	8004-8006	of	_	
38-37	8007-8014	regions	_	
38-38	8015-8021	within	_	
38-39	8022-8025	the	_	
38-40	8026-8041	fronto-parietal	_	
38-41	8042-8049	network	_	
38-42	8049-8050	.	_	

#Text=These insights elucidate the complex mechanisms by which genomic variation influences schizophrenia-related cognitive performance through its effect on neural circuitry.
39-1	8051-8056	These	_	
39-2	8057-8065	insights	_	
39-3	8066-8075	elucidate	_	
39-4	8076-8079	the	_	
39-5	8080-8087	complex	_	
39-6	8088-8098	mechanisms	_	
39-7	8099-8101	by	_	
39-8	8102-8107	which	_	
39-9	8108-8115	genomic	_	
39-10	8116-8125	variation	_	
39-11	8126-8136	influences	_	
39-12	8137-8158	schizophrenia-related	_	
39-13	8159-8168	cognitive	_	
39-14	8169-8180	performance	_	
39-15	8181-8188	through	_	
39-16	8189-8192	its	_	
39-17	8193-8199	effect	_	
39-18	8200-8202	on	_	
39-19	8203-8209	neural	_	
39-20	8210-8219	circuitry	_	
39-21	8219-8220	.	_	

#Text=We only found that dopamine gene-related PGRS was correlated to functional connectivity with substructures of the dorsal striatum.
40-1	8221-8223	We	_	
40-2	8224-8228	only	_	
40-3	8229-8234	found	_	
40-4	8235-8239	that	_	
40-5	8240-8248	dopamine	_	
40-6	8249-8261	gene-related	_	
40-7	8262-8266	PGRS	_	
40-8	8267-8270	was	_	
40-9	8271-8281	correlated	_	
40-10	8282-8284	to	_	
40-11	8285-8295	functional	_	
40-12	8296-8308	connectivity	_	
40-13	8309-8313	with	_	
40-14	8314-8327	substructures	_	
40-15	8328-8330	of	_	
40-16	8331-8334	the	_	
40-17	8335-8341	dorsal	_	
40-18	8342-8350	striatum	_	
40-19	8350-8351	.	_	

#Text=These results were consistent with previous case-control studies, Dandash et al. also found that only the functional connectivity with dorsal striatum was changed in subjects with an at-risk mental state for psychosis, moreover altered functional connectivity was closely related to positive psychotic symptoms.
41-1	8352-8357	These	_	
41-2	8358-8365	results	_	
41-3	8366-8370	were	_	
41-4	8371-8381	consistent	_	
41-5	8382-8386	with	_	
41-6	8387-8395	previous	_	
41-7	8396-8408	case-control	_	
41-8	8409-8416	studies	_	
41-9	8416-8417	,	_	
41-10	8418-8425	Dandash	_	
41-11	8426-8428	et	_	
41-12	8429-8431	al	_	
41-13	8431-8432	.	_	
41-14	8433-8437	also	_	
41-15	8438-8443	found	_	
41-16	8444-8448	that	_	
41-17	8449-8453	only	_	
41-18	8454-8457	the	_	
41-19	8458-8468	functional	_	
41-20	8469-8481	connectivity	_	
41-21	8482-8486	with	_	
41-22	8487-8493	dorsal	_	
41-23	8494-8502	striatum	_	
41-24	8503-8506	was	_	
41-25	8507-8514	changed	_	
41-26	8515-8517	in	_	
41-27	8518-8526	subjects	_	
41-28	8527-8531	with	_	
41-29	8532-8534	an	_	
41-30	8535-8542	at-risk	_	
41-31	8543-8549	mental	_	
41-32	8550-8555	state	_	
41-33	8556-8559	for	_	
41-34	8560-8569	psychosis	_	
41-35	8569-8570	,	_	
41-36	8571-8579	moreover	_	
41-37	8580-8587	altered	_	
41-38	8588-8598	functional	_	
41-39	8599-8611	connectivity	_	
41-40	8612-8615	was	_	
41-41	8616-8623	closely	_	
41-42	8624-8631	related	_	
41-43	8632-8634	to	_	
41-44	8635-8643	positive	_	
41-45	8644-8653	psychotic	_	
41-46	8654-8662	symptoms	_	
41-47	8662-8663	.	_	

#Text=In addition, Wenjin Zhang et al. utilized resting-state fMRI in a group of never-medicated patients with long-term schizophrenia and also found increased spontaneous neural activity in the putamen bilaterally.
42-1	8664-8666	In	_	
42-2	8667-8675	addition	_	
42-3	8675-8676	,	_	
42-4	8677-8683	Wenjin	_	
42-5	8684-8689	Zhang	_	
42-6	8690-8692	et	_	
42-7	8693-8695	al	_	
42-8	8695-8696	.	_	
42-9	8697-8705	utilized	_	
42-10	8706-8719	resting-state	_	
42-11	8720-8724	fMRI	_	
42-12	8725-8727	in	_	
42-13	8728-8729	a	_	
42-14	8730-8735	group	_	
42-15	8736-8738	of	_	
42-16	8739-8754	never-medicated	_	
42-17	8755-8763	patients	_	
42-18	8764-8768	with	_	
42-19	8769-8778	long-term	_	
42-20	8779-8792	schizophrenia	_	
42-21	8793-8796	and	_	
42-22	8797-8801	also	_	
42-23	8802-8807	found	_	
42-24	8808-8817	increased	_	
42-25	8818-8829	spontaneous	_	
42-26	8830-8836	neural	_	
42-27	8837-8845	activity	_	
42-28	8846-8848	in	_	
42-29	8849-8852	the	_	
42-30	8853-8860	putamen	_	
42-31	8861-8872	bilaterally	_	
42-32	8872-8873	.	_	

#Text=It is intriguing to speculate that dysfunctions of the dopaminergic system are related to alterations in neural activity, and this might be a relevant pathophysiological mechanism that increases the risk of schizophrenia.
43-1	8874-8876	It	_	
43-2	8877-8879	is	_	
43-3	8880-8890	intriguing	_	
43-4	8891-8893	to	_	
43-5	8894-8903	speculate	_	
43-6	8904-8908	that	_	
43-7	8909-8921	dysfunctions	_	
43-8	8922-8924	of	_	
43-9	8925-8928	the	_	
43-10	8929-8941	dopaminergic	_	
43-11	8942-8948	system	_	
43-12	8949-8952	are	_	
43-13	8953-8960	related	_	
43-14	8961-8963	to	_	
43-15	8964-8975	alterations	_	
43-16	8976-8978	in	_	
43-17	8979-8985	neural	_	
43-18	8986-8994	activity	_	
43-19	8994-8995	,	_	
43-20	8996-8999	and	_	
43-21	9000-9004	this	_	
43-22	9005-9010	might	_	
43-23	9011-9013	be	_	
43-24	9014-9015	a	_	
43-25	9016-9024	relevant	_	
43-26	9025-9043	pathophysiological	_	
43-27	9044-9053	mechanism	_	
43-28	9054-9058	that	_	
43-29	9059-9068	increases	_	
43-30	9069-9072	the	_	
43-31	9073-9077	risk	_	
43-32	9078-9080	of	_	
43-33	9081-9094	schizophrenia	_	
43-34	9094-9095	.	_	

#Text=We also observed that the brain areas correlated with the dopamine gene-related PGRS were located in the default mode network and the fronto-parietal network, whereas the putamen and caudate nucleus belong to the salience network.
44-1	9096-9098	We	_	
44-2	9099-9103	also	_	
44-3	9104-9112	observed	_	
44-4	9113-9117	that	_	
44-5	9118-9121	the	_	
44-6	9122-9127	brain	_	
44-7	9128-9133	areas	_	
44-8	9134-9144	correlated	_	
44-9	9145-9149	with	_	
44-10	9150-9153	the	_	
44-11	9154-9162	dopamine	_	
44-12	9163-9175	gene-related	_	
44-13	9176-9180	PGRS	_	
44-14	9181-9185	were	_	
44-15	9186-9193	located	_	
44-16	9194-9196	in	_	
44-17	9197-9200	the	_	
44-18	9201-9208	default	_	
44-19	9209-9213	mode	_	
44-20	9214-9221	network	_	
44-21	9222-9225	and	_	
44-22	9226-9229	the	_	
44-23	9230-9245	fronto-parietal	_	
44-24	9246-9253	network	_	
44-25	9253-9254	,	_	
44-26	9255-9262	whereas	_	
44-27	9263-9266	the	_	
44-28	9267-9274	putamen	_	
44-29	9275-9278	and	_	
44-30	9279-9286	caudate	_	
44-31	9287-9294	nucleus	_	
44-32	9295-9301	belong	_	
44-33	9302-9304	to	_	
44-34	9305-9308	the	_	
44-35	9309-9317	salience	_	
44-36	9318-9325	network	_	
44-37	9325-9326	.	_	

#Text=Williamson proposed that anomalous coordination of the default mode network and the task-related network might be a probable etiology of schizophrenia.
45-1	9327-9337	Williamson	_	
45-2	9338-9346	proposed	_	
45-3	9347-9351	that	_	
45-4	9352-9361	anomalous	_	
45-5	9362-9374	coordination	_	
45-6	9375-9377	of	_	
45-7	9378-9381	the	_	
45-8	9382-9389	default	_	
45-9	9390-9394	mode	_	
45-10	9395-9402	network	_	
45-11	9403-9406	and	_	
45-12	9407-9410	the	_	
45-13	9411-9423	task-related	_	
45-14	9424-9431	network	_	
45-15	9432-9437	might	_	
45-16	9438-9440	be	_	
45-17	9441-9442	a	_	
45-18	9443-9451	probable	_	
45-19	9452-9460	etiology	_	
45-20	9461-9463	of	_	
45-21	9464-9477	schizophrenia	_	
45-22	9477-9478	.	_	

#Text=Subsequently, Menon further introduced the salience network, suggesting that aberrant functional integration and interconnectivity of the default mode network, the central executive network (similar to the task-related network) and the salience network might be the major cause of most psychiatric disorders.
46-1	9479-9491	Subsequently	_	
46-2	9491-9492	,	_	
46-3	9493-9498	Menon	_	
46-4	9499-9506	further	_	
46-5	9507-9517	introduced	_	
46-6	9518-9521	the	_	
46-7	9522-9530	salience	_	
46-8	9531-9538	network	_	
46-9	9538-9539	,	_	
46-10	9540-9550	suggesting	_	
46-11	9551-9555	that	_	
46-12	9556-9564	aberrant	_	
46-13	9565-9575	functional	_	
46-14	9576-9587	integration	_	
46-15	9588-9591	and	_	
46-16	9592-9609	interconnectivity	_	
46-17	9610-9612	of	_	
46-18	9613-9616	the	_	
46-19	9617-9624	default	_	
46-20	9625-9629	mode	_	
46-21	9630-9637	network	_	
46-22	9637-9638	,	_	
46-23	9639-9642	the	_	
46-24	9643-9650	central	_	
46-25	9651-9660	executive	_	
46-26	9661-9668	network	_	
46-27	9669-9670	(	_	
46-28	9670-9677	similar	_	
46-29	9678-9680	to	_	
46-30	9681-9684	the	_	
46-31	9685-9697	task-related	_	
46-32	9698-9705	network	_	
46-33	9705-9706	)	_	
46-34	9707-9710	and	_	
46-35	9711-9714	the	_	
46-36	9715-9723	salience	_	
46-37	9724-9731	network	_	
46-38	9732-9737	might	_	
46-39	9738-9740	be	_	
46-40	9741-9744	the	_	
46-41	9745-9750	major	_	
46-42	9751-9756	cause	_	
46-43	9757-9759	of	_	
46-44	9760-9764	most	_	
46-45	9765-9776	psychiatric	_	
46-46	9777-9786	disorders	_	
46-47	9786-9787	.	_	

#Text=The default mode network mainly contains the medial prefrontal cortex extending to the ventral anterior cingulate and the posterior cingulate extending to the precuneus, and the lateral parietal cortex.
47-1	9788-9791	The	_	
47-2	9792-9799	default	_	
47-3	9800-9804	mode	_	
47-4	9805-9812	network	_	
47-5	9813-9819	mainly	_	
47-6	9820-9828	contains	_	
47-7	9829-9832	the	_	
47-8	9833-9839	medial	_	
47-9	9840-9850	prefrontal	_	
47-10	9851-9857	cortex	_	
47-11	9858-9867	extending	_	
47-12	9868-9870	to	_	
47-13	9871-9874	the	_	
47-14	9875-9882	ventral	_	
47-15	9883-9891	anterior	_	
47-16	9892-9901	cingulate	_	
47-17	9902-9905	and	_	
47-18	9906-9909	the	_	
47-19	9910-9919	posterior	_	
47-20	9920-9929	cingulate	_	
47-21	9930-9939	extending	_	
47-22	9940-9942	to	_	
47-23	9943-9946	the	_	
47-24	9947-9956	precuneus	_	
47-25	9956-9957	,	_	
47-26	9958-9961	and	_	
47-27	9962-9965	the	_	
47-28	9966-9973	lateral	_	
47-29	9974-9982	parietal	_	
47-30	9983-9989	cortex	_	
47-31	9989-9990	.	_	

#Text=Dysfunction of the default mode network may lead to cognitive impairments including decreased concentration, deterioration of working memory, and schizophrenia-related positive clinical symptoms such as delusions and hallucinations.
48-1	9991-10002	Dysfunction	_	
48-2	10003-10005	of	_	
48-3	10006-10009	the	_	
48-4	10010-10017	default	_	
48-5	10018-10022	mode	_	
48-6	10023-10030	network	_	
48-7	10031-10034	may	_	
48-8	10035-10039	lead	_	
48-9	10040-10042	to	_	
48-10	10043-10052	cognitive	_	
48-11	10053-10064	impairments	_	
48-12	10065-10074	including	_	
48-13	10075-10084	decreased	_	
48-14	10085-10098	concentration	_	
48-15	10098-10099	,	_	
48-16	10100-10113	deterioration	_	
48-17	10114-10116	of	_	
48-18	10117-10124	working	_	
48-19	10125-10131	memory	_	
48-20	10131-10132	,	_	
48-21	10133-10136	and	_	
48-22	10137-10158	schizophrenia-related	_	
48-23	10159-10167	positive	_	
48-24	10168-10176	clinical	_	
48-25	10177-10185	symptoms	_	
48-26	10186-10190	such	_	
48-27	10191-10193	as	_	
48-28	10194-10203	delusions	_	
48-29	10204-10207	and	_	
48-30	10208-10222	hallucinations	_	
48-31	10222-10223	.	_	

#Text=Extensive studies have indicated that schizophrenia patients and non-psychiatric relatives exhibited hyper-activation and hyper-connectivity of the default mode network.
49-1	10224-10233	Extensive	_	
49-2	10234-10241	studies	_	
49-3	10242-10246	have	_	
49-4	10247-10256	indicated	_	
49-5	10257-10261	that	_	
49-6	10262-10275	schizophrenia	_	
49-7	10276-10284	patients	_	
49-8	10285-10288	and	_	
49-9	10289-10304	non-psychiatric	_	
49-10	10305-10314	relatives	_	
49-11	10315-10324	exhibited	_	
49-12	10325-10341	hyper-activation	_	
49-13	10342-10345	and	_	
49-14	10346-10364	hyper-connectivity	_	
49-15	10365-10367	of	_	
49-16	10368-10371	the	_	
49-17	10372-10379	default	_	
49-18	10380-10384	mode	_	
49-19	10385-10392	network	_	
49-20	10392-10393	.	_	

#Text=Moreover, weaker task-related suppression of the default mode network is consistently found in both task and resting-state fMRI analysis of schizophrenia patients.
50-1	10394-10402	Moreover	_	
50-2	10402-10403	,	_	
50-3	10404-10410	weaker	_	
50-4	10411-10423	task-related	_	
50-5	10424-10435	suppression	_	
50-6	10436-10438	of	_	
50-7	10439-10442	the	_	
50-8	10443-10450	default	_	
50-9	10451-10455	mode	_	
50-10	10456-10463	network	_	
50-11	10464-10466	is	_	
50-12	10467-10479	consistently	_	
50-13	10480-10485	found	_	
50-14	10486-10488	in	_	
50-15	10489-10493	both	_	
50-16	10494-10498	task	_	
50-17	10499-10502	and	_	
50-18	10503-10516	resting-state	_	
50-19	10517-10521	fMRI	_	
50-20	10522-10530	analysis	_	
50-21	10531-10533	of	_	
50-22	10534-10547	schizophrenia	_	
50-23	10548-10556	patients	_	
50-24	10556-10557	.	_	

#Text=Our present results exhibited a consistent trend: for individuals, higher risk of schizophrenia was associated with stronger connections between the dorsal striatum and the default mode network.
51-1	10558-10561	Our	_	
51-2	10562-10569	present	_	
51-3	10570-10577	results	_	
51-4	10578-10587	exhibited	_	
51-5	10588-10589	a	_	
51-6	10590-10600	consistent	_	
51-7	10601-10606	trend	_	
51-8	10606-10607	:	_	
51-9	10608-10611	for	_	
51-10	10612-10623	individuals	_	
51-11	10623-10624	,	_	
51-12	10625-10631	higher	_	
51-13	10632-10636	risk	_	
51-14	10637-10639	of	_	
51-15	10640-10653	schizophrenia	_	
51-16	10654-10657	was	_	
51-17	10658-10668	associated	_	
51-18	10669-10673	with	_	
51-19	10674-10682	stronger	_	
51-20	10683-10694	connections	_	
51-21	10695-10702	between	_	
51-22	10703-10706	the	_	
51-23	10707-10713	dorsal	_	
51-24	10714-10722	striatum	_	
51-25	10723-10726	and	_	
51-26	10727-10730	the	_	
51-27	10731-10738	default	_	
51-28	10739-10743	mode	_	
51-29	10744-10751	network	_	
51-30	10751-10752	.	_	

#Text=However, the fronto-parietal network is a task-positive network involved in top-down cognitive control, and its functional connectivity is positively correlated to working memory capacity.
52-1	10753-10760	However	_	
52-2	10760-10761	,	_	
52-3	10762-10765	the	_	
52-4	10766-10781	fronto-parietal	_	
52-5	10782-10789	network	_	
52-6	10790-10792	is	_	
52-7	10793-10794	a	_	
52-8	10795-10808	task-positive	_	
52-9	10809-10816	network	_	
52-10	10817-10825	involved	_	
52-11	10826-10828	in	_	
52-12	10829-10837	top-down	_	
52-13	10838-10847	cognitive	_	
52-14	10848-10855	control	_	
52-15	10855-10856	,	_	
52-16	10857-10860	and	_	
52-17	10861-10864	its	_	
52-18	10865-10875	functional	_	
52-19	10876-10888	connectivity	_	
52-20	10889-10891	is	_	
52-21	10892-10902	positively	_	
52-22	10903-10913	correlated	_	
52-23	10914-10916	to	_	
52-24	10917-10924	working	_	
52-25	10925-10931	memory	_	
52-26	10932-10940	capacity	_	
52-27	10940-10941	.	_	

#Text=Numerous studies have found that brain regions in the fronto-parietal network show decreased task-related activation in multiple-tasks.
53-1	10942-10950	Numerous	_	
53-2	10951-10958	studies	_	
53-3	10959-10963	have	_	
53-4	10964-10969	found	_	
53-5	10970-10974	that	_	
53-6	10975-10980	brain	_	
53-7	10981-10988	regions	_	
53-8	10989-10991	in	_	
53-9	10992-10995	the	_	
53-10	10996-11011	fronto-parietal	_	
53-11	11012-11019	network	_	
53-12	11020-11024	show	_	
53-13	11025-11034	decreased	_	
53-14	11035-11047	task-related	_	
53-15	11048-11058	activation	_	
53-16	11059-11061	in	_	
53-17	11062-11076	multiple-tasks	_	
53-18	11076-11077	.	_	

#Text=Resting-state fMRI analyses have also revealed reduced intra- and inter-connectivity of the fronto-parietal network.
54-1	11078-11091	Resting-state	_	
54-2	11092-11096	fMRI	_	
54-3	11097-11105	analyses	_	
54-4	11106-11110	have	_	
54-5	11111-11115	also	_	
54-6	11116-11124	revealed	_	
54-7	11125-11132	reduced	_	
54-8	11133-11138	intra	_	
54-9	11138-11139	-	_	
54-10	11140-11143	and	_	
54-11	11144-11162	inter-connectivity	_	
54-12	11163-11165	of	_	
54-13	11166-11169	the	_	
54-14	11170-11185	fronto-parietal	_	
54-15	11186-11193	network	_	
54-16	11193-11194	.	_	

#Text=Our findings were consistent with previous reports suggesting that increasing risk of schizophrenia was accompanied by suppressed activity in the task-positive network and increased activity in the task-negative network.
55-1	11195-11198	Our	_	
55-2	11199-11207	findings	_	
55-3	11208-11212	were	_	
55-4	11213-11223	consistent	_	
55-5	11224-11228	with	_	
55-6	11229-11237	previous	_	
55-7	11238-11245	reports	_	
55-8	11246-11256	suggesting	_	
55-9	11257-11261	that	_	
55-10	11262-11272	increasing	_	
55-11	11273-11277	risk	_	
55-12	11278-11280	of	_	
55-13	11281-11294	schizophrenia	_	
55-14	11295-11298	was	_	
55-15	11299-11310	accompanied	_	
55-16	11311-11313	by	_	
55-17	11314-11324	suppressed	_	
55-18	11325-11333	activity	_	
55-19	11334-11336	in	_	
55-20	11337-11340	the	_	
55-21	11341-11354	task-positive	_	
55-22	11355-11362	network	_	
55-23	11363-11366	and	_	
55-24	11367-11376	increased	_	
55-25	11377-11385	activity	_	
55-26	11386-11388	in	_	
55-27	11389-11392	the	_	
55-28	11393-11406	task-negative	_	
55-29	11407-11414	network	_	
55-30	11414-11415	.	_	

#Text=Interestingly, the dorsal striatum showed entirely opposite correlations with the default network and fronto-parietal network.
56-1	11416-11429	Interestingly	_	
56-2	11429-11430	,	_	
56-3	11431-11434	the	_	
56-4	11435-11441	dorsal	_	
56-5	11442-11450	striatum	_	
56-6	11451-11457	showed	_	
56-7	11458-11466	entirely	_	
56-8	11467-11475	opposite	_	
56-9	11476-11488	correlations	_	
56-10	11489-11493	with	_	
56-11	11494-11497	the	_	
56-12	11498-11505	default	_	
56-13	11506-11513	network	_	
56-14	11514-11517	and	_	
56-15	11518-11533	fronto-parietal	_	
56-16	11534-11541	network	_	
56-17	11541-11542	.	_	

#Text=Power and others proposed that the functional organization of the human brain can be mainly divided into processing system, including the visual, sensorimotor and default networks, and control system, including the fronto-parietal, attention and salience networks.
57-1	11543-11548	Power	_	
57-2	11549-11552	and	_	
57-3	11553-11559	others	_	
57-4	11560-11568	proposed	_	
57-5	11569-11573	that	_	
57-6	11574-11577	the	_	
57-7	11578-11588	functional	_	
57-8	11589-11601	organization	_	
57-9	11602-11604	of	_	
57-10	11605-11608	the	_	
57-11	11609-11614	human	_	
57-12	11615-11620	brain	_	
57-13	11621-11624	can	_	
57-14	11625-11627	be	_	
57-15	11628-11634	mainly	_	
57-16	11635-11642	divided	_	
57-17	11643-11647	into	_	
57-18	11648-11658	processing	_	
57-19	11659-11665	system	_	
57-20	11665-11666	,	_	
57-21	11667-11676	including	_	
57-22	11677-11680	the	_	
57-23	11681-11687	visual	_	
57-24	11687-11688	,	_	
57-25	11689-11701	sensorimotor	_	
57-26	11702-11705	and	_	
57-27	11706-11713	default	_	
57-28	11714-11722	networks	_	
57-29	11722-11723	,	_	
57-30	11724-11727	and	_	
57-31	11728-11735	control	_	
57-32	11736-11742	system	_	
57-33	11742-11743	,	_	
57-34	11744-11753	including	_	
57-35	11754-11757	the	_	
57-36	11758-11773	fronto-parietal	_	
57-37	11773-11774	,	_	
57-38	11775-11784	attention	_	
57-39	11785-11788	and	_	
57-40	11789-11797	salience	_	
57-41	11798-11806	networks	_	
57-42	11806-11807	.	_	

#Text=The processing system are relatively stable, whereas the control system is involved in completing various dynamic tasks and is therefore more flexible, allowing it to adapt and to manage multiple complex tasks.
58-1	11808-11811	The	_	
58-2	11812-11822	processing	_	
58-3	11823-11829	system	_	
58-4	11830-11833	are	_	
58-5	11834-11844	relatively	_	
58-6	11845-11851	stable	_	
58-7	11851-11852	,	_	
58-8	11853-11860	whereas	_	
58-9	11861-11864	the	_	
58-10	11865-11872	control	_	
58-11	11873-11879	system	_	
58-12	11880-11882	is	_	
58-13	11883-11891	involved	_	
58-14	11892-11894	in	_	
58-15	11895-11905	completing	_	
58-16	11906-11913	various	_	
58-17	11914-11921	dynamic	_	
58-18	11922-11927	tasks	_	
58-19	11928-11931	and	_	
58-20	11932-11934	is	_	
58-21	11935-11944	therefore	_	
58-22	11945-11949	more	_	
58-23	11950-11958	flexible	_	
58-24	11958-11959	,	_	
58-25	11960-11968	allowing	_	
58-26	11969-11971	it	_	
58-27	11972-11974	to	_	
58-28	11975-11980	adapt	_	
58-29	11981-11984	and	_	
58-30	11985-11987	to	_	
58-31	11988-11994	manage	_	
58-32	11995-12003	multiple	_	
58-33	12004-12011	complex	_	
58-34	12012-12017	tasks	_	
58-35	12017-12018	.	_	

#Text=Moreover, in our previous study of resting-state functional connectivity density, the modulation patterns of the dopamine system on these two types of brain systems were opposite.
59-1	12019-12027	Moreover	_	
59-2	12027-12028	,	_	
59-3	12029-12031	in	_	
59-4	12032-12035	our	_	
59-5	12036-12044	previous	_	
59-6	12045-12050	study	_	
59-7	12051-12053	of	_	
59-8	12054-12067	resting-state	_	
59-9	12068-12078	functional	_	
59-10	12079-12091	connectivity	_	
59-11	12092-12099	density	_	
59-12	12099-12100	,	_	
59-13	12101-12104	the	_	
59-14	12105-12115	modulation	_	
59-15	12116-12124	patterns	_	
59-16	12125-12127	of	_	
59-17	12128-12131	the	_	
59-18	12132-12140	dopamine	_	
59-19	12141-12147	system	_	
59-20	12148-12150	on	_	
59-21	12151-12156	these	_	
59-22	12157-12160	two	_	
59-23	12161-12166	types	_	
59-24	12167-12169	of	_	
59-25	12170-12175	brain	_	
59-26	12176-12183	systems	_	
59-27	12184-12188	were	_	
59-28	12189-12197	opposite	_	
59-29	12197-12198	.	_	

#Text=These results are consistent with the regulation model of catecholaminergic signaling on stress-induced brain activity during working memory processing.
60-1	12199-12204	These	_	
60-2	12205-12212	results	_	
60-3	12213-12216	are	_	
60-4	12217-12227	consistent	_	
60-5	12228-12232	with	_	
60-6	12233-12236	the	_	
60-7	12237-12247	regulation	_	
60-8	12248-12253	model	_	
60-9	12254-12256	of	_	
60-10	12257-12274	catecholaminergic	_	
60-11	12275-12284	signaling	_	
60-12	12285-12287	on	_	
60-13	12288-12302	stress-induced	_	
60-14	12303-12308	brain	_	
60-15	12309-12317	activity	_	
60-16	12318-12324	during	_	
60-17	12325-12332	working	_	
60-18	12333-12339	memory	_	
60-19	12340-12350	processing	_	
60-20	12350-12351	.	_	

#Text=For the moment, at least, these inverse modulation patterns have been observed in several studies, although we cannot identify the neural mechanism underlying the functional system-dependent modulation of the dopamine system.
61-1	12352-12355	For	_	
61-2	12356-12359	the	_	
61-3	12360-12366	moment	_	
61-4	12366-12367	,	_	
61-5	12368-12370	at	_	
61-6	12371-12376	least	_	
61-7	12376-12377	,	_	
61-8	12378-12383	these	_	
61-9	12384-12391	inverse	_	
61-10	12392-12402	modulation	_	
61-11	12403-12411	patterns	_	
61-12	12412-12416	have	_	
61-13	12417-12421	been	_	
61-14	12422-12430	observed	_	
61-15	12431-12433	in	_	
61-16	12434-12441	several	_	
61-17	12442-12449	studies	_	
61-18	12449-12450	,	_	
61-19	12451-12459	although	_	
61-20	12460-12462	we	_	
61-21	12463-12469	cannot	_	
61-22	12470-12478	identify	_	
61-23	12479-12482	the	_	
61-24	12483-12489	neural	_	
61-25	12490-12499	mechanism	_	
61-26	12500-12510	underlying	_	
61-27	12511-12514	the	_	
61-28	12515-12525	functional	_	
61-29	12526-12542	system-dependent	_	
61-30	12543-12553	modulation	_	
61-31	12554-12556	of	_	
61-32	12557-12560	the	_	
61-33	12561-12569	dopamine	_	
61-34	12570-12576	system	_	
61-35	12576-12577	.	_	

#Text=Moreover, it is striking that only the left substructure of the dorsal striatum showed a connection with the dopamine gene-related PGRS, possibly due to brain asymmetry.
62-1	12578-12586	Moreover	_	
62-2	12586-12587	,	_	
62-3	12588-12590	it	_	
62-4	12591-12593	is	_	
62-5	12594-12602	striking	_	
62-6	12603-12607	that	_	
62-7	12608-12612	only	_	
62-8	12613-12616	the	_	
62-9	12617-12621	left	_	
62-10	12622-12634	substructure	_	
62-11	12635-12637	of	_	
62-12	12638-12641	the	_	
62-13	12642-12648	dorsal	_	
62-14	12649-12657	striatum	_	
62-15	12658-12664	showed	_	
62-16	12665-12666	a	_	
62-17	12667-12677	connection	_	
62-18	12678-12682	with	_	
62-19	12683-12686	the	_	
62-20	12687-12695	dopamine	_	
62-21	12696-12708	gene-related	_	
62-22	12709-12713	PGRS	_	
62-23	12713-12714	,	_	
62-24	12715-12723	possibly	_	
62-25	12724-12727	due	_	
62-26	12728-12730	to	_	
62-27	12731-12736	brain	_	
62-28	12737-12746	asymmetry	_	
62-29	12746-12747	.	_	

#Text=Previous studies have indicated that the levels of dopamine and dopamine transporters and the density of dopamine D2 receptors in presynaptic neurons showed right laterality in healthy controls, whereas these physiologic asymmetries are reduced in schizophrenia patients.
63-1	12748-12756	Previous	_	
63-2	12757-12764	studies	_	
63-3	12765-12769	have	_	
63-4	12770-12779	indicated	_	
63-5	12780-12784	that	_	
63-6	12785-12788	the	_	
63-7	12789-12795	levels	_	
63-8	12796-12798	of	_	
63-9	12799-12807	dopamine	_	
63-10	12808-12811	and	_	
63-11	12812-12820	dopamine	_	
63-12	12821-12833	transporters	_	
63-13	12834-12837	and	_	
63-14	12838-12841	the	_	
63-15	12842-12849	density	_	
63-16	12850-12852	of	_	
63-17	12853-12861	dopamine	_	
63-18	12862-12864	D2	_	
63-19	12865-12874	receptors	_	
63-20	12875-12877	in	_	
63-21	12878-12889	presynaptic	_	
63-22	12890-12897	neurons	_	
63-23	12898-12904	showed	_	
63-24	12905-12910	right	_	
63-25	12911-12921	laterality	_	
63-26	12922-12924	in	_	
63-27	12925-12932	healthy	_	
63-28	12933-12941	controls	_	
63-29	12941-12942	,	_	
63-30	12943-12950	whereas	_	
63-31	12951-12956	these	_	
63-32	12957-12968	physiologic	_	
63-33	12969-12980	asymmetries	_	
63-34	12981-12984	are	_	
63-35	12985-12992	reduced	_	
63-36	12993-12995	in	_	
63-37	12996-13009	schizophrenia	_	
63-38	13010-13018	patients	_	
63-39	13018-13019	.	_	

#Text=A study by Muller and others showed that schizophrenia patients exhibited weaker left-against-right asymmetry in the caudate nucleus than did healthy controls.
64-1	13020-13021	A	_	
64-2	13022-13027	study	_	
64-3	13028-13030	by	_	
64-4	13031-13037	Muller	_	
64-5	13038-13041	and	_	
64-6	13042-13048	others	_	
64-7	13049-13055	showed	_	
64-8	13056-13060	that	_	
64-9	13061-13074	schizophrenia	_	
64-10	13075-13083	patients	_	
64-11	13084-13093	exhibited	_	
64-12	13094-13100	weaker	_	
64-13	13101-13119	left-against-right	_	
64-14	13120-13129	asymmetry	_	
64-15	13130-13132	in	_	
64-16	13133-13136	the	_	
64-17	13137-13144	caudate	_	
64-18	13145-13152	nucleus	_	
64-19	13153-13157	than	_	
64-20	13158-13161	did	_	
64-21	13162-13169	healthy	_	
64-22	13170-13178	controls	_	
64-23	13178-13179	.	_	

#Text=This might indicate that the right laterality of striatal dopamine metabolism is always connected with the left-against-right asymmetry of striatal hemispheric specialization in healthy subjects and that this laterality is diminished in schizophrenia.
65-1	13180-13184	This	_	
65-2	13185-13190	might	_	
65-3	13191-13199	indicate	_	
65-4	13200-13204	that	_	
65-5	13205-13208	the	_	
65-6	13209-13214	right	_	
65-7	13215-13225	laterality	_	
65-8	13226-13228	of	_	
65-9	13229-13237	striatal	_	
65-10	13238-13246	dopamine	_	
65-11	13247-13257	metabolism	_	
65-12	13258-13260	is	_	
65-13	13261-13267	always	_	
65-14	13268-13277	connected	_	
65-15	13278-13282	with	_	
65-16	13283-13286	the	_	
65-17	13287-13305	left-against-right	_	
65-18	13306-13315	asymmetry	_	
65-19	13316-13318	of	_	
65-20	13319-13327	striatal	_	
65-21	13328-13339	hemispheric	_	
65-22	13340-13354	specialization	_	
65-23	13355-13357	in	_	
65-24	13358-13365	healthy	_	
65-25	13366-13374	subjects	_	
65-26	13375-13378	and	_	
65-27	13379-13383	that	_	
65-28	13384-13388	this	_	
65-29	13389-13399	laterality	_	
65-30	13400-13402	is	_	
65-31	13403-13413	diminished	_	
65-32	13414-13416	in	_	
65-33	13417-13430	schizophrenia	_	
65-34	13430-13431	.	_	

#Text=Thus, the structure and function of the left dorsal striatum are sensitive to risk for schizophrenia.
66-1	13432-13436	Thus	_	
66-2	13436-13437	,	_	
66-3	13438-13441	the	_	
66-4	13442-13451	structure	_	
66-5	13452-13455	and	_	
66-6	13456-13464	function	_	
66-7	13465-13467	of	_	
66-8	13468-13471	the	_	
66-9	13472-13476	left	_	
66-10	13477-13483	dorsal	_	
66-11	13484-13492	striatum	_	
66-12	13493-13496	are	_	
66-13	13497-13506	sensitive	_	
66-14	13507-13509	to	_	
66-15	13510-13514	risk	_	
66-16	13515-13518	for	_	
66-17	13519-13532	schizophrenia	_	
66-18	13532-13533	.	_	

#Text=Several deficiencies in this study cannot be ignored, particularly the following: firstly, the uncertainty of imputation for un-genotyped SNPs may be due to different choices regarding parameters such as the slide window, sample size and imputation methods; secondly, the polygenic risk score is calculated based on the assumption of additive gene effects without considering gene interaction; lastly, although the largest GWAS of schizophrenia to date was used, most of these subjects are of European ancestry.
67-1	13534-13541	Several	_	
67-2	13542-13554	deficiencies	_	
67-3	13555-13557	in	_	
67-4	13558-13562	this	_	
67-5	13563-13568	study	_	
67-6	13569-13575	cannot	_	
67-7	13576-13578	be	_	
67-8	13579-13586	ignored	_	
67-9	13586-13587	,	_	
67-10	13588-13600	particularly	_	
67-11	13601-13604	the	_	
67-12	13605-13614	following	_	
67-13	13614-13615	:	_	
67-14	13616-13623	firstly	_	
67-15	13623-13624	,	_	
67-16	13625-13628	the	_	
67-17	13629-13640	uncertainty	_	
67-18	13641-13643	of	_	
67-19	13644-13654	imputation	_	
67-20	13655-13658	for	_	
67-21	13659-13671	un-genotyped	_	
67-22	13672-13676	SNPs	_	
67-23	13677-13680	may	_	
67-24	13681-13683	be	_	
67-25	13684-13687	due	_	
67-26	13688-13690	to	_	
67-27	13691-13700	different	_	
67-28	13701-13708	choices	_	
67-29	13709-13718	regarding	_	
67-30	13719-13729	parameters	_	
67-31	13730-13734	such	_	
67-32	13735-13737	as	_	
67-33	13738-13741	the	_	
67-34	13742-13747	slide	_	
67-35	13748-13754	window	_	
67-36	13754-13755	,	_	
67-37	13756-13762	sample	_	
67-38	13763-13767	size	_	
67-39	13768-13771	and	_	
67-40	13772-13782	imputation	_	
67-41	13783-13790	methods	_	
67-42	13790-13791	;	_	
67-43	13792-13800	secondly	_	
67-44	13800-13801	,	_	
67-45	13802-13805	the	_	
67-46	13806-13815	polygenic	_	
67-47	13816-13820	risk	_	
67-48	13821-13826	score	_	
67-49	13827-13829	is	_	
67-50	13830-13840	calculated	_	
67-51	13841-13846	based	_	
67-52	13847-13849	on	_	
67-53	13850-13853	the	_	
67-54	13854-13864	assumption	_	
67-55	13865-13867	of	_	
67-56	13868-13876	additive	_	
67-57	13877-13881	gene	_	
67-58	13882-13889	effects	_	
67-59	13890-13897	without	_	
67-60	13898-13909	considering	_	
67-61	13910-13914	gene	_	
67-62	13915-13926	interaction	_	
67-63	13926-13927	;	_	
67-64	13928-13934	lastly	_	
67-65	13934-13935	,	_	
67-66	13936-13944	although	_	
67-67	13945-13948	the	_	
67-68	13949-13956	largest	_	
67-69	13957-13961	GWAS	_	
67-70	13962-13964	of	_	
67-71	13965-13978	schizophrenia	_	
67-72	13979-13981	to	_	
67-73	13982-13986	date	_	
67-74	13987-13990	was	_	
67-75	13991-13995	used	_	
67-76	13995-13996	,	_	
67-77	13997-14001	most	_	
67-78	14002-14004	of	_	
67-79	14005-14010	these	_	
67-80	14011-14019	subjects	_	
67-81	14020-14023	are	_	
67-82	14024-14026	of	_	
67-83	14027-14035	European	_	
67-84	14036-14044	ancestry	_	
67-85	14044-14045	.	_	

#Text=Previous study have found that the association between several SNPs in ZNF804A, NRGN and schizophrenia were different across distinct ethic population, the significance level in Asian populations were not across the whole genome.
68-1	14046-14054	Previous	_	
68-2	14055-14060	study	_	
68-3	14061-14065	have	_	
68-4	14066-14071	found	_	
68-5	14072-14076	that	_	
68-6	14077-14080	the	_	
68-7	14081-14092	association	_	
68-8	14093-14100	between	_	
68-9	14101-14108	several	_	
68-10	14109-14113	SNPs	_	
68-11	14114-14116	in	_	
68-12	14117-14124	ZNF804A	_	
68-13	14124-14125	,	_	
68-14	14126-14130	NRGN	_	
68-15	14131-14134	and	_	
68-16	14135-14148	schizophrenia	_	
68-17	14149-14153	were	_	
68-18	14154-14163	different	_	
68-19	14164-14170	across	_	
68-20	14171-14179	distinct	_	
68-21	14180-14185	ethic	_	
68-22	14186-14196	population	_	
68-23	14196-14197	,	_	
68-24	14198-14201	the	_	
68-25	14202-14214	significance	_	
68-26	14215-14220	level	_	
68-27	14221-14223	in	_	
68-28	14224-14229	Asian	_	
68-29	14230-14241	populations	_	
68-30	14242-14246	were	_	
68-31	14247-14250	not	_	
68-32	14251-14257	across	_	
68-33	14258-14261	the	_	
68-34	14262-14267	whole	_	
68-35	14268-14274	genome	_	
68-36	14274-14275	.	_	

#Text=However, although several genetic variants showed genetic heterogeneity among distinct populations, the combination of these variants did not statistically differ between Asian and European groups.
69-1	14276-14283	However	_	
69-2	14283-14284	,	_	
69-3	14285-14293	although	_	
69-4	14294-14301	several	_	
69-5	14302-14309	genetic	_	
69-6	14310-14318	variants	_	
69-7	14319-14325	showed	_	
69-8	14326-14333	genetic	_	
69-9	14334-14347	heterogeneity	_	
69-10	14348-14353	among	_	
69-11	14354-14362	distinct	_	
69-12	14363-14374	populations	_	
69-13	14374-14375	,	_	
69-14	14376-14379	the	_	
69-15	14380-14391	combination	_	
69-16	14392-14394	of	_	
69-17	14395-14400	these	_	
69-18	14401-14409	variants	_	
69-19	14410-14413	did	_	
69-20	14414-14417	not	_	
69-21	14418-14431	statistically	_	
69-22	14432-14438	differ	_	
69-23	14439-14446	between	_	
69-24	14447-14452	Asian	_	
69-25	14453-14456	and	_	
69-26	14457-14465	European	_	
69-27	14466-14472	groups	_	
69-28	14472-14473	.	_	

#Text=And we initially defined a loose threshold to include as many significant SNPs conferring risk for schizophrenia as possible, so our research should remain meaningful.
70-1	14474-14477	And	_	
70-2	14478-14480	we	_	
70-3	14481-14490	initially	_	
70-4	14491-14498	defined	_	
70-5	14499-14500	a	_	
70-6	14501-14506	loose	_	
70-7	14507-14516	threshold	_	
70-8	14517-14519	to	_	
70-9	14520-14527	include	_	
70-10	14528-14530	as	_	
70-11	14531-14535	many	_	
70-12	14536-14547	significant	_	
70-13	14548-14552	SNPs	_	
70-14	14553-14563	conferring	_	
70-15	14564-14568	risk	_	
70-16	14569-14572	for	_	
70-17	14573-14586	schizophrenia	_	
70-18	14587-14589	as	_	
70-19	14590-14598	possible	_	
70-20	14598-14599	,	_	
70-21	14600-14602	so	_	
70-22	14603-14606	our	_	
70-23	14607-14615	research	_	
70-24	14616-14622	should	_	
70-25	14623-14629	remain	_	
70-26	14630-14640	meaningful	_	
70-27	14640-14641	.	_	

#Text=In conclusion, the dopamine gene-related polygenic risk for schizophrenia score has predictive utility for the dorsal striatal volume, functional connectivity within the dopaminergic circuits and working memory performance.
71-1	14642-14644	In	_	
71-2	14645-14655	conclusion	_	
71-3	14655-14656	,	_	
71-4	14657-14660	the	_	
71-5	14661-14669	dopamine	_	
71-6	14670-14682	gene-related	_	
71-7	14683-14692	polygenic	_	
71-8	14693-14697	risk	_	
71-9	14698-14701	for	_	
71-10	14702-14715	schizophrenia	_	
71-11	14716-14721	score	_	
71-12	14722-14725	has	_	
71-13	14726-14736	predictive	_	
71-14	14737-14744	utility	_	
71-15	14745-14748	for	_	
71-16	14749-14752	the	_	
71-17	14753-14759	dorsal	_	
71-18	14760-14768	striatal	_	
71-19	14769-14775	volume	_	
71-20	14775-14776	,	_	
71-21	14777-14787	functional	_	
71-22	14788-14800	connectivity	_	
71-23	14801-14807	within	_	
71-24	14808-14811	the	_	
71-25	14812-14824	dopaminergic	_	
71-26	14825-14833	circuits	_	
71-27	14834-14837	and	_	
71-28	14838-14845	working	_	
71-29	14846-14852	memory	_	
71-30	14853-14864	performance	_	
71-31	14864-14865	.	_	

#Text=Furthermore, we only included genes associated with the dopaminergic genetic pathway in order to minimize the confounding effects of other types of neurotransmitters on schizophrenia-related brain regions.
72-1	14866-14877	Furthermore	_	
72-2	14877-14878	,	_	
72-3	14879-14881	we	_	
72-4	14882-14886	only	_	
72-5	14887-14895	included	_	
72-6	14896-14901	genes	_	
72-7	14902-14912	associated	_	
72-8	14913-14917	with	_	
72-9	14918-14921	the	_	
72-10	14922-14934	dopaminergic	_	
72-11	14935-14942	genetic	_	
72-12	14943-14950	pathway	_	
72-13	14951-14953	in	_	
72-14	14954-14959	order	_	
72-15	14960-14962	to	_	
72-16	14963-14971	minimize	_	
72-17	14972-14975	the	_	
72-18	14976-14987	confounding	_	
72-19	14988-14995	effects	_	
72-20	14996-14998	of	_	
72-21	14999-15004	other	_	
72-22	15005-15010	types	_	
72-23	15011-15013	of	_	
72-24	15014-15031	neurotransmitters	_	
72-25	15032-15034	on	_	
72-26	15035-15056	schizophrenia-related	_	
72-27	15057-15062	brain	_	
72-28	15063-15070	regions	_	
72-29	15070-15071	.	_	

#Text=This approach may help us to clarify the underlying neurobiological mechanism of “the dopamine hypothesis” for schizophrenia, and provide some evidences regarding the polygenic risk for schizophrenia.
73-1	15072-15076	This	_	
73-2	15077-15085	approach	_	
73-3	15086-15089	may	_	
73-4	15090-15094	help	_	
73-5	15095-15097	us	_	
73-6	15098-15100	to	_	
73-7	15101-15108	clarify	_	
73-8	15109-15112	the	_	
73-9	15113-15123	underlying	_	
73-10	15124-15139	neurobiological	_	
73-11	15140-15149	mechanism	_	
73-12	15150-15152	of	_	
73-13	15153-15154	“	_	
73-14	15154-15157	the	_	
73-15	15158-15166	dopamine	_	
73-16	15167-15177	hypothesis	_	
73-17	15177-15178	”	_	
73-18	15179-15182	for	_	
73-19	15183-15196	schizophrenia	_	
73-20	15196-15197	,	_	
73-21	15198-15201	and	_	
73-22	15202-15209	provide	_	
73-23	15210-15214	some	_	
73-24	15215-15224	evidences	_	
73-25	15225-15234	regarding	_	
73-26	15235-15238	the	_	
73-27	15239-15248	polygenic	_	
73-28	15249-15253	risk	_	
73-29	15254-15257	for	_	
73-30	15258-15271	schizophrenia	_	
73-31	15271-15272	.	_	

#Text=Future studies are warranted to investigate the effects of different subgroups of dopamine functioning, which might help us elucidate the effect of dopaminergic activity in the risk for schizophrenia.
74-1	15273-15279	Future	_	
74-2	15280-15287	studies	_	
74-3	15288-15291	are	_	
74-4	15292-15301	warranted	_	
74-5	15302-15304	to	_	
74-6	15305-15316	investigate	_	
74-7	15317-15320	the	_	
74-8	15321-15328	effects	_	
74-9	15329-15331	of	_	
74-10	15332-15341	different	_	
74-11	15342-15351	subgroups	_	
74-12	15352-15354	of	_	
74-13	15355-15363	dopamine	_	
74-14	15364-15375	functioning	_	
74-15	15375-15376	,	_	
74-16	15377-15382	which	_	
74-17	15383-15388	might	_	
74-18	15389-15393	help	_	
74-19	15394-15396	us	_	
74-20	15397-15406	elucidate	_	
74-21	15407-15410	the	_	
74-22	15411-15417	effect	_	
74-23	15418-15420	of	_	
74-24	15421-15433	dopaminergic	_	
74-25	15434-15442	activity	_	
74-26	15443-15445	in	_	
74-27	15446-15449	the	_	
74-28	15450-15454	risk	_	
74-29	15455-15458	for	_	
74-30	15459-15472	schizophrenia	_	
74-31	15472-15473	.	_	

#Text=Materials and Methods
#Text=Subjects
#Text=Demographic Characteristics of the participants.
75-1	15474-15483	Materials	http://www.case.edu/ProvCaRe/provcare#StudyMethod[1]	
75-2	15484-15487	and	http://www.case.edu/ProvCaRe/provcare#StudyMethod[1]	
75-3	15488-15495	Methods	http://www.case.edu/ProvCaRe/provcare#StudyMethod[1]	
75-4	15496-15504	Subjects	_	
75-5	15505-15516	Demographic	_	
75-6	15517-15532	Characteristics	_	
75-7	15533-15535	of	_	
75-8	15536-15539	the	_	
75-9	15540-15552	participants	_	
75-10	15552-15553	.	_	

#Text=Demographic Characteristics\t \tNumber of subjects\t315\t \tMale (%)\t48.9%\t \tAge (Mean )\t22.73 ± 2.50\t \tAge range\t18–31 years\t \t
#Text=Three hundred twenty-three healthy young Chinese subjects (mean age: 22.7 ± 2.5 years; age range = 18–31 years; 157 males) were recruited.
76-1	15555-15566	Demographic	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[2]	
76-2	15567-15582	Characteristics	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[2]	
76-3	15585-15591	Number	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[2]	
76-4	15592-15594	of	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[2]	
76-5	15595-15603	subjects	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[2]	
76-6	15604-15607	315	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[2]	
76-7	15610-15614	Male	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[2]	
76-8	15615-15616	(	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[2]	
76-9	15616-15617	%	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[2]	
76-10	15617-15618	)	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[2]	
76-11	15619-15624	48.9%	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[2]	
76-12	15627-15630	Age	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[2]	
76-13	15631-15632	(	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[2]	
76-14	15632-15636	Mean	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[2]	
76-15	15637-15638	)	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[2]	
76-16	15639-15644	22.73	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[2]	
76-17	15645-15646	±	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[2]	
76-18	15647-15651	2.50	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[2]	
76-19	15654-15657	Age	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[2]	
76-20	15658-15663	range	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[2]	
76-21	15664-15666	18	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[2]	
76-22	15666-15667	–	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[2]	
76-23	15667-15669	31	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[2]	
76-24	15670-15675	years	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[2]	
76-25	15679-15684	Three	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[2]	
76-26	15685-15692	hundred	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[2]	
76-27	15693-15705	twenty-three	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[2]	
76-28	15706-15713	healthy	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[2]	
76-29	15714-15719	young	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[2]	
76-30	15720-15727	Chinese	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[2]	
76-31	15728-15736	subjects	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[2]	
76-32	15737-15738	(	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[2]	
76-33	15738-15742	mean	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[2]	
76-34	15743-15746	age	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[2]	
76-35	15746-15747	:	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[2]	
76-36	15748-15752	22.7	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[2]	
76-37	15753-15754	±	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[2]	
76-38	15755-15758	2.5	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[2]	
76-39	15759-15764	years	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[2]	
76-40	15764-15765	;	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[2]	
76-41	15766-15769	age	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[2]	
76-42	15770-15775	range	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[2]	
76-43	15776-15777	=	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[2]	
76-44	15778-15780	18	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[2]	
76-45	15780-15781	–	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[2]	
76-46	15781-15783	31	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[2]	
76-47	15784-15789	years	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[2]	
76-48	15789-15790	;	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[2]	
76-49	15791-15794	157	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[2]	
76-50	15795-15800	males	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[2]	
76-51	15800-15801	)	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[2]	
76-52	15802-15806	were	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[2]	
76-53	15807-15816	recruited	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[2]	
76-54	15816-15817	.	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[2]	

#Text=The exclusion criteria were identical to our previous study that used the same database.
77-1	15818-15821	The	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[3]	
77-2	15822-15831	exclusion	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[3]	
77-3	15832-15840	criteria	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[3]	
77-4	15841-15845	were	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[3]	
77-5	15846-15855	identical	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[3]	
77-6	15856-15858	to	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[3]	
77-7	15859-15862	our	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[3]	
77-8	15863-15871	previous	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[3]	
77-9	15872-15877	study	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[3]	
77-10	15878-15882	that	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[3]	
77-11	15883-15887	used	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[3]	
77-12	15888-15891	the	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[3]	
77-13	15892-15896	same	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[3]	
77-14	15897-15905	database	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[3]	
77-15	15905-15906	.	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[3]	

#Text=We carefully asked subjects to ensure that had no personal or family history of neurological or psychiatric disease, head injury, psychiatric treatment, drug or alcohol abuse, hypothyroidism or other mental diseases and no contraindications to magnetic resonance imaging (MRI) screening.
78-1	15907-15909	We	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[4]	
78-2	15910-15919	carefully	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[4]	
78-3	15920-15925	asked	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[4]	
78-4	15926-15934	subjects	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[4]	
78-5	15935-15937	to	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[4]	
78-6	15938-15944	ensure	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[4]	
78-7	15945-15949	that	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[4]	
78-8	15950-15953	had	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[4]	
78-9	15954-15956	no	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[4]	
78-10	15957-15965	personal	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[4]	
78-11	15966-15968	or	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[4]	
78-12	15969-15975	family	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[4]	
78-13	15976-15983	history	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[4]	
78-14	15984-15986	of	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[4]	
78-15	15987-15999	neurological	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[4]	
78-16	16000-16002	or	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[4]	
78-17	16003-16014	psychiatric	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[4]	
78-18	16015-16022	disease	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[4]	
78-19	16022-16023	,	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[4]	
78-20	16024-16028	head	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[4]	
78-21	16029-16035	injury	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[4]	
78-22	16035-16036	,	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[4]	
78-23	16037-16048	psychiatric	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[4]	
78-24	16049-16058	treatment	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[4]	
78-25	16058-16059	,	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[4]	
78-26	16060-16064	drug	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[4]	
78-27	16065-16067	or	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[4]	
78-28	16068-16075	alcohol	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[4]	
78-29	16076-16081	abuse	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[4]	
78-30	16081-16082	,	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[4]	
78-31	16083-16097	hypothyroidism	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[4]	
78-32	16098-16100	or	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[4]	
78-33	16101-16106	other	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[4]	
78-34	16107-16113	mental	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[4]	
78-35	16114-16122	diseases	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[4]	
78-36	16123-16126	and	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[4]	
78-37	16127-16129	no	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[4]	
78-38	16130-16147	contraindications	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[4]	
78-39	16148-16150	to	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[4]	
78-40	16151-16159	magnetic	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[4]|http://maven.renci.org/NeuroBridge/neurobridge#MagneticResonanceImaging[5]	
78-41	16160-16169	resonance	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[4]|http://maven.renci.org/NeuroBridge/neurobridge#MagneticResonanceImaging[5]	
78-42	16170-16177	imaging	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[4]|http://maven.renci.org/NeuroBridge/neurobridge#MagneticResonanceImaging[5]	
78-43	16178-16179	(	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[4]|http://maven.renci.org/NeuroBridge/neurobridge#MagneticResonanceImaging[5]	
78-44	16179-16182	MRI	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[4]|http://maven.renci.org/NeuroBridge/neurobridge#MagneticResonanceImaging[5]	
78-45	16182-16183	)	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[4]|http://maven.renci.org/NeuroBridge/neurobridge#MagneticResonanceImaging[5]	
78-46	16184-16193	screening	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[4]	
78-47	16193-16194	.	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[4]	

#Text=All of the participants and their first-degree relatives had no history of psychiatric disease.
79-1	16195-16198	All	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[6]	
79-2	16199-16201	of	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[6]	
79-3	16202-16205	the	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[6]	
79-4	16206-16218	participants	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[6]	
79-5	16219-16222	and	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[6]	
79-6	16223-16228	their	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[6]	
79-7	16229-16241	first-degree	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[6]	
79-8	16242-16251	relatives	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[6]	
79-9	16252-16255	had	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[6]	
79-10	16256-16258	no	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[6]	
79-11	16259-16266	history	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[6]	
79-12	16267-16269	of	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[6]	
79-13	16270-16281	psychiatric	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[6]	
79-14	16282-16289	disease	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[6]	
79-15	16289-16290	.	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[6]	

#Text=The study was approved by the local Medical Research Ethics Committee of Tianjin Medical University.
80-1	16291-16294	The	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[7]	
80-2	16295-16300	study	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[7]	
80-3	16301-16304	was	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[7]	
80-4	16305-16313	approved	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[7]	
80-5	16314-16316	by	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[7]	
80-6	16317-16320	the	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[7]	
80-7	16321-16326	local	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[7]	
80-8	16327-16334	Medical	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[7]	
80-9	16335-16343	Research	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[7]	
80-10	16344-16350	Ethics	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[7]	
80-11	16351-16360	Committee	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[7]	
80-12	16361-16363	of	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[7]	
80-13	16364-16371	Tianjin	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[7]	
80-14	16372-16379	Medical	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[7]	
80-15	16380-16390	University	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[7]	
80-16	16390-16391	.	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[7]	

#Text=All experimental methods were performed in accordance with the relevant guidelines and regulations, and written informed consents were obtained from each subject.
81-1	16392-16395	All	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[8]	
81-2	16396-16408	experimental	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[8]	
81-3	16409-16416	methods	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[8]	
81-4	16417-16421	were	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[8]	
81-5	16422-16431	performed	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[8]	
81-6	16432-16434	in	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[8]	
81-7	16435-16445	accordance	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[8]	
81-8	16446-16450	with	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[8]	
81-9	16451-16454	the	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[8]	
81-10	16455-16463	relevant	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[8]	
81-11	16464-16474	guidelines	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[8]	
81-12	16475-16478	and	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[8]	
81-13	16479-16490	regulations	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[8]	
81-14	16490-16491	,	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[8]	
81-15	16492-16495	and	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[8]	
81-16	16496-16503	written	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[8]	
81-17	16504-16512	informed	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[8]	
81-18	16513-16521	consents	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[8]	
81-19	16522-16526	were	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[8]	
81-20	16527-16535	obtained	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[8]	
81-21	16536-16540	from	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[8]	
81-22	16541-16545	each	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[8]	
81-23	16546-16553	subject	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[8]	
81-24	16553-16554	.	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[8]	

#Text=N-back working memory tasks were used to assess working memory before MRI acquisition.
82-1	16555-16561	N-back	http://maven.renci.org/NeuroBridge/neurobridge#N-BackTaskTest	
82-2	16562-16569	working	_	
82-3	16570-16576	memory	_	
82-4	16577-16582	tasks	_	
82-5	16583-16587	were	_	
82-6	16588-16592	used	_	
82-7	16593-16595	to	_	
82-8	16596-16602	assess	_	
82-9	16603-16610	working	_	
82-10	16611-16617	memory	_	
82-11	16618-16624	before	_	
82-12	16625-16628	MRI	http://maven.renci.org/NeuroBridge/neurobridge#MagneticResonanceImaging	
82-13	16629-16640	acquisition	_	
82-14	16640-16641	.	_	

#Text=The letter 2-back and 3-back tasks were described previously.
83-1	16642-16645	The	_	
83-2	16646-16652	letter	_	
83-3	16653-16654	2	_	
83-4	16654-16655	-	_	
83-5	16655-16659	back	_	
83-6	16660-16663	and	_	
83-7	16664-16665	3	_	
83-8	16665-16666	-	_	
83-9	16666-16670	back	_	
83-10	16671-16676	tasks	_	
83-11	16677-16681	were	_	
83-12	16682-16691	described	_	
83-13	16692-16702	previously	_	
83-14	16702-16703	.	_	

#Text=Briefly speaking, a series of letters were sequentially presented on the screen, each subject was asked to view and judge whether the letter of the current screen was identical to the one displayed two trials (2-back) and three trials (3-back) back.
84-1	16704-16711	Briefly	_	
84-2	16712-16720	speaking	_	
84-3	16720-16721	,	_	
84-4	16722-16723	a	_	
84-5	16724-16730	series	_	
84-6	16731-16733	of	_	
84-7	16734-16741	letters	_	
84-8	16742-16746	were	_	
84-9	16747-16759	sequentially	_	
84-10	16760-16769	presented	_	
84-11	16770-16772	on	_	
84-12	16773-16776	the	_	
84-13	16777-16783	screen	_	
84-14	16783-16784	,	_	
84-15	16785-16789	each	_	
84-16	16790-16797	subject	_	
84-17	16798-16801	was	_	
84-18	16802-16807	asked	_	
84-19	16808-16810	to	_	
84-20	16811-16815	view	_	
84-21	16816-16819	and	_	
84-22	16820-16825	judge	_	
84-23	16826-16833	whether	_	
84-24	16834-16837	the	_	
84-25	16838-16844	letter	_	
84-26	16845-16847	of	_	
84-27	16848-16851	the	_	
84-28	16852-16859	current	_	
84-29	16860-16866	screen	_	
84-30	16867-16870	was	_	
84-31	16871-16880	identical	_	
84-32	16881-16883	to	_	
84-33	16884-16887	the	_	
84-34	16888-16891	one	_	
84-35	16892-16901	displayed	_	
84-36	16902-16905	two	_	
84-37	16906-16912	trials	_	
84-38	16913-16914	(	_	
84-39	16914-16915	2	_	
84-40	16915-16916	-	_	
84-41	16916-16920	back	_	
84-42	16920-16921	)	_	
84-43	16922-16925	and	_	
84-44	16926-16931	three	_	
84-45	16932-16938	trials	_	
84-46	16939-16940	(	_	
84-47	16940-16941	3	_	
84-48	16941-16942	-	_	
84-49	16942-16946	back	_	
84-50	16946-16947	)	_	
84-51	16948-16952	back	_	
84-52	16952-16953	.	_	

#Text=The N-back task contained three blocks (30 trials each block).
85-1	16954-16957	The	_	
85-2	16958-16964	N-back	_	
85-3	16965-16969	task	_	
85-4	16970-16979	contained	_	
85-5	16980-16985	three	_	
85-6	16986-16992	blocks	_	
85-7	16993-16994	(	_	
85-8	16994-16996	30	_	
85-9	16997-17003	trials	_	
85-10	17004-17008	each	_	
85-11	17009-17014	block	_	
85-12	17014-17015	)	_	
85-13	17015-17016	.	_	

#Text=Before the formal tasks, participants were instructed and took a practice.
86-1	17017-17023	Before	_	
86-2	17024-17027	the	_	
86-3	17028-17034	formal	_	
86-4	17035-17040	tasks	_	
86-5	17040-17041	,	_	
86-6	17042-17054	participants	_	
86-7	17055-17059	were	_	
86-8	17060-17070	instructed	_	
86-9	17071-17074	and	_	
86-10	17075-17079	took	_	
86-11	17080-17081	a	_	
86-12	17082-17090	practice	_	
86-13	17090-17091	.	_	

#Text=The numbers of correct and false responses were recorded to compute the accuracy as the index of working memory.
87-1	17092-17095	The	_	
87-2	17096-17103	numbers	_	
87-3	17104-17106	of	_	
87-4	17107-17114	correct	_	
87-5	17115-17118	and	_	
87-6	17119-17124	false	_	
87-7	17125-17134	responses	_	
87-8	17135-17139	were	_	
87-9	17140-17148	recorded	_	
87-10	17149-17151	to	_	
87-11	17152-17159	compute	_	
87-12	17160-17163	the	_	
87-13	17164-17172	accuracy	_	
87-14	17173-17175	as	_	
87-15	17176-17179	the	_	
87-16	17180-17185	index	_	
87-17	17186-17188	of	_	
87-18	17189-17196	working	_	
87-19	17197-17203	memory	_	
87-20	17203-17204	.	_	

#Text=Eight subjects were discarded from further analysis due to missing genotype data (see Table 1 for demographic characteristics).
88-1	17205-17210	Eight	_	
88-2	17211-17219	subjects	_	
88-3	17220-17224	were	_	
88-4	17225-17234	discarded	_	
88-5	17235-17239	from	_	
88-6	17240-17247	further	_	
88-7	17248-17256	analysis	_	
88-8	17257-17260	due	_	
88-9	17261-17263	to	_	
88-10	17264-17271	missing	_	
88-11	17272-17280	genotype	_	
88-12	17281-17285	data	_	
88-13	17286-17287	(	_	
88-14	17287-17290	see	_	
88-15	17291-17296	Table	_	
88-16	17296-17297	 	_	
88-17	17297-17298	1	_	
88-18	17299-17302	for	_	
88-19	17303-17314	demographic	_	
88-20	17315-17330	characteristics	_	
88-21	17330-17331	)	_	
88-22	17331-17332	.	_	

#Text=DNA extraction and genotyping
#Text=DNA was extracted from venous whole blood samples treated with ethylene diamine tetraaceticacid (EDTA) as an anticoagulant by using the EZgene Blood gDNAMiniprep Kit (BioMiga, San Diego, CA).
89-1	17333-17336	DNA	_	
89-2	17337-17347	extraction	_	
89-3	17348-17351	and	_	
89-4	17352-17362	genotyping	_	
89-5	17363-17366	DNA	_	
89-6	17367-17370	was	_	
89-7	17371-17380	extracted	_	
89-8	17381-17385	from	_	
89-9	17386-17392	venous	_	
89-10	17393-17398	whole	_	
89-11	17399-17404	blood	_	
89-12	17405-17412	samples	_	
89-13	17413-17420	treated	_	
89-14	17421-17425	with	_	
89-15	17426-17434	ethylene	_	
89-16	17435-17442	diamine	_	
89-17	17443-17458	tetraaceticacid	_	
89-18	17459-17460	(	_	
89-19	17460-17464	EDTA	_	
89-20	17464-17465	)	_	
89-21	17466-17468	as	_	
89-22	17469-17471	an	_	
89-23	17472-17485	anticoagulant	_	
89-24	17486-17488	by	_	
89-25	17489-17494	using	_	
89-26	17495-17498	the	_	
89-27	17499-17505	EZgene	_	
89-28	17506-17511	Blood	_	
89-29	17512-17524	gDNAMiniprep	_	
89-30	17525-17528	Kit	_	
89-31	17529-17530	(	_	
89-32	17530-17537	BioMiga	_	
89-33	17537-17538	,	_	
89-34	17539-17542	San	_	
89-35	17543-17548	Diego	_	
89-36	17548-17549	,	_	
89-37	17550-17552	CA	_	
89-38	17552-17553	)	_	
89-39	17553-17554	.	_	

#Text=Genotyping used the standard Illumina genotyping protocol (Illumina) on Illumina Human OmniZhongHua-8 Bead Chips.
90-1	17555-17565	Genotyping	_	
90-2	17566-17570	used	_	
90-3	17571-17574	the	_	
90-4	17575-17583	standard	_	
90-5	17584-17592	Illumina	_	
90-6	17593-17603	genotyping	_	
90-7	17604-17612	protocol	_	
90-8	17613-17614	(	_	
90-9	17614-17622	Illumina	_	
90-10	17622-17623	)	_	
90-11	17624-17626	on	_	
90-12	17627-17635	Illumina	_	
90-13	17636-17641	Human	_	
90-14	17642-17654	OmniZhongHua	_	
90-15	17654-17655	-	_	
90-16	17655-17656	8	_	
90-17	17657-17661	Bead	_	
90-18	17662-17667	Chips	_	
90-19	17667-17668	.	_	

#Text=The following quality control procedures were carried out using PLINK version 1.07.
91-1	17669-17672	The	_	
91-2	17673-17682	following	_	
91-3	17683-17690	quality	_	
91-4	17691-17698	control	_	
91-5	17699-17709	procedures	_	
91-6	17710-17714	were	_	
91-7	17715-17722	carried	_	
91-8	17723-17726	out	_	
91-9	17727-17732	using	_	
91-10	17733-17738	PLINK	_	
91-11	17739-17746	version	_	
91-12	17747-17751	1.07	_	
91-13	17751-17752	.	_	

#Text=The SNPs were removed where the call rate was <95%, if the minor allele frequency was <1%, or if the χ2 test of Hardy-Weinberg equilibrium was <10−3.
92-1	17753-17756	The	_	
92-2	17757-17761	SNPs	_	
92-3	17762-17766	were	_	
92-4	17767-17774	removed	_	
92-5	17775-17780	where	_	
92-6	17781-17784	the	_	
92-7	17785-17789	call	_	
92-8	17790-17794	rate	_	
92-9	17795-17798	was	_	
92-10	17799-17800	<	_	
92-11	17800-17803	95%	_	
92-12	17803-17804	,	_	
92-13	17805-17807	if	_	
92-14	17808-17811	the	_	
92-15	17812-17817	minor	_	
92-16	17818-17824	allele	_	
92-17	17825-17834	frequency	_	
92-18	17835-17838	was	_	
92-19	17839-17840	<	_	
92-20	17840-17842	1%	_	
92-21	17842-17843	,	_	
92-22	17844-17846	or	_	
92-23	17847-17849	if	_	
92-24	17850-17853	the	_	
92-25	17854-17856	χ2	_	
92-26	17857-17861	test	_	
92-27	17862-17864	of	_	
92-28	17865-17879	Hardy-Weinberg	_	
92-29	17880-17891	equilibrium	_	
92-30	17892-17895	was	_	
92-31	17896-17897	<	_	
92-32	17897-17899	10	_	
92-33	17899-17900	−	_	
92-34	17900-17901	3	_	
92-35	17901-17902	.	_	

#Text=In addition, individuals were removed from the study if their missing genotype rates were >5%, if the estimate of pairwise identity-by-descent (IBD) was >0.1875, or if the gender identified by X chromosome markers differed from the patient records.
93-1	17903-17905	In	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[9]	
93-2	17906-17914	addition	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[9]	
93-3	17914-17915	,	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[9]	
93-4	17916-17927	individuals	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[9]	
93-5	17928-17932	were	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[9]	
93-6	17933-17940	removed	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[9]	
93-7	17941-17945	from	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[9]	
93-8	17946-17949	the	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[9]	
93-9	17950-17955	study	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[9]	
93-10	17956-17958	if	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[9]	
93-11	17959-17964	their	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[9]	
93-12	17965-17972	missing	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[9]	
93-13	17973-17981	genotype	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[9]	
93-14	17982-17987	rates	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[9]	
93-15	17988-17992	were	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[9]	
93-16	17993-17994	>	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[9]	
93-17	17994-17996	5%	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[9]	
93-18	17996-17997	,	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[9]	
93-19	17998-18000	if	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[9]	
93-20	18001-18004	the	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[9]	
93-21	18005-18013	estimate	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[9]	
93-22	18014-18016	of	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[9]	
93-23	18017-18025	pairwise	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[9]	
93-24	18026-18045	identity-by-descent	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[9]	
93-25	18046-18047	(	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[9]	
93-26	18047-18050	IBD	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[9]	
93-27	18050-18051	)	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[9]	
93-28	18052-18055	was	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[9]	
93-29	18056-18057	>	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[9]	
93-30	18057-18063	0.1875	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[9]	
93-31	18063-18064	,	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[9]	
93-32	18065-18067	or	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[9]	
93-33	18068-18070	if	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[9]	
93-34	18071-18074	the	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[9]	
93-35	18075-18081	gender	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[9]	
93-36	18082-18092	identified	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[9]	
93-37	18093-18095	by	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[9]	
93-38	18096-18097	X	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[9]	
93-39	18098-18108	chromosome	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[9]	
93-40	18109-18116	markers	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[9]	
93-41	18117-18125	differed	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[9]	
93-42	18126-18130	from	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[9]	
93-43	18131-18134	the	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[9]	
93-44	18135-18142	patient	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[9]	
93-45	18143-18150	records	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[9]	
93-46	18150-18151	.	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[9]	

#Text=To control for population stratification, we ascertained population structure using principal component analyses (PCA) in EIGENSTRAT software (http://www.hsph.harvard.edu/alkes-price/files/eigensoftfaq.htm) on autosomal SNPs with the HapMap phase 3 reference data set.
94-1	18152-18154	To	_	
94-2	18155-18162	control	_	
94-3	18163-18166	for	_	
94-4	18167-18177	population	_	
94-5	18178-18192	stratification	_	
94-6	18192-18193	,	_	
94-7	18194-18196	we	_	
94-8	18197-18208	ascertained	_	
94-9	18209-18219	population	_	
94-10	18220-18229	structure	_	
94-11	18230-18235	using	_	
94-12	18236-18245	principal	_	
94-13	18246-18255	component	_	
94-14	18256-18264	analyses	_	
94-15	18265-18266	(	_	
94-16	18266-18269	PCA	_	
94-17	18269-18270	)	_	
94-18	18271-18273	in	_	
94-19	18274-18284	EIGENSTRAT	_	
94-20	18285-18293	software	_	
94-21	18294-18295	(	_	
94-22	18295-18299	http	_	
94-23	18299-18300	:	_	
94-24	18300-18301	/	_	
94-25	18301-18302	/	_	
94-26	18302-18322	www.hsph.harvard.edu	_	
94-27	18322-18323	/	_	
94-28	18323-18334	alkes-price	_	
94-29	18334-18335	/	_	
94-30	18335-18340	files	_	
94-31	18340-18341	/	_	
94-32	18341-18357	eigensoftfaq.htm	_	
94-33	18357-18358	)	_	
94-34	18359-18361	on	_	
94-35	18362-18371	autosomal	_	
94-36	18372-18376	SNPs	_	
94-37	18377-18381	with	_	
94-38	18382-18385	the	_	
94-39	18386-18392	HapMap	_	
94-40	18393-18398	phase	_	
94-41	18399-18400	3	_	
94-42	18401-18410	reference	_	
94-43	18411-18415	data	_	
94-44	18416-18419	set	_	
94-45	18419-18420	.	_	

#Text=Prior to the PCA, we removed chromosomal regions of long-range linkage disequilibrium (LD) and retained SNPs that were in low LD with each other.
95-1	18421-18426	Prior	_	
95-2	18427-18429	to	_	
95-3	18430-18433	the	_	
95-4	18434-18437	PCA	_	
95-5	18437-18438	,	_	
95-6	18439-18441	we	_	
95-7	18442-18449	removed	_	
95-8	18450-18461	chromosomal	_	
95-9	18462-18469	regions	_	
95-10	18470-18472	of	_	
95-11	18473-18483	long-range	_	
95-12	18484-18491	linkage	_	
95-13	18492-18506	disequilibrium	_	
95-14	18507-18508	(	_	
95-15	18508-18510	LD	_	
95-16	18510-18511	)	_	
95-17	18512-18515	and	_	
95-18	18516-18524	retained	_	
95-19	18525-18529	SNPs	_	
95-20	18530-18534	that	_	
95-21	18535-18539	were	_	
95-22	18540-18542	in	_	
95-23	18543-18546	low	_	
95-24	18547-18549	LD	_	
95-25	18550-18554	with	_	
95-26	18555-18559	each	_	
95-27	18560-18565	other	_	
95-28	18565-18566	.	_	

#Text=After extracting 10 principal components, we removed the samples outside 6 standard deviations.
96-1	18567-18572	After	_	
96-2	18573-18583	extracting	_	
96-3	18584-18586	10	_	
96-4	18587-18596	principal	_	
96-5	18597-18607	components	_	
96-6	18607-18608	,	_	
96-7	18609-18611	we	_	
96-8	18612-18619	removed	_	
96-9	18620-18623	the	_	
96-10	18624-18631	samples	_	
96-11	18632-18639	outside	_	
96-12	18640-18641	6	_	
96-13	18642-18650	standard	_	
96-14	18651-18661	deviations	_	
96-15	18661-18662	.	_	

#Text=The data were then imputed using SHAPEITv2 (https://mathgen.stats.ox.ac.uk/genetics_software/shapeit/shapeit.html) and IMPUTE2 (https://mathgen.stats.ox.ac.uk/impute/impute_v2.html) with the 1000 Genomes Phase 1 reference dataset.
97-1	18663-18666	The	_	
97-2	18667-18671	data	_	
97-3	18672-18676	were	_	
97-4	18677-18681	then	_	
97-5	18682-18689	imputed	_	
97-6	18690-18695	using	_	
97-7	18696-18705	SHAPEITv2	_	
97-8	18706-18707	(	_	
97-9	18707-18712	https	_	
97-10	18712-18713	:	_	
97-11	18713-18714	/	_	
97-12	18714-18715	/	_	
97-13	18715-18737	mathgen.stats.ox.ac.uk	_	
97-14	18737-18738	/	_	
97-15	18738-18755	genetics_software	_	
97-16	18755-18756	/	_	
97-17	18756-18763	shapeit	_	
97-18	18763-18764	/	_	
97-19	18764-18776	shapeit.html	_	
97-20	18776-18777	)	_	
97-21	18778-18781	and	_	
97-22	18782-18789	IMPUTE2	_	
97-23	18790-18791	(	_	
97-24	18791-18796	https	_	
97-25	18796-18797	:	_	
97-26	18797-18798	/	_	
97-27	18798-18799	/	_	
97-28	18799-18821	mathgen.stats.ox.ac.uk	_	
97-29	18821-18822	/	_	
97-30	18822-18828	impute	_	
97-31	18828-18829	/	_	
97-32	18829-18838	impute_v2	_	
97-33	18838-18839	.	_	
97-34	18839-18843	html	_	
97-35	18843-18844	)	_	
97-36	18845-18849	with	_	
97-37	18850-18853	the	_	
97-38	18854-18858	1000	_	
97-39	18859-18866	Genomes	_	
97-40	18867-18872	Phase	_	
97-41	18873-18874	1	_	
97-42	18875-18884	reference	_	
97-43	18885-18892	dataset	_	
97-44	18892-18893	.	_	

#Text=Further analyses focused on 315 subjects with more than 7 million autosomal SNPs, whose imputation quality scores were greater than 0.8.
98-1	18894-18901	Further	_	
98-2	18902-18910	analyses	_	
98-3	18911-18918	focused	_	
98-4	18919-18921	on	_	
98-5	18922-18925	315	_	
98-6	18926-18934	subjects	_	
98-7	18935-18939	with	_	
98-8	18940-18944	more	_	
98-9	18945-18949	than	_	
98-10	18950-18951	7	_	
98-11	18952-18959	million	_	
98-12	18960-18969	autosomal	_	
98-13	18970-18974	SNPs	_	
98-14	18974-18975	,	_	
98-15	18976-18981	whose	_	
98-16	18982-18992	imputation	_	
98-17	18993-19000	quality	_	
98-18	19001-19007	scores	_	
98-19	19008-19012	were	_	
98-20	19013-19020	greater	_	
98-21	19021-19025	than	_	
98-22	19026-19029	0.8	_	
98-23	19029-19030	.	_	

#Text=Computation of dopamine genes-related PGRS
#Text=We used the “score” function implemented in PLINK to compute the dopamine genes-related polygenic schizophrenia-risk score.
99-1	19031-19042	Computation	_	
99-2	19043-19045	of	_	
99-3	19046-19054	dopamine	_	
99-4	19055-19068	genes-related	_	
99-5	19069-19073	PGRS	_	
99-6	19074-19076	We	_	
99-7	19077-19081	used	_	
99-8	19082-19085	the	_	
99-9	19086-19087	“	_	
99-10	19087-19092	score	_	
99-11	19092-19093	”	_	
99-12	19094-19102	function	_	
99-13	19103-19114	implemented	_	
99-14	19115-19117	in	_	
99-15	19118-19123	PLINK	_	
99-16	19124-19126	to	_	
99-17	19127-19134	compute	_	
99-18	19135-19138	the	_	
99-19	19139-19147	dopamine	_	
99-20	19148-19161	genes-related	_	
99-21	19162-19171	polygenic	_	
99-22	19172-19190	schizophrenia-risk	_	
99-23	19191-19196	score	_	
99-24	19196-19197	.	_	

#Text=The PGRS was calculated according to the method developed by Purcell et al..
100-1	19198-19201	The	_	
100-2	19202-19206	PGRS	_	
100-3	19207-19210	was	_	
100-4	19211-19221	calculated	_	
100-5	19222-19231	according	_	
100-6	19232-19234	to	_	
100-7	19235-19238	the	_	
100-8	19239-19245	method	_	
100-9	19246-19255	developed	_	
100-10	19256-19258	by	_	
100-11	19259-19266	Purcell	_	
100-12	19267-19269	et	_	
100-13	19270-19272	al	_	
100-14	19272-19273	.	_	
100-15	19273-19274	.	_	

#Text=Our analyses focused on those genes involved in dopamine functioning: (i) synthesis (tyrosine hydroxylase (TH), dopa decarboxylase (DDC), and vesicular monoamine transporter (VMAT)); (ii) uptake and metabolism (dopamine transporter (DAT) and catechol-O-methyl transferase (COMT)); (iii) receptors (D1 and D5 receptors in D1 family, as well as D2, D3 and D4 in D2 family).
101-1	19275-19278	Our	_	
101-2	19279-19287	analyses	_	
101-3	19288-19295	focused	_	
101-4	19296-19298	on	_	
101-5	19299-19304	those	_	
101-6	19305-19310	genes	_	
101-7	19311-19319	involved	_	
101-8	19320-19322	in	_	
101-9	19323-19331	dopamine	_	
101-10	19332-19343	functioning	_	
101-11	19343-19344	:	_	
101-12	19345-19346	(	_	
101-13	19346-19347	i	_	
101-14	19347-19348	)	_	
101-15	19349-19358	synthesis	_	
101-16	19359-19360	(	_	
101-17	19360-19368	tyrosine	_	
101-18	19369-19380	hydroxylase	_	
101-19	19381-19382	(	_	
101-20	19382-19384	TH	_	
101-21	19384-19385	)	_	
101-22	19385-19386	,	_	
101-23	19387-19391	dopa	_	
101-24	19392-19405	decarboxylase	_	
101-25	19406-19407	(	_	
101-26	19407-19410	DDC	_	
101-27	19410-19411	)	_	
101-28	19411-19412	,	_	
101-29	19413-19416	and	_	
101-30	19417-19426	vesicular	_	
101-31	19427-19436	monoamine	_	
101-32	19437-19448	transporter	_	
101-33	19449-19450	(	_	
101-34	19450-19454	VMAT	_	
101-35	19454-19455	)	_	
101-36	19455-19456	)	_	
101-37	19456-19457	;	_	
101-38	19458-19459	(	_	
101-39	19459-19461	ii	_	
101-40	19461-19462	)	_	
101-41	19463-19469	uptake	_	
101-42	19470-19473	and	_	
101-43	19474-19484	metabolism	_	
101-44	19485-19486	(	_	
101-45	19486-19494	dopamine	_	
101-46	19495-19506	transporter	_	
101-47	19507-19508	(	_	
101-48	19508-19511	DAT	_	
101-49	19511-19512	)	_	
101-50	19513-19516	and	_	
101-51	19517-19534	catechol-O-methyl	_	
101-52	19535-19546	transferase	_	
101-53	19547-19548	(	_	
101-54	19548-19552	COMT	_	
101-55	19552-19553	)	_	
101-56	19553-19554	)	_	
101-57	19554-19555	;	_	
101-58	19556-19557	(	_	
101-59	19557-19560	iii	_	
101-60	19560-19561	)	_	
101-61	19562-19571	receptors	_	
101-62	19572-19573	(	_	
101-63	19573-19575	D1	_	
101-64	19576-19579	and	_	
101-65	19580-19582	D5	_	
101-66	19583-19592	receptors	_	
101-67	19593-19595	in	_	
101-68	19596-19598	D1	_	
101-69	19599-19605	family	_	
101-70	19605-19606	,	_	
101-71	19607-19609	as	_	
101-72	19610-19614	well	_	
101-73	19615-19617	as	_	
101-74	19618-19620	D2	_	
101-75	19620-19621	,	_	
101-76	19622-19624	D3	_	
101-77	19625-19628	and	_	
101-78	19629-19631	D4	_	
101-79	19632-19634	in	_	
101-80	19635-19637	D2	_	
101-81	19638-19644	family	_	
101-82	19644-19645	)	_	
101-83	19645-19646	.	_	

#Text=We evaluated all available SNPs both occurring in the area 5000 bp upstream and downstream of each candidate gene and meeting a significance level of p ≤ 0.05 in the multi-stage schizophrenia GWAS study because this was the level that most efficiently discriminated individuals with and without schizophrenia.
102-1	19647-19649	We	_	
102-2	19650-19659	evaluated	_	
102-3	19660-19663	all	_	
102-4	19664-19673	available	_	
102-5	19674-19678	SNPs	_	
102-6	19679-19683	both	_	
102-7	19684-19693	occurring	_	
102-8	19694-19696	in	_	
102-9	19697-19700	the	_	
102-10	19701-19705	area	_	
102-11	19706-19710	5000	_	
102-12	19711-19713	bp	_	
102-13	19714-19722	upstream	_	
102-14	19723-19726	and	_	
102-15	19727-19737	downstream	_	
102-16	19738-19740	of	_	
102-17	19741-19745	each	_	
102-18	19746-19755	candidate	_	
102-19	19756-19760	gene	_	
102-20	19761-19764	and	_	
102-21	19765-19772	meeting	_	
102-22	19773-19774	a	_	
102-23	19775-19787	significance	_	
102-24	19788-19793	level	_	
102-25	19794-19796	of	_	
102-26	19797-19798	p	_	
102-27	19799-19800	≤	_	
102-28	19801-19805	0.05	_	
102-29	19806-19808	in	_	
102-30	19809-19812	the	_	
102-31	19813-19824	multi-stage	_	
102-32	19825-19838	schizophrenia	http://maven.renci.org/NeuroBridge/neurobridge#Schizophrenia	
102-33	19839-19843	GWAS	_	
102-34	19844-19849	study	_	
102-35	19850-19857	because	_	
102-36	19858-19862	this	_	
102-37	19863-19866	was	_	
102-38	19867-19870	the	_	
102-39	19871-19876	level	_	
102-40	19877-19881	that	_	
102-41	19882-19886	most	_	
102-42	19887-19898	efficiently	_	
102-43	19899-19912	discriminated	_	
102-44	19913-19924	individuals	_	
102-45	19925-19929	with	_	
102-46	19930-19933	and	_	
102-47	19934-19941	without	_	
102-48	19942-19955	schizophrenia	http://maven.renci.org/NeuroBridge/neurobridge#Schizophrenia	
102-49	19955-19956	.	_	

#Text=The SNPs were pruned using the “clump” utility in PLINK with a cutoff of r2 = 0.50 within a 250 kb window to ensure that the polygenic effects come from independent SNPs in linkage disequilibrium with each other (Supplementary table 1 showed the SNPs and weights used to generate the PGRS).
103-1	19957-19960	The	_	
103-2	19961-19965	SNPs	_	
103-3	19966-19970	were	_	
103-4	19971-19977	pruned	_	
103-5	19978-19983	using	_	
103-6	19984-19987	the	_	
103-7	19988-19989	“	_	
103-8	19989-19994	clump	_	
103-9	19994-19995	”	_	
103-10	19996-20003	utility	_	
103-11	20004-20006	in	_	
103-12	20007-20012	PLINK	_	
103-13	20013-20017	with	_	
103-14	20018-20019	a	_	
103-15	20020-20026	cutoff	_	
103-16	20027-20029	of	_	
103-17	20030-20032	r2	_	
103-18	20033-20034	=	_	
103-19	20035-20039	0.50	_	
103-20	20040-20046	within	_	
103-21	20047-20048	a	_	
103-22	20049-20052	250	_	
103-23	20053-20055	kb	_	
103-24	20056-20062	window	_	
103-25	20063-20065	to	_	
103-26	20066-20072	ensure	_	
103-27	20073-20077	that	_	
103-28	20078-20081	the	_	
103-29	20082-20091	polygenic	_	
103-30	20092-20099	effects	_	
103-31	20100-20104	come	_	
103-32	20105-20109	from	_	
103-33	20110-20121	independent	_	
103-34	20122-20126	SNPs	_	
103-35	20127-20129	in	_	
103-36	20130-20137	linkage	_	
103-37	20138-20152	disequilibrium	_	
103-38	20153-20157	with	_	
103-39	20158-20162	each	_	
103-40	20163-20168	other	_	
103-41	20169-20170	(	_	
103-42	20170-20183	Supplementary	_	
103-43	20184-20189	table	_	
103-44	20189-20190	 	_	
103-45	20190-20191	1	_	
103-46	20192-20198	showed	_	
103-47	20199-20202	the	_	
103-48	20203-20207	SNPs	_	
103-49	20208-20211	and	_	
103-50	20212-20219	weights	_	
103-51	20220-20224	used	_	
103-52	20225-20227	to	_	
103-53	20228-20236	generate	_	
103-54	20237-20240	the	_	
103-55	20241-20245	PGRS	_	
103-56	20245-20246	)	_	
103-57	20246-20247	.	_	

#Text=Image acquisition and processing
#Text=Images were collected using a single 3T GE scanner (SIGNAHDX3.0 T scanner; GE Healthcare; Milwaukee, WI, USA).
104-1	20248-20253	Image	_	
104-2	20254-20265	acquisition	_	
104-3	20266-20269	and	_	
104-4	20270-20280	processing	_	
104-5	20281-20287	Images	_	
104-6	20288-20292	were	_	
104-7	20293-20302	collected	_	
104-8	20303-20308	using	_	
104-9	20309-20310	a	_	
104-10	20311-20317	single	_	
104-11	20318-20320	3T	_	
104-12	20321-20323	GE	_	
104-13	20324-20331	scanner	_	
104-14	20332-20333	(	_	
104-15	20333-20344	SIGNAHDX3.0	_	
104-16	20345-20346	T	_	
104-17	20347-20354	scanner	_	
104-18	20354-20355	;	_	
104-19	20356-20358	GE	_	
104-20	20359-20369	Healthcare	_	
104-21	20369-20370	;	_	
104-22	20371-20380	Milwaukee	_	
104-23	20380-20381	,	_	
104-24	20382-20384	WI	_	
104-25	20384-20385	,	_	
104-26	20386-20389	USA	_	
104-27	20389-20390	)	_	
104-28	20390-20391	.	_	

#Text=A single-shot, T2*-weighted gradient echo, echo-planar-imaging sequence (TR = 2000 ms, TE = 30 ms, no gap, voxel size = 3.75 mm × 3.75 mm × 4.0 mm, FOV = 240 × 240 mm2, matrix = 64 × 64, flip angle = 90°, 40 slices, 180 volumes) was used to obtain resting-state functional magnetic resonance imaging data (fMRI).
105-1	20392-20393	A	_	
105-2	20394-20405	single-shot	_	
105-3	20405-20406	,	_	
105-4	20407-20409	T2	http://maven.renci.org/NeuroBridge/neurobridge#T2WeightedImaging[10]	
105-5	20409-20410	*	http://maven.renci.org/NeuroBridge/neurobridge#T2WeightedImaging[10]	
105-6	20410-20411	-	http://maven.renci.org/NeuroBridge/neurobridge#T2WeightedImaging[10]	
105-7	20411-20419	weighted	http://maven.renci.org/NeuroBridge/neurobridge#T2WeightedImaging[10]	
105-8	20420-20428	gradient	_	
105-9	20429-20433	echo	_	
105-10	20433-20434	,	_	
105-11	20435-20454	echo-planar-imaging	_	
105-12	20455-20463	sequence	_	
105-13	20464-20465	(	_	
105-14	20465-20467	TR	_	
105-15	20468-20469	=	_	
105-16	20470-20474	2000	_	
105-17	20475-20477	ms	_	
105-18	20477-20478	,	_	
105-19	20479-20481	TE	_	
105-20	20482-20483	=	_	
105-21	20484-20486	30	_	
105-22	20487-20489	ms	_	
105-23	20489-20490	,	_	
105-24	20491-20493	no	_	
105-25	20494-20497	gap	_	
105-26	20497-20498	,	_	
105-27	20499-20504	voxel	_	
105-28	20505-20509	size	_	
105-29	20510-20511	=	_	
105-30	20512-20516	3.75	_	
105-31	20517-20519	mm	_	
105-32	20520-20521	×	_	
105-33	20522-20526	3.75	_	
105-34	20527-20529	mm	_	
105-35	20530-20531	×	_	
105-36	20532-20535	4.0	_	
105-37	20536-20538	mm	_	
105-38	20538-20539	,	_	
105-39	20540-20543	FOV	_	
105-40	20544-20545	=	_	
105-41	20546-20549	240	_	
105-42	20550-20551	×	_	
105-43	20552-20555	240	_	
105-44	20556-20559	mm2	_	
105-45	20559-20560	,	_	
105-46	20561-20567	matrix	_	
105-47	20568-20569	=	_	
105-48	20570-20572	64	_	
105-49	20573-20574	×	_	
105-50	20575-20577	64	_	
105-51	20577-20578	,	_	
105-52	20579-20583	flip	_	
105-53	20584-20589	angle	_	
105-54	20590-20591	=	_	
105-55	20592-20594	90	_	
105-56	20594-20595	°	_	
105-57	20595-20596	,	_	
105-58	20597-20599	40	_	
105-59	20600-20606	slices	_	
105-60	20606-20607	,	_	
105-61	20608-20611	180	_	
105-62	20612-20619	volumes	_	
105-63	20619-20620	)	_	
105-64	20621-20624	was	_	
105-65	20625-20629	used	_	
105-66	20630-20632	to	_	
105-67	20633-20639	obtain	_	
105-68	20640-20653	resting-state	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalMagneticResonanceImaging[11]	
105-69	20654-20664	functional	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalMagneticResonanceImaging[11]	
105-70	20665-20673	magnetic	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalMagneticResonanceImaging[11]	
105-71	20674-20683	resonance	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalMagneticResonanceImaging[11]	
105-72	20684-20691	imaging	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalMagneticResonanceImaging[11]	
105-73	20692-20696	data	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalMagneticResonanceImaging[11]	
105-74	20697-20698	(	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalMagneticResonanceImaging[11]	
105-75	20698-20702	fMRI	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalMagneticResonanceImaging[11]	
105-76	20702-20703	)	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalMagneticResonanceImaging[11]	
105-77	20703-20704	.	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalMagneticResonanceImaging[11]	

#Text=All subjects were requested to relax and to not fall asleep.
106-1	20705-20708	All	_	
106-2	20709-20717	subjects	_	
106-3	20718-20722	were	_	
106-4	20723-20732	requested	_	
106-5	20733-20735	to	_	
106-6	20736-20741	relax	_	
106-7	20742-20745	and	_	
106-8	20746-20748	to	_	
106-9	20749-20752	not	_	
106-10	20753-20757	fall	_	
106-11	20758-20764	asleep	_	
106-12	20764-20765	.	_	

#Text=Two experienced radiologists inspected all the raw MRI data.
107-1	20766-20769	Two	_	
107-2	20770-20781	experienced	_	
107-3	20782-20794	radiologists	_	
107-4	20795-20804	inspected	_	
107-5	20805-20808	all	_	
107-6	20809-20812	the	_	
107-7	20813-20816	raw	_	
107-8	20817-20820	MRI	http://maven.renci.org/NeuroBridge/neurobridge#MagneticResonanceImaging	
107-9	20821-20825	data	_	
107-10	20825-20826	.	_	

#Text=Preprocessing of functional images was performed using DPARSFA (Data Processing Assistant for Resting-State fMRI Advanced Edition, http://www.restfmri.net/forum/DPARSF) in statistical parametric mapping software (SPM8, http://www.fil.ion.ucl.ac.uk/spm).
108-1	20827-20840	Preprocessing	_	
108-2	20841-20843	of	_	
108-3	20844-20854	functional	_	
108-4	20855-20861	images	_	
108-5	20862-20865	was	_	
108-6	20866-20875	performed	_	
108-7	20876-20881	using	_	
108-8	20882-20889	DPARSFA	_	
108-9	20890-20891	(	_	
108-10	20891-20895	Data	_	
108-11	20896-20906	Processing	_	
108-12	20907-20916	Assistant	_	
108-13	20917-20920	for	_	
108-14	20921-20934	Resting-State	http://maven.renci.org/NeuroBridge/neurobridge#RestingStateImaging[12]	
108-15	20935-20939	fMRI	http://maven.renci.org/NeuroBridge/neurobridge#RestingStateImaging[12]	
108-16	20940-20948	Advanced	_	
108-17	20949-20956	Edition	_	
108-18	20956-20957	,	_	
108-19	20958-20962	http	_	
108-20	20962-20963	:	_	
108-21	20963-20964	/	_	
108-22	20964-20965	/	_	
108-23	20965-20981	www.restfmri.net	_	
108-24	20981-20982	/	_	
108-25	20982-20987	forum	_	
108-26	20987-20988	/	_	
108-27	20988-20994	DPARSF	_	
108-28	20994-20995	)	_	
108-29	20996-20998	in	_	
108-30	20999-21010	statistical	_	
108-31	21011-21021	parametric	_	
108-32	21022-21029	mapping	_	
108-33	21030-21038	software	_	
108-34	21039-21040	(	_	
108-35	21040-21044	SPM8	_	
108-36	21044-21045	,	_	
108-37	21046-21050	http	_	
108-38	21050-21051	:	_	
108-39	21051-21052	/	_	
108-40	21052-21053	/	_	
108-41	21053-21074	www.fil.ion.ucl.ac.uk	_	
108-42	21074-21075	/	_	
108-43	21075-21078	spm	_	
108-44	21078-21079	)	_	
108-45	21079-21080	.	_	

#Text=The preprocessing included discarding the first 10 volumes, slice timing, head motion correction, spatially normalizing to the Montreal Neurological Institute (MNI) template, resampling to 3 × 3 × 3 mm3, smoothing with a 6 mm Gaussian kernel, temporal band-pass filtering, and linear regression to remove the influence of nuisance signals including head motion parameters and white matter, cerebrospinal fluid and global signals.
109-1	21081-21084	The	_	
109-2	21085-21098	preprocessing	_	
109-3	21099-21107	included	_	
109-4	21108-21118	discarding	_	
109-5	21119-21122	the	_	
109-6	21123-21128	first	_	
109-7	21129-21131	10	_	
109-8	21132-21139	volumes	_	
109-9	21139-21140	,	_	
109-10	21141-21146	slice	_	
109-11	21147-21153	timing	_	
109-12	21153-21154	,	_	
109-13	21155-21159	head	_	
109-14	21160-21166	motion	_	
109-15	21167-21177	correction	_	
109-16	21177-21178	,	_	
109-17	21179-21188	spatially	_	
109-18	21189-21200	normalizing	_	
109-19	21201-21203	to	_	
109-20	21204-21207	the	_	
109-21	21208-21216	Montreal	_	
109-22	21217-21229	Neurological	_	
109-23	21230-21239	Institute	_	
109-24	21240-21241	(	_	
109-25	21241-21244	MNI	_	
109-26	21244-21245	)	_	
109-27	21246-21254	template	_	
109-28	21254-21255	,	_	
109-29	21256-21266	resampling	_	
109-30	21267-21269	to	_	
109-31	21270-21271	3	_	
109-32	21272-21273	×	_	
109-33	21274-21275	3	_	
109-34	21276-21277	×	_	
109-35	21278-21279	3	_	
109-36	21280-21283	mm3	_	
109-37	21283-21284	,	_	
109-38	21285-21294	smoothing	_	
109-39	21295-21299	with	_	
109-40	21300-21301	a	_	
109-41	21302-21303	6	_	
109-42	21304-21306	mm	_	
109-43	21307-21315	Gaussian	_	
109-44	21316-21322	kernel	_	
109-45	21322-21323	,	_	
109-46	21324-21332	temporal	_	
109-47	21333-21342	band-pass	_	
109-48	21343-21352	filtering	_	
109-49	21352-21353	,	_	
109-50	21354-21357	and	_	
109-51	21358-21364	linear	_	
109-52	21365-21375	regression	_	
109-53	21376-21378	to	_	
109-54	21379-21385	remove	_	
109-55	21386-21389	the	_	
109-56	21390-21399	influence	_	
109-57	21400-21402	of	_	
109-58	21403-21411	nuisance	_	
109-59	21412-21419	signals	_	
109-60	21420-21429	including	_	
109-61	21430-21434	head	_	
109-62	21435-21441	motion	_	
109-63	21442-21452	parameters	_	
109-64	21453-21456	and	_	
109-65	21457-21462	white	_	
109-66	21463-21469	matter	_	
109-67	21469-21470	,	_	
109-68	21471-21484	cerebrospinal	_	
109-69	21485-21490	fluid	_	
109-70	21491-21494	and	_	
109-71	21495-21501	global	_	
109-72	21502-21509	signals	_	
109-73	21509-21510	.	_	

#Text=Then, we discarded 14 participants whose maximum displacement in any of the cardinal directions (x, y, z) was greater than 2 mm or whose maximum spin (x, y, z) was greater than 2°.
110-1	21511-21515	Then	_	
110-2	21515-21516	,	_	
110-3	21517-21519	we	_	
110-4	21520-21529	discarded	_	
110-5	21530-21532	14	_	
110-6	21533-21545	participants	_	
110-7	21546-21551	whose	_	
110-8	21552-21559	maximum	_	
110-9	21560-21572	displacement	_	
110-10	21573-21575	in	_	
110-11	21576-21579	any	_	
110-12	21580-21582	of	_	
110-13	21583-21586	the	_	
110-14	21587-21595	cardinal	_	
110-15	21596-21606	directions	_	
110-16	21607-21608	(	_	
110-17	21608-21609	x	_	
110-18	21609-21610	,	_	
110-19	21611-21612	y	_	
110-20	21612-21613	,	_	
110-21	21614-21615	z	_	
110-22	21615-21616	)	_	
110-23	21617-21620	was	_	
110-24	21621-21628	greater	_	
110-25	21629-21633	than	_	
110-26	21634-21635	2	_	
110-27	21636-21638	mm	_	
110-28	21639-21641	or	_	
110-29	21642-21647	whose	_	
110-30	21648-21655	maximum	_	
110-31	21656-21660	spin	_	
110-32	21661-21662	(	_	
110-33	21662-21663	x	_	
110-34	21663-21664	,	_	
110-35	21665-21666	y	_	
110-36	21666-21667	,	_	
110-37	21668-21669	z	_	
110-38	21669-21670	)	_	
110-39	21671-21674	was	_	
110-40	21675-21682	greater	_	
110-41	21683-21687	than	_	
110-42	21688-21689	2	_	
110-43	21689-21690	°	_	
110-44	21690-21691	.	_	

#Text=In the end, 286 subjects remained in the functional connectivity analysis.
111-1	21692-21694	In	_	
111-2	21695-21698	the	_	
111-3	21699-21702	end	_	
111-4	21702-21703	,	_	
111-5	21704-21707	286	_	
111-6	21708-21716	subjects	_	
111-7	21717-21725	remained	_	
111-8	21726-21728	in	_	
111-9	21729-21732	the	_	
111-10	21733-21743	functional	_	
111-11	21744-21756	connectivity	_	
111-12	21757-21765	analysis	_	
111-13	21765-21766	.	_	

#Text=The seed regions (bilateral caudate nucleus, putamen and ventral striatum) were extracted based on the Oxford-GSK-Imanova Structural-anatomical Striatal Atlas, and the masks for the seed regions were resampled to 3 × 3 × 3 mm3 in MNI space.
112-1	21767-21770	The	_	
112-2	21771-21775	seed	_	
112-3	21776-21783	regions	_	
112-4	21784-21785	(	_	
112-5	21785-21794	bilateral	_	
112-6	21795-21802	caudate	_	
112-7	21803-21810	nucleus	_	
112-8	21810-21811	,	_	
112-9	21812-21819	putamen	_	
112-10	21820-21823	and	_	
112-11	21824-21831	ventral	_	
112-12	21832-21840	striatum	_	
112-13	21840-21841	)	_	
112-14	21842-21846	were	_	
112-15	21847-21856	extracted	_	
112-16	21857-21862	based	_	
112-17	21863-21865	on	_	
112-18	21866-21869	the	_	
112-19	21870-21888	Oxford-GSK-Imanova	_	
112-20	21889-21910	Structural-anatomical	_	
112-21	21911-21919	Striatal	_	
112-22	21920-21925	Atlas	_	
112-23	21925-21926	,	_	
112-24	21927-21930	and	_	
112-25	21931-21934	the	_	
112-26	21935-21940	masks	_	
112-27	21941-21944	for	_	
112-28	21945-21948	the	_	
112-29	21949-21953	seed	_	
112-30	21954-21961	regions	_	
112-31	21962-21966	were	_	
112-32	21967-21976	resampled	_	
112-33	21977-21979	to	_	
112-34	21980-21981	3	_	
112-35	21982-21983	×	_	
112-36	21984-21985	3	_	
112-37	21986-21987	×	_	
112-38	21988-21989	3	_	
112-39	21990-21993	mm3	_	
112-40	21994-21996	in	_	
112-41	21997-22000	MNI	_	
112-42	22001-22006	space	_	
112-43	22006-22007	.	_	

#Text=We calculated the Pearson’s correlation coefficient between the average time series of the seed regions and those of all the voxels of the whole brain.
113-1	22008-22010	We	_	
113-2	22011-22021	calculated	_	
113-3	22022-22025	the	_	
113-4	22026-22033	Pearson	_	
113-5	22033-22034	’	_	
113-6	22034-22035	s	_	
113-7	22036-22047	correlation	_	
113-8	22048-22059	coefficient	_	
113-9	22060-22067	between	_	
113-10	22068-22071	the	_	
113-11	22072-22079	average	_	
113-12	22080-22084	time	_	
113-13	22085-22091	series	_	
113-14	22092-22094	of	_	
113-15	22095-22098	the	_	
113-16	22099-22103	seed	_	
113-17	22104-22111	regions	_	
113-18	22112-22115	and	_	
113-19	22116-22121	those	_	
113-20	22122-22124	of	_	
113-21	22125-22128	all	_	
113-22	22129-22132	the	_	
113-23	22133-22139	voxels	_	
113-24	22140-22142	of	_	
113-25	22143-22146	the	_	
113-26	22147-22152	whole	_	
113-27	22153-22158	brain	_	
113-28	22158-22159	.	_	

#Text=Then, we transformed the r correlation into a Z score via Fisher’s r-to-z transformation in order to obtain Z maps for each subject.
114-1	22160-22164	Then	_	
114-2	22164-22165	,	_	
114-3	22166-22168	we	_	
114-4	22169-22180	transformed	_	
114-5	22181-22184	the	_	
114-6	22185-22186	r	_	
114-7	22187-22198	correlation	_	
114-8	22199-22203	into	_	
114-9	22204-22205	a	_	
114-10	22206-22207	Z	_	
114-11	22208-22213	score	_	
114-12	22214-22217	via	_	
114-13	22218-22224	Fisher	_	
114-14	22224-22225	’	_	
114-15	22225-22226	s	_	
114-16	22227-22233	r-to-z	_	
114-17	22234-22248	transformation	_	
114-18	22249-22251	in	_	
114-19	22252-22257	order	_	
114-20	22258-22260	to	_	
114-21	22261-22267	obtain	_	
114-22	22268-22269	Z	_	
114-23	22270-22274	maps	_	
114-24	22275-22278	for	_	
114-25	22279-22283	each	_	
114-26	22284-22291	subject	_	
114-27	22291-22292	.	_	

#Text=Next, one-sample t-tests were used to determine the main functional connectivities in for each striatal sub-region.
115-1	22293-22297	Next	_	
115-2	22297-22298	,	_	
115-3	22299-22309	one-sample	_	
115-4	22310-22317	t-tests	_	
115-5	22318-22322	were	_	
115-6	22323-22327	used	_	
115-7	22328-22330	to	_	
115-8	22331-22340	determine	_	
115-9	22341-22344	the	_	
115-10	22345-22349	main	_	
115-11	22350-22360	functional	_	
115-12	22361-22375	connectivities	_	
115-13	22376-22378	in	_	
115-14	22379-22382	for	_	
115-15	22383-22387	each	_	
115-16	22388-22396	striatal	_	
115-17	22397-22407	sub-region	_	
115-18	22407-22408	.	_	

#Text=Then, we used the masks of the one-sample t-tests results for subsequent multiple regression analysis.
116-1	22409-22413	Then	_	
116-2	22413-22414	,	_	
116-3	22415-22417	we	_	
116-4	22418-22422	used	_	
116-5	22423-22426	the	_	
116-6	22427-22432	masks	_	
116-7	22433-22435	of	_	
116-8	22436-22439	the	_	
116-9	22440-22450	one-sample	_	
116-10	22451-22458	t-tests	_	
116-11	22459-22466	results	_	
116-12	22467-22470	for	_	
116-13	22471-22481	subsequent	_	
116-14	22482-22490	multiple	_	
116-15	22491-22501	regression	_	
116-16	22502-22510	analysis	_	
116-17	22510-22511	.	_	

#Text=Statistical analysis
#Text=Voxel-wise multiple regression analysis was implemented in SPM8 to investigate the correlation between dopamine gene-related PGRS and the seed-based functional connectivity.
117-1	22512-22523	Statistical	_	
117-2	22524-22532	analysis	_	
117-3	22533-22543	Voxel-wise	_	
117-4	22544-22552	multiple	_	
117-5	22553-22563	regression	_	
117-6	22564-22572	analysis	_	
117-7	22573-22576	was	_	
117-8	22577-22588	implemented	_	
117-9	22589-22591	in	_	
117-10	22592-22596	SPM8	_	
117-11	22597-22599	to	_	
117-12	22600-22611	investigate	_	
117-13	22612-22615	the	_	
117-14	22616-22627	correlation	_	
117-15	22628-22635	between	_	
117-16	22636-22644	dopamine	_	
117-17	22645-22657	gene-related	_	
117-18	22658-22662	PGRS	_	
117-19	22663-22666	and	_	
117-20	22667-22670	the	_	
117-21	22671-22681	seed-based	_	
117-22	22682-22692	functional	_	
117-23	22693-22705	connectivity	_	
117-24	22705-22706	.	_	

#Text=To correct for multiple statistical testing, we maintained a cluster-level false-positive detection rate at p < 0.05 using a voxel-level threshold of p < 0.001 (Supplementary Figures S1 and S2) and a voxel-level threshold of p < 0.005 with a cluster extent determined by Monte Carlo simulations (n = 5000 iterations).
118-1	22707-22709	To	_	
118-2	22710-22717	correct	_	
118-3	22718-22721	for	_	
118-4	22722-22730	multiple	_	
118-5	22731-22742	statistical	_	
118-6	22743-22750	testing	_	
118-7	22750-22751	,	_	
118-8	22752-22754	we	_	
118-9	22755-22765	maintained	_	
118-10	22766-22767	a	_	
118-11	22768-22781	cluster-level	_	
118-12	22782-22796	false-positive	_	
118-13	22797-22806	detection	_	
118-14	22807-22811	rate	_	
118-15	22812-22814	at	_	
118-16	22815-22816	p	_	
118-17	22817-22818	<	_	
118-18	22819-22823	0.05	_	
118-19	22824-22829	using	_	
118-20	22830-22831	a	_	
118-21	22832-22843	voxel-level	_	
118-22	22844-22853	threshold	_	
118-23	22854-22856	of	_	
118-24	22857-22858	p	_	
118-25	22859-22860	<	_	
118-26	22861-22866	0.001	_	
118-27	22867-22868	(	_	
118-28	22868-22881	Supplementary	_	
118-29	22882-22889	Figures	_	
118-30	22889-22890	 	_	
118-31	22890-22892	S1	_	
118-32	22893-22896	and	_	
118-33	22897-22899	S2	_	
118-34	22899-22900	)	_	
118-35	22901-22904	and	_	
118-36	22905-22906	a	_	
118-37	22907-22918	voxel-level	_	
118-38	22919-22928	threshold	_	
118-39	22929-22931	of	_	
118-40	22932-22933	p	_	
118-41	22934-22935	<	_	
118-42	22936-22941	0.005	_	
118-43	22942-22946	with	_	
118-44	22947-22948	a	_	
118-45	22949-22956	cluster	_	
118-46	22957-22963	extent	_	
118-47	22964-22974	determined	_	
118-48	22975-22977	by	_	
118-49	22978-22983	Monte	_	
118-50	22984-22989	Carlo	_	
118-51	22990-23001	simulations	_	
118-52	23002-23003	(	_	
118-53	23003-23004	n	_	
118-54	23005-23006	=	_	
118-55	23007-23011	5000	_	
118-56	23012-23022	iterations	_	
118-57	23022-23023	)	_	
118-58	23023-23024	.	_	

#Text=We accomplished this step using Alphasim implemented in the Data Processing & Analysis for Brain Imaging V2.3 (DPABI, http://rfmri.org/dpabi).
119-1	23025-23027	We	_	
119-2	23028-23040	accomplished	_	
119-3	23041-23045	this	_	
119-4	23046-23050	step	_	
119-5	23051-23056	using	_	
119-6	23057-23065	Alphasim	_	
119-7	23066-23077	implemented	_	
119-8	23078-23080	in	_	
119-9	23081-23084	the	_	
119-10	23085-23089	Data	_	
119-11	23090-23100	Processing	_	
119-12	23101-23102	&	_	
119-13	23103-23111	Analysis	_	
119-14	23112-23115	for	_	
119-15	23116-23121	Brain	_	
119-16	23122-23129	Imaging	_	
119-17	23130-23134	V2.3	_	
119-18	23135-23136	(	_	
119-19	23136-23141	DPABI	_	
119-20	23141-23142	,	_	
119-21	23143-23147	http	_	
119-22	23147-23148	:	_	
119-23	23148-23149	/	_	
119-24	23149-23150	/	_	
119-25	23150-23159	rfmri.org	_	
119-26	23159-23160	/	_	
119-27	23160-23165	dpabi	_	
119-28	23165-23166	)	_	
119-29	23166-23167	.	_	

#Text=To determine the functional networks to which brain regions with significant correlation with the PGRS belonged, we performed group independent component analysis (group ICA) to separate the blood oxygen level-dependent signal into independent components using theprogram Group ICA of fMRI Toolbox (GIFT) (http://icatb.sourceforge.net/).
120-1	23168-23170	To	_	
120-2	23171-23180	determine	_	
120-3	23181-23184	the	_	
120-4	23185-23195	functional	_	
120-5	23196-23204	networks	_	
120-6	23205-23207	to	_	
120-7	23208-23213	which	_	
120-8	23214-23219	brain	_	
120-9	23220-23227	regions	_	
120-10	23228-23232	with	_	
120-11	23233-23244	significant	_	
120-12	23245-23256	correlation	_	
120-13	23257-23261	with	_	
120-14	23262-23265	the	_	
120-15	23266-23270	PGRS	_	
120-16	23271-23279	belonged	_	
120-17	23279-23280	,	_	
120-18	23281-23283	we	_	
120-19	23284-23293	performed	_	
120-20	23294-23299	group	_	
120-21	23300-23311	independent	_	
120-22	23312-23321	component	_	
120-23	23322-23330	analysis	_	
120-24	23331-23332	(	_	
120-25	23332-23337	group	_	
120-26	23338-23341	ICA	_	
120-27	23341-23342	)	_	
120-28	23343-23345	to	_	
120-29	23346-23354	separate	_	
120-30	23355-23358	the	_	
120-31	23359-23364	blood	_	
120-32	23365-23371	oxygen	_	
120-33	23372-23387	level-dependent	_	
120-34	23388-23394	signal	_	
120-35	23395-23399	into	_	
120-36	23400-23411	independent	_	
120-37	23412-23422	components	_	
120-38	23423-23428	using	_	
120-39	23429-23439	theprogram	_	
120-40	23440-23445	Group	_	
120-41	23446-23449	ICA	_	
120-42	23450-23452	of	_	
120-43	23453-23457	fMRI	_	
120-44	23458-23465	Toolbox	_	
120-45	23466-23467	(	_	
120-46	23467-23471	GIFT	_	
120-47	23471-23472	)	_	
120-48	23473-23474	(	_	
120-49	23474-23478	http	_	
120-50	23478-23479	:	_	
120-51	23479-23480	/	_	
120-52	23480-23481	/	_	
120-53	23481-23502	icatb.sourceforge.net	_	
120-54	23502-23503	/	_	
120-55	23503-23504	)	_	
120-56	23504-23505	.	_	

#Text=Based on a previous study by Simth et al., we identified nine resting-state networks, including the default mode network and the fronto-parietal network, and we obtained the mean component masks.
121-1	23506-23511	Based	_	
121-2	23512-23514	on	_	
121-3	23515-23516	a	_	
121-4	23517-23525	previous	_	
121-5	23526-23531	study	_	
121-6	23532-23534	by	_	
121-7	23535-23540	Simth	_	
121-8	23541-23543	et	_	
121-9	23544-23546	al	_	
121-10	23546-23547	.	_	
121-11	23547-23548	,	_	
121-12	23549-23551	we	_	
121-13	23552-23562	identified	_	
121-14	23563-23567	nine	_	
121-15	23568-23581	resting-state	_	
121-16	23582-23590	networks	_	
121-17	23590-23591	,	_	
121-18	23592-23601	including	_	
121-19	23602-23605	the	_	
121-20	23606-23613	default	_	
121-21	23614-23618	mode	_	
121-22	23619-23626	network	_	
121-23	23627-23630	and	_	
121-24	23631-23634	the	_	
121-25	23635-23650	fronto-parietal	_	
121-26	23651-23658	network	_	
121-27	23658-23659	,	_	
121-28	23660-23663	and	_	
121-29	23664-23666	we	_	
121-30	23667-23675	obtained	_	
121-31	23676-23679	the	_	
121-32	23680-23684	mean	_	
121-33	23685-23694	component	_	
121-34	23695-23700	masks	_	
121-35	23700-23701	.	_	

#Text=In addition, partial correlation analysis was performed to test the correlation between the PGRS and working memory performance as well as functional connectivity with striatal sub-regions with age, gender and the first three genetic principal components as covariates.
122-1	23702-23704	In	_	
122-2	23705-23713	addition	_	
122-3	23713-23714	,	_	
122-4	23715-23722	partial	_	
122-5	23723-23734	correlation	_	
122-6	23735-23743	analysis	_	
122-7	23744-23747	was	_	
122-8	23748-23757	performed	_	
122-9	23758-23760	to	_	
122-10	23761-23765	test	_	
122-11	23766-23769	the	_	
122-12	23770-23781	correlation	_	
122-13	23782-23789	between	_	
122-14	23790-23793	the	_	
122-15	23794-23798	PGRS	_	
122-16	23799-23802	and	_	
122-17	23803-23810	working	_	
122-18	23811-23817	memory	_	
122-19	23818-23829	performance	_	
122-20	23830-23832	as	_	
122-21	23833-23837	well	_	
122-22	23838-23840	as	_	
122-23	23841-23851	functional	_	
122-24	23852-23864	connectivity	_	
122-25	23865-23869	with	_	
122-26	23870-23878	striatal	_	
122-27	23879-23890	sub-regions	_	
122-28	23891-23895	with	_	
122-29	23896-23899	age	_	
122-30	23899-23900	,	_	
122-31	23901-23907	gender	_	
122-32	23908-23911	and	_	
122-33	23912-23915	the	_	
122-34	23916-23921	first	_	
122-35	23922-23927	three	_	
122-36	23928-23935	genetic	_	
122-37	23936-23945	principal	_	
122-38	23946-23956	components	_	
122-39	23957-23959	as	_	
122-40	23960-23970	covariates	_	
122-41	23970-23971	.	_	

#Text=We further did post-hoc tests to determine which SNPs might be the most responsible for the observed effect using PLINK version 1.07.
123-1	23972-23974	We	_	
123-2	23975-23982	further	_	
123-3	23983-23986	did	_	
123-4	23987-23995	post-hoc	_	
123-5	23996-24001	tests	_	
123-6	24002-24004	to	_	
123-7	24005-24014	determine	_	
123-8	24015-24020	which	_	
123-9	24021-24025	SNPs	_	
123-10	24026-24031	might	_	
123-11	24032-24034	be	_	
123-12	24035-24038	the	_	
123-13	24039-24043	most	_	
123-14	24044-24055	responsible	_	
123-15	24056-24059	for	_	
123-16	24060-24063	the	_	
123-17	24064-24072	observed	_	
123-18	24073-24079	effect	_	
123-19	24080-24085	using	_	
123-20	24086-24091	PLINK	_	
123-21	24092-24099	version	_	
123-22	24100-24104	1.07	_	
123-23	24104-24105	.	_	

#Text=Data availability
#Text=The datasets analyzed during the current study are available from the corresponding author on reasonable request.
124-1	24106-24110	Data	_	
124-2	24111-24123	availability	_	
124-3	24124-24127	The	_	
124-4	24128-24136	datasets	_	
124-5	24137-24145	analyzed	_	
124-6	24146-24152	during	_	
124-7	24153-24156	the	_	
124-8	24157-24164	current	_	
124-9	24165-24170	study	_	
124-10	24171-24174	are	_	
124-11	24175-24184	available	_	
124-12	24185-24189	from	_	
124-13	24190-24193	the	_	
124-14	24194-24207	corresponding	_	
124-15	24208-24214	author	_	
124-16	24215-24217	on	_	
124-17	24218-24228	reasonable	_	
124-18	24229-24236	request	_	
124-19	24236-24237	.	_	

#Text=Electronic supplementary material
#Text=Chao Wang and Bing Liu contributed equally to this work.
125-1	24238-24248	Electronic	_	
125-2	24249-24262	supplementary	_	
125-3	24263-24271	material	_	
125-4	24272-24276	Chao	_	
125-5	24277-24281	Wang	_	
125-6	24282-24285	and	_	
125-7	24286-24290	Bing	_	
125-8	24291-24294	Liu	_	
125-9	24295-24306	contributed	_	
125-10	24307-24314	equally	_	
125-11	24315-24317	to	_	
125-12	24318-24322	this	_	
125-13	24323-24327	work	_	
125-14	24327-24328	.	_	

#Text=Electronic supplementary material
#Text=Supplementary information accompanies this paper at 10.1038/s41598-018-23191-y.
126-1	24329-24339	Electronic	_	
126-2	24340-24353	supplementary	_	
126-3	24354-24362	material	_	
126-4	24363-24376	Supplementary	_	
126-5	24377-24388	information	_	
126-6	24389-24400	accompanies	_	
126-7	24401-24405	this	_	
126-8	24406-24411	paper	_	
126-9	24412-24414	at	_	
126-10	24415-24422	10.1038	_	
126-11	24422-24423	/	_	
126-12	24423-24429	s41598	_	
126-13	24429-24430	-	_	
126-14	24430-24433	018	_	
126-15	24433-24434	-	_	
126-16	24434-24439	23191	_	
126-17	24439-24440	-	_	
126-18	24440-24441	y	_	
126-19	24441-24442	.	_	

#Text=Publisher's note: Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
127-1	24443-24454	Publisher's	_	
127-2	24455-24459	note	_	
127-3	24459-24460	:	_	
127-4	24461-24469	Springer	_	
127-5	24470-24476	Nature	_	
127-6	24477-24484	remains	_	
127-7	24485-24492	neutral	_	
127-8	24493-24497	with	_	
127-9	24498-24504	regard	_	
127-10	24505-24507	to	_	
127-11	24508-24522	jurisdictional	_	
127-12	24523-24529	claims	_	
127-13	24530-24532	in	_	
127-14	24533-24542	published	_	
127-15	24543-24547	maps	_	
127-16	24548-24551	and	_	
127-17	24552-24565	institutional	_	
127-18	24566-24578	affiliations	_	
127-19	24578-24579	.	_	

#Text=Author Contributions
#Text=T.J. supervised the study.
128-1	24580-24586	Author	_	
128-2	24587-24600	Contributions	_	
128-3	24601-24604	T.J	_	
128-4	24604-24605	.	_	
128-5	24606-24616	supervised	_	
128-6	24617-24620	the	_	
128-7	24621-24626	study	_	
128-8	24626-24627	.	_	

#Text=C.W. and B.L. performed the experiments, analyzed results, and wrote the manuscript with assistance from X.Z., Y.C. and C.S.
129-1	24628-24631	C.W	_	
129-2	24631-24632	.	_	
129-3	24633-24636	and	_	
129-4	24637-24640	B.L	_	
129-5	24640-24641	.	_	
129-6	24642-24651	performed	_	
129-7	24652-24655	the	_	
129-8	24656-24667	experiments	_	
129-9	24667-24668	,	_	
129-10	24669-24677	analyzed	_	
129-11	24678-24685	results	_	
129-12	24685-24686	,	_	
129-13	24687-24690	and	_	
129-14	24691-24696	wrote	_	
129-15	24697-24700	the	_	
129-16	24701-24711	manuscript	_	
129-17	24712-24716	with	_	
129-18	24717-24727	assistance	_	
129-19	24728-24732	from	_	
129-20	24733-24736	X.Z	_	
129-21	24736-24737	.	_	
129-22	24737-24738	,	_	
129-23	24739-24742	Y.C	_	
129-24	24742-24743	.	_	
129-25	24744-24747	and	_	
129-26	24748-24751	C.S	_	
129-27	24751-24752	.	_	

#Text=All authors discussed the results and reviewed the manuscript.
130-1	24753-24756	All	_	
130-2	24757-24764	authors	_	
130-3	24765-24774	discussed	_	
130-4	24775-24778	the	_	
130-5	24779-24786	results	_	
130-6	24787-24790	and	_	
130-7	24791-24799	reviewed	_	
130-8	24800-24803	the	_	
130-9	24804-24814	manuscript	_	
130-10	24814-24815	.	_	

#Text=Competing Interests
#Text=The authors declare no competing interests.
131-1	24816-24825	Competing	_	
131-2	24826-24835	Interests	_	
131-3	24836-24839	The	_	
131-4	24840-24847	authors	_	
131-5	24848-24855	declare	_	
131-6	24856-24858	no	_	
131-7	24859-24868	competing	_	
131-8	24869-24878	interests	_	
131-9	24878-24879	.	_	

#Text=References
#Text=Half a century of antipsychotics and still a central role for dopamine D2 receptors
#Text=Schizophrenia and dopamine receptors
#Text=Increased synaptic dopamine function in associative regions of the striatum in schizophrenia
#Text=Association of dorsolateral prefrontal cortex dysfunction with disrupted coordinated brain activity in schizophrenia: relationship with impaired cognition, behavioral disorganization, and global function
#Text=Impaired prefrontal-basal ganglia functional connectivity and substantia nigra hyperactivity in schizophrenia
#Text=The case of frontostriatal dysfunction in schizophrenia
#Text=Prefrontal cortex regulates burst firing and transmitter release in rat mesolimbic dopamine neurons studied in vivo
#Text=Neurocognitive dysfunction in bipolar and schizophrenia spectrum disorders depends on history of psychosis rather than diagnostic group
#Text=Hyperactivity and hyperconnectivity of the default network in schizophrenia and in first-degree relatives of persons with schizophrenia
#Text=Working memory and DLPFC inefficiency in schizophrenia: the FBIRN study
#Text=Striatal dopamine and working memory
#Text=Genome-wide association analysis identifies 13 new risk loci for schizophrenia
#Text=Common polygenic variation contributes to risk of schizophrenia and bipolar disorder
#Text=Cross-Disorder Group of the Psychiatric Genomics, C.
132-1	24880-24890	References	_	
132-2	24891-24895	Half	_	
132-3	24896-24897	a	_	
132-4	24898-24905	century	_	
132-5	24906-24908	of	_	
132-6	24909-24923	antipsychotics	_	
132-7	24924-24927	and	_	
132-8	24928-24933	still	_	
132-9	24934-24935	a	_	
132-10	24936-24943	central	_	
132-11	24944-24948	role	_	
132-12	24949-24952	for	_	
132-13	24953-24961	dopamine	_	
132-14	24962-24964	D2	_	
132-15	24965-24974	receptors	_	
132-16	24975-24988	Schizophrenia	_	
132-17	24989-24992	and	_	
132-18	24993-25001	dopamine	_	
132-19	25002-25011	receptors	_	
132-20	25012-25021	Increased	_	
132-21	25022-25030	synaptic	_	
132-22	25031-25039	dopamine	_	
132-23	25040-25048	function	_	
132-24	25049-25051	in	_	
132-25	25052-25063	associative	_	
132-26	25064-25071	regions	_	
132-27	25072-25074	of	_	
132-28	25075-25078	the	_	
132-29	25079-25087	striatum	_	
132-30	25088-25090	in	_	
132-31	25091-25104	schizophrenia	_	
132-32	25105-25116	Association	_	
132-33	25117-25119	of	_	
132-34	25120-25132	dorsolateral	_	
132-35	25133-25143	prefrontal	_	
132-36	25144-25150	cortex	_	
132-37	25151-25162	dysfunction	_	
132-38	25163-25167	with	_	
132-39	25168-25177	disrupted	_	
132-40	25178-25189	coordinated	_	
132-41	25190-25195	brain	_	
132-42	25196-25204	activity	_	
132-43	25205-25207	in	_	
132-44	25208-25221	schizophrenia	_	
132-45	25221-25222	:	_	
132-46	25223-25235	relationship	_	
132-47	25236-25240	with	_	
132-48	25241-25249	impaired	_	
132-49	25250-25259	cognition	_	
132-50	25259-25260	,	_	
132-51	25261-25271	behavioral	_	
132-52	25272-25287	disorganization	_	
132-53	25287-25288	,	_	
132-54	25289-25292	and	_	
132-55	25293-25299	global	_	
132-56	25300-25308	function	_	
132-57	25309-25317	Impaired	_	
132-58	25318-25334	prefrontal-basal	_	
132-59	25335-25342	ganglia	_	
132-60	25343-25353	functional	_	
132-61	25354-25366	connectivity	_	
132-62	25367-25370	and	_	
132-63	25371-25381	substantia	_	
132-64	25382-25387	nigra	_	
132-65	25388-25401	hyperactivity	_	
132-66	25402-25404	in	_	
132-67	25405-25418	schizophrenia	_	
132-68	25419-25422	The	_	
132-69	25423-25427	case	_	
132-70	25428-25430	of	_	
132-71	25431-25445	frontostriatal	_	
132-72	25446-25457	dysfunction	_	
132-73	25458-25460	in	_	
132-74	25461-25474	schizophrenia	_	
132-75	25475-25485	Prefrontal	_	
132-76	25486-25492	cortex	_	
132-77	25493-25502	regulates	_	
132-78	25503-25508	burst	_	
132-79	25509-25515	firing	_	
132-80	25516-25519	and	_	
132-81	25520-25531	transmitter	_	
132-82	25532-25539	release	_	
132-83	25540-25542	in	_	
132-84	25543-25546	rat	_	
132-85	25547-25557	mesolimbic	_	
132-86	25558-25566	dopamine	_	
132-87	25567-25574	neurons	_	
132-88	25575-25582	studied	_	
132-89	25583-25585	in	_	
132-90	25586-25590	vivo	_	
132-91	25591-25605	Neurocognitive	_	
132-92	25606-25617	dysfunction	_	
132-93	25618-25620	in	_	
132-94	25621-25628	bipolar	_	
132-95	25629-25632	and	_	
132-96	25633-25646	schizophrenia	_	
132-97	25647-25655	spectrum	_	
132-98	25656-25665	disorders	_	
132-99	25666-25673	depends	_	
132-100	25674-25676	on	_	
132-101	25677-25684	history	_	
132-102	25685-25687	of	_	
132-103	25688-25697	psychosis	_	
132-104	25698-25704	rather	_	
132-105	25705-25709	than	_	
132-106	25710-25720	diagnostic	_	
132-107	25721-25726	group	_	
132-108	25727-25740	Hyperactivity	_	
132-109	25741-25744	and	_	
132-110	25745-25762	hyperconnectivity	_	
132-111	25763-25765	of	_	
132-112	25766-25769	the	_	
132-113	25770-25777	default	_	
132-114	25778-25785	network	_	
132-115	25786-25788	in	_	
132-116	25789-25802	schizophrenia	_	
132-117	25803-25806	and	_	
132-118	25807-25809	in	_	
132-119	25810-25822	first-degree	_	
132-120	25823-25832	relatives	_	
132-121	25833-25835	of	_	
132-122	25836-25843	persons	_	
132-123	25844-25848	with	_	
132-124	25849-25862	schizophrenia	_	
132-125	25863-25870	Working	_	
132-126	25871-25877	memory	_	
132-127	25878-25881	and	_	
132-128	25882-25887	DLPFC	_	
132-129	25888-25900	inefficiency	_	
132-130	25901-25903	in	_	
132-131	25904-25917	schizophrenia	_	
132-132	25917-25918	:	_	
132-133	25919-25922	the	_	
132-134	25923-25928	FBIRN	_	
132-135	25929-25934	study	_	
132-136	25935-25943	Striatal	_	
132-137	25944-25952	dopamine	_	
132-138	25953-25956	and	_	
132-139	25957-25964	working	_	
132-140	25965-25971	memory	_	
132-141	25972-25983	Genome-wide	_	
132-142	25984-25995	association	_	
132-143	25996-26004	analysis	_	
132-144	26005-26015	identifies	_	
132-145	26016-26018	13	_	
132-146	26019-26022	new	_	
132-147	26023-26027	risk	_	
132-148	26028-26032	loci	_	
132-149	26033-26036	for	_	
132-150	26037-26050	schizophrenia	_	
132-151	26051-26057	Common	_	
132-152	26058-26067	polygenic	_	
132-153	26068-26077	variation	_	
132-154	26078-26089	contributes	_	
132-155	26090-26092	to	_	
132-156	26093-26097	risk	_	
132-157	26098-26100	of	_	
132-158	26101-26114	schizophrenia	_	
132-159	26115-26118	and	_	
132-160	26119-26126	bipolar	_	
132-161	26127-26135	disorder	_	
132-162	26136-26150	Cross-Disorder	_	
132-163	26151-26156	Group	_	
132-164	26157-26159	of	_	
132-165	26160-26163	the	_	
132-166	26164-26175	Psychiatric	_	
132-167	26176-26184	Genomics	_	
132-168	26184-26185	,	_	
132-169	26186-26187	C	_	
132-170	26187-26188	.	_	

#Text=Identification of risk loci with shared effects on five major psychiatric disorders: a genome-wide analysis.
133-1	26189-26203	Identification	_	
133-2	26204-26206	of	_	
133-3	26207-26211	risk	_	
133-4	26212-26216	loci	_	
133-5	26217-26221	with	_	
133-6	26222-26228	shared	_	
133-7	26229-26236	effects	_	
133-8	26237-26239	on	_	
133-9	26240-26244	five	_	
133-10	26245-26250	major	_	
133-11	26251-26262	psychiatric	_	
133-12	26263-26272	disorders	_	
133-13	26272-26273	:	_	
133-14	26274-26275	a	_	
133-15	26276-26287	genome-wide	_	
133-16	26288-26296	analysis	_	
133-17	26296-26297	.	_	

#Text=Lancet381, 1371–1379, 10.1016/S0140-6736(12)62129-1 (2013).
134-1	26298-26307	Lancet381	_	
134-2	26307-26308	,	_	
134-3	26309-26313	1371	_	
134-4	26313-26314	–	_	
134-5	26314-26318	1379	_	
134-6	26318-26319	,	_	
134-7	26320-26327	10.1016	_	
134-8	26327-26328	/	_	
134-9	26328-26333	S0140	_	
134-10	26333-26334	-	_	
134-11	26334-26338	6736	_	
134-12	26338-26339	(	_	
134-13	26339-26341	12	_	
134-14	26341-26342	)	_	
134-15	26342-26347	62129	_	
134-16	26347-26348	-	_	
134-17	26348-26349	1	_	
134-18	26350-26351	(	_	
134-19	26351-26355	2013	_	
134-20	26355-26356	)	_	
134-21	26356-26357	.	_	

#Text=Prefrontal inefficiency is associated with polygenic risk for schizophrenia
#Text=Cumulative genetic risk and prefrontal activity in patients with schizophrenia
#Text=Genetic and Environmental Contributions to Functional Connectivity Architecture of the Human Brain
#Text=Genetic control over the resting brain
#Text=Schizophrenia Working Group of the Psychiatric Genomics, C.
135-1	26358-26368	Prefrontal	_	
135-2	26369-26381	inefficiency	_	
135-3	26382-26384	is	_	
135-4	26385-26395	associated	_	
135-5	26396-26400	with	_	
135-6	26401-26410	polygenic	_	
135-7	26411-26415	risk	_	
135-8	26416-26419	for	_	
135-9	26420-26433	schizophrenia	_	
135-10	26434-26444	Cumulative	_	
135-11	26445-26452	genetic	_	
135-12	26453-26457	risk	_	
135-13	26458-26461	and	_	
135-14	26462-26472	prefrontal	_	
135-15	26473-26481	activity	_	
135-16	26482-26484	in	_	
135-17	26485-26493	patients	_	
135-18	26494-26498	with	_	
135-19	26499-26512	schizophrenia	_	
135-20	26513-26520	Genetic	_	
135-21	26521-26524	and	_	
135-22	26525-26538	Environmental	_	
135-23	26539-26552	Contributions	_	
135-24	26553-26555	to	_	
135-25	26556-26566	Functional	_	
135-26	26567-26579	Connectivity	_	
135-27	26580-26592	Architecture	_	
135-28	26593-26595	of	_	
135-29	26596-26599	the	_	
135-30	26600-26605	Human	_	
135-31	26606-26611	Brain	_	
135-32	26612-26619	Genetic	_	
135-33	26620-26627	control	_	
135-34	26628-26632	over	_	
135-35	26633-26636	the	_	
135-36	26637-26644	resting	_	
135-37	26645-26650	brain	_	
135-38	26651-26664	Schizophrenia	_	
135-39	26665-26672	Working	_	
135-40	26673-26678	Group	_	
135-41	26679-26681	of	_	
135-42	26682-26685	the	_	
135-43	26686-26697	Psychiatric	_	
135-44	26698-26706	Genomics	_	
135-45	26706-26707	,	_	
135-46	26708-26709	C	_	
135-47	26709-26710	.	_	

#Text=Biological insights from 108 schizophrenia-associated genetic loci.
136-1	26711-26721	Biological	_	
136-2	26722-26730	insights	_	
136-3	26731-26735	from	_	
136-4	26736-26739	108	_	
136-5	26740-26764	schizophrenia-associated	_	
136-6	26765-26772	genetic	_	
136-7	26773-26777	loci	_	
136-8	26777-26778	.	_	

#Text=Nature511, 421–427, doi:10.1038/nature13595 (2014).
137-1	26779-26788	Nature511	_	
137-2	26788-26789	,	_	
137-3	26790-26793	421	_	
137-4	26793-26794	–	_	
137-5	26794-26797	427	_	
137-6	26797-26798	,	_	
137-7	26799-26802	doi	_	
137-8	26802-26803	:	_	
137-9	26803-26810	10.1038	_	
137-10	26810-26811	/	_	
137-11	26811-26822	nature13595	_	
137-12	26823-26824	(	_	
137-13	26824-26828	2014	_	
137-14	26828-26829	)	_	
137-15	26829-26830	.	_	

#Text=Altered striatal functional connectivity in subjects with an at-risk mental state for psychosis
#Text=Brain Structural Abnormalities in a Group of Never-Medicated Patients With Long-Term Schizophrenia
#Text=Anatomical and functional brain abnormalities in drug-naive first-episode schizophrenia
#Text=Loss of intranetwork and internetwork resting state functional connections with Alzheimer’s disease progression
#Text=Are anticorrelated networks in the brain relevant to schizophrenia?
138-1	26831-26838	Altered	_	
138-2	26839-26847	striatal	_	
138-3	26848-26858	functional	_	
138-4	26859-26871	connectivity	_	
138-5	26872-26874	in	_	
138-6	26875-26883	subjects	_	
138-7	26884-26888	with	_	
138-8	26889-26891	an	_	
138-9	26892-26899	at-risk	_	
138-10	26900-26906	mental	_	
138-11	26907-26912	state	_	
138-12	26913-26916	for	_	
138-13	26917-26926	psychosis	_	
138-14	26927-26932	Brain	_	
138-15	26933-26943	Structural	_	
138-16	26944-26957	Abnormalities	_	
138-17	26958-26960	in	_	
138-18	26961-26962	a	_	
138-19	26963-26968	Group	_	
138-20	26969-26971	of	_	
138-21	26972-26987	Never-Medicated	_	
138-22	26988-26996	Patients	_	
138-23	26997-27001	With	_	
138-24	27002-27011	Long-Term	_	
138-25	27012-27025	Schizophrenia	_	
138-26	27026-27036	Anatomical	_	
138-27	27037-27040	and	_	
138-28	27041-27051	functional	_	
138-29	27052-27057	brain	_	
138-30	27058-27071	abnormalities	_	
138-31	27072-27074	in	_	
138-32	27075-27085	drug-naive	_	
138-33	27086-27099	first-episode	_	
138-34	27100-27113	schizophrenia	_	
138-35	27114-27118	Loss	_	
138-36	27119-27121	of	_	
138-37	27122-27134	intranetwork	_	
138-38	27135-27138	and	_	
138-39	27139-27151	internetwork	_	
138-40	27152-27159	resting	_	
138-41	27160-27165	state	_	
138-42	27166-27176	functional	_	
138-43	27177-27188	connections	_	
138-44	27189-27193	with	_	
138-45	27194-27203	Alzheimer	_	
138-46	27203-27204	’	_	
138-47	27204-27205	s	_	
138-48	27206-27213	disease	_	
138-49	27214-27225	progression	_	
138-50	27226-27229	Are	_	
138-51	27230-27244	anticorrelated	_	
138-52	27245-27253	networks	_	
138-53	27254-27256	in	_	
138-54	27257-27260	the	_	
138-55	27261-27266	brain	_	
138-56	27267-27275	relevant	_	
138-57	27276-27278	to	_	
138-58	27279-27292	schizophrenia	_	
138-59	27292-27293	?	_	

#Text=Large-scale brain networks and psychopathology: a unifying triple network model
#Text=A default mode of brain function
#Text=Psychopathological and neuropsychological correlates of source monitoring impairment in schizophrenia
#Text=A framework for interpreting functional networks in schizophrenia
#Text=Collaborative activity between parietal and dorso-lateral prefrontal cortex in dynamic spatial working memory revealed by fMRI
#Text=Aberrant salience network (bilateral insula and anterior cingulate cortex) connectivity during information processing in schizophrenia
#Text=Fronto-parietal and cingulo-opercular network integrity and cognition in health and schizophrenia
#Text=Brain network connectivity in individuals with schizophrenia and their siblings
#Text=Functional network organization of the human brain
#Text=The attention system of the human brain: 20 years after
#Text=Functional connectivity in healthy subjects is nonlinearly modulated by the COMT and DRD2 polymorphisms in a functional system-dependent manner
#Text=The effect of moderate acute psychological stress on working memory-related neural activity is modulated by a genetic variation in catecholaminergic function in humans
#Text=Dopamine transporter change in drug-naive schizophrenia: an imaging study with 99mTc-TRODAT-1
#Text=Abnormalities in hemispheric specialization of caudate nucleus connectivity in schizophrenia
#Text=A comprehensive meta-analysis of ZNF804A SNPs in the risk of schizophrenia among Asian populations
#Text=Functional genetic variation at the NRGN gene and schizophrenia: evidence from a gene-based case-control study and gene expression analysis.
139-1	27294-27305	Large-scale	_	
139-2	27306-27311	brain	_	
139-3	27312-27320	networks	_	
139-4	27321-27324	and	_	
139-5	27325-27340	psychopathology	_	
139-6	27340-27341	:	_	
139-7	27342-27343	a	_	
139-8	27344-27352	unifying	_	
139-9	27353-27359	triple	_	
139-10	27360-27367	network	_	
139-11	27368-27373	model	_	
139-12	27374-27375	A	_	
139-13	27376-27383	default	_	
139-14	27384-27388	mode	_	
139-15	27389-27391	of	_	
139-16	27392-27397	brain	_	
139-17	27398-27406	function	_	
139-18	27407-27425	Psychopathological	_	
139-19	27426-27429	and	_	
139-20	27430-27448	neuropsychological	_	
139-21	27449-27459	correlates	_	
139-22	27460-27462	of	_	
139-23	27463-27469	source	_	
139-24	27470-27480	monitoring	_	
139-25	27481-27491	impairment	_	
139-26	27492-27494	in	_	
139-27	27495-27508	schizophrenia	_	
139-28	27509-27510	A	_	
139-29	27511-27520	framework	_	
139-30	27521-27524	for	_	
139-31	27525-27537	interpreting	_	
139-32	27538-27548	functional	_	
139-33	27549-27557	networks	_	
139-34	27558-27560	in	_	
139-35	27561-27574	schizophrenia	_	
139-36	27575-27588	Collaborative	_	
139-37	27589-27597	activity	_	
139-38	27598-27605	between	_	
139-39	27606-27614	parietal	_	
139-40	27615-27618	and	_	
139-41	27619-27632	dorso-lateral	_	
139-42	27633-27643	prefrontal	_	
139-43	27644-27650	cortex	_	
139-44	27651-27653	in	_	
139-45	27654-27661	dynamic	_	
139-46	27662-27669	spatial	_	
139-47	27670-27677	working	_	
139-48	27678-27684	memory	_	
139-49	27685-27693	revealed	_	
139-50	27694-27696	by	_	
139-51	27697-27701	fMRI	_	
139-52	27702-27710	Aberrant	_	
139-53	27711-27719	salience	_	
139-54	27720-27727	network	_	
139-55	27728-27729	(	_	
139-56	27729-27738	bilateral	_	
139-57	27739-27745	insula	_	
139-58	27746-27749	and	_	
139-59	27750-27758	anterior	_	
139-60	27759-27768	cingulate	_	
139-61	27769-27775	cortex	_	
139-62	27775-27776	)	_	
139-63	27777-27789	connectivity	_	
139-64	27790-27796	during	_	
139-65	27797-27808	information	_	
139-66	27809-27819	processing	_	
139-67	27820-27822	in	_	
139-68	27823-27836	schizophrenia	_	
139-69	27837-27852	Fronto-parietal	_	
139-70	27853-27856	and	_	
139-71	27857-27874	cingulo-opercular	_	
139-72	27875-27882	network	_	
139-73	27883-27892	integrity	_	
139-74	27893-27896	and	_	
139-75	27897-27906	cognition	_	
139-76	27907-27909	in	_	
139-77	27910-27916	health	_	
139-78	27917-27920	and	_	
139-79	27921-27934	schizophrenia	_	
139-80	27935-27940	Brain	_	
139-81	27941-27948	network	_	
139-82	27949-27961	connectivity	_	
139-83	27962-27964	in	_	
139-84	27965-27976	individuals	_	
139-85	27977-27981	with	_	
139-86	27982-27995	schizophrenia	_	
139-87	27996-27999	and	_	
139-88	28000-28005	their	_	
139-89	28006-28014	siblings	_	
139-90	28015-28025	Functional	_	
139-91	28026-28033	network	_	
139-92	28034-28046	organization	_	
139-93	28047-28049	of	_	
139-94	28050-28053	the	_	
139-95	28054-28059	human	_	
139-96	28060-28065	brain	_	
139-97	28066-28069	The	_	
139-98	28070-28079	attention	_	
139-99	28080-28086	system	_	
139-100	28087-28089	of	_	
139-101	28090-28093	the	_	
139-102	28094-28099	human	_	
139-103	28100-28105	brain	_	
139-104	28105-28106	:	_	
139-105	28107-28109	20	_	
139-106	28110-28115	years	_	
139-107	28116-28121	after	_	
139-108	28122-28132	Functional	_	
139-109	28133-28145	connectivity	_	
139-110	28146-28148	in	_	
139-111	28149-28156	healthy	_	
139-112	28157-28165	subjects	_	
139-113	28166-28168	is	_	
139-114	28169-28180	nonlinearly	_	
139-115	28181-28190	modulated	_	
139-116	28191-28193	by	_	
139-117	28194-28197	the	_	
139-118	28198-28202	COMT	_	
139-119	28203-28206	and	_	
139-120	28207-28211	DRD2	_	
139-121	28212-28225	polymorphisms	_	
139-122	28226-28228	in	_	
139-123	28229-28230	a	_	
139-124	28231-28241	functional	_	
139-125	28242-28258	system-dependent	_	
139-126	28259-28265	manner	_	
139-127	28266-28269	The	_	
139-128	28270-28276	effect	_	
139-129	28277-28279	of	_	
139-130	28280-28288	moderate	_	
139-131	28289-28294	acute	_	
139-132	28295-28308	psychological	_	
139-133	28309-28315	stress	_	
139-134	28316-28318	on	_	
139-135	28319-28326	working	_	
139-136	28327-28341	memory-related	_	
139-137	28342-28348	neural	_	
139-138	28349-28357	activity	_	
139-139	28358-28360	is	_	
139-140	28361-28370	modulated	_	
139-141	28371-28373	by	_	
139-142	28374-28375	a	_	
139-143	28376-28383	genetic	_	
139-144	28384-28393	variation	_	
139-145	28394-28396	in	_	
139-146	28397-28414	catecholaminergic	_	
139-147	28415-28423	function	_	
139-148	28424-28426	in	_	
139-149	28427-28433	humans	_	
139-150	28434-28442	Dopamine	_	
139-151	28443-28454	transporter	_	
139-152	28455-28461	change	_	
139-153	28462-28464	in	_	
139-154	28465-28475	drug-naive	_	
139-155	28476-28489	schizophrenia	_	
139-156	28489-28490	:	_	
139-157	28491-28493	an	_	
139-158	28494-28501	imaging	_	
139-159	28502-28507	study	_	
139-160	28508-28512	with	_	
139-161	28513-28525	99mTc-TRODAT	_	
139-162	28525-28526	-	_	
139-163	28526-28527	1	_	
139-164	28528-28541	Abnormalities	_	
139-165	28542-28544	in	_	
139-166	28545-28556	hemispheric	_	
139-167	28557-28571	specialization	_	
139-168	28572-28574	of	_	
139-169	28575-28582	caudate	_	
139-170	28583-28590	nucleus	_	
139-171	28591-28603	connectivity	_	
139-172	28604-28606	in	_	
139-173	28607-28620	schizophrenia	_	
139-174	28621-28622	A	_	
139-175	28623-28636	comprehensive	_	
139-176	28637-28650	meta-analysis	_	
139-177	28651-28653	of	_	
139-178	28654-28661	ZNF804A	_	
139-179	28662-28666	SNPs	_	
139-180	28667-28669	in	_	
139-181	28670-28673	the	_	
139-182	28674-28678	risk	_	
139-183	28679-28681	of	_	
139-184	28682-28695	schizophrenia	_	
139-185	28696-28701	among	_	
139-186	28702-28707	Asian	_	
139-187	28708-28719	populations	_	
139-188	28720-28730	Functional	_	
139-189	28731-28738	genetic	_	
139-190	28739-28748	variation	_	
139-191	28749-28751	at	_	
139-192	28752-28755	the	_	
139-193	28756-28760	NRGN	_	
139-194	28761-28765	gene	_	
139-195	28766-28769	and	_	
139-196	28770-28783	schizophrenia	_	
139-197	28783-28784	:	_	
139-198	28785-28793	evidence	_	
139-199	28794-28798	from	_	
139-200	28799-28800	a	_	
139-201	28801-28811	gene-based	_	
139-202	28812-28824	case-control	_	
139-203	28825-28830	study	_	
139-204	28831-28834	and	_	
139-205	28835-28839	gene	_	
139-206	28840-28850	expression	_	
139-207	28851-28859	analysis	_	
139-208	28859-28860	.	_	

#Text=American journal of medical genetics.
140-1	28861-28869	American	_	
140-2	28870-28877	journal	_	
140-3	28878-28880	of	_	
140-4	28881-28888	medical	_	
140-5	28889-28897	genetics	_	
140-6	28897-28898	.	_	

#Text=Part B
#Text=Variability of 128 schizophrenia-associated gene variants across distinct ethnic populations
#Text=Dosage effects of BDNF Val66Met polymorphism on cortical surface area and functional connectivity
#Text=N-back working memory paradigm: a meta-analysis of normative functional neuroimaging studies
#Text=Neurobiological basis of head motion in brain imaging
#Text=PLINK: a tool set for whole-genome association and population-based linkage analyses
#Text=Population structure and eigenanalysis
#Text=Principal components analysis corrects for stratification in genome-wide association studies
#Text=The International HapMap Project Web site
#Text=A linear complexity phasing method for thousands of genomes
#Text=A flexible and accurate genotype imputation method for the next generation of genome-wide association studies
#Text=Common polygenic variation contributes to risk of schizophrenia and bipolar disorder
#Text=Dissociable contribution of prefrontal and striatal dopaminergic genes to learning in economic games
#Text=Imaging dopamine receptors in humans with [11C]-(+)-PHNO: dissection of D3 signal and anatomy
#Text=DPABI: Data Processing & Analysis for (Resting-State) Brain Imaging
#Text=Correspondence of the brain’s functional architecture during activation and rest
141-1	28899-28903	Part	_	
141-2	28904-28905	B	_	
141-3	28906-28917	Variability	_	
141-4	28918-28920	of	_	
141-5	28921-28924	128	_	
141-6	28925-28949	schizophrenia-associated	_	
141-7	28950-28954	gene	_	
141-8	28955-28963	variants	_	
141-9	28964-28970	across	_	
141-10	28971-28979	distinct	_	
141-11	28980-28986	ethnic	_	
141-12	28987-28998	populations	_	
141-13	28999-29005	Dosage	_	
141-14	29006-29013	effects	_	
141-15	29014-29016	of	_	
141-16	29017-29021	BDNF	_	
141-17	29022-29030	Val66Met	_	
141-18	29031-29043	polymorphism	_	
141-19	29044-29046	on	_	
141-20	29047-29055	cortical	_	
141-21	29056-29063	surface	_	
141-22	29064-29068	area	_	
141-23	29069-29072	and	_	
141-24	29073-29083	functional	_	
141-25	29084-29096	connectivity	_	
141-26	29097-29103	N-back	_	
141-27	29104-29111	working	_	
141-28	29112-29118	memory	_	
141-29	29119-29127	paradigm	_	
141-30	29127-29128	:	_	
141-31	29129-29130	a	_	
141-32	29131-29144	meta-analysis	_	
141-33	29145-29147	of	_	
141-34	29148-29157	normative	_	
141-35	29158-29168	functional	_	
141-36	29169-29181	neuroimaging	_	
141-37	29182-29189	studies	_	
141-38	29190-29205	Neurobiological	_	
141-39	29206-29211	basis	_	
141-40	29212-29214	of	_	
141-41	29215-29219	head	_	
141-42	29220-29226	motion	_	
141-43	29227-29229	in	_	
141-44	29230-29235	brain	_	
141-45	29236-29243	imaging	_	
141-46	29244-29249	PLINK	_	
141-47	29249-29250	:	_	
141-48	29251-29252	a	_	
141-49	29253-29257	tool	_	
141-50	29258-29261	set	_	
141-51	29262-29265	for	_	
141-52	29266-29278	whole-genome	_	
141-53	29279-29290	association	_	
141-54	29291-29294	and	_	
141-55	29295-29311	population-based	_	
141-56	29312-29319	linkage	_	
141-57	29320-29328	analyses	_	
141-58	29329-29339	Population	_	
141-59	29340-29349	structure	_	
141-60	29350-29353	and	_	
141-61	29354-29367	eigenanalysis	_	
141-62	29368-29377	Principal	_	
141-63	29378-29388	components	_	
141-64	29389-29397	analysis	_	
141-65	29398-29406	corrects	_	
141-66	29407-29410	for	_	
141-67	29411-29425	stratification	_	
141-68	29426-29428	in	_	
141-69	29429-29440	genome-wide	_	
141-70	29441-29452	association	_	
141-71	29453-29460	studies	_	
141-72	29461-29464	The	_	
141-73	29465-29478	International	_	
141-74	29479-29485	HapMap	_	
141-75	29486-29493	Project	_	
141-76	29494-29497	Web	_	
141-77	29498-29502	site	_	
141-78	29503-29504	A	_	
141-79	29505-29511	linear	_	
141-80	29512-29522	complexity	_	
141-81	29523-29530	phasing	_	
141-82	29531-29537	method	_	
141-83	29538-29541	for	_	
141-84	29542-29551	thousands	_	
141-85	29552-29554	of	_	
141-86	29555-29562	genomes	_	
141-87	29563-29564	A	_	
141-88	29565-29573	flexible	_	
141-89	29574-29577	and	_	
141-90	29578-29586	accurate	_	
141-91	29587-29595	genotype	_	
141-92	29596-29606	imputation	_	
141-93	29607-29613	method	_	
141-94	29614-29617	for	_	
141-95	29618-29621	the	_	
141-96	29622-29626	next	_	
141-97	29627-29637	generation	_	
141-98	29638-29640	of	_	
141-99	29641-29652	genome-wide	_	
141-100	29653-29664	association	_	
141-101	29665-29672	studies	_	
141-102	29673-29679	Common	_	
141-103	29680-29689	polygenic	_	
141-104	29690-29699	variation	_	
141-105	29700-29711	contributes	_	
141-106	29712-29714	to	_	
141-107	29715-29719	risk	_	
141-108	29720-29722	of	_	
141-109	29723-29736	schizophrenia	_	
141-110	29737-29740	and	_	
141-111	29741-29748	bipolar	_	
141-112	29749-29757	disorder	_	
141-113	29758-29769	Dissociable	_	
141-114	29770-29782	contribution	_	
141-115	29783-29785	of	_	
141-116	29786-29796	prefrontal	_	
141-117	29797-29800	and	_	
141-118	29801-29809	striatal	_	
141-119	29810-29822	dopaminergic	_	
141-120	29823-29828	genes	_	
141-121	29829-29831	to	_	
141-122	29832-29840	learning	_	
141-123	29841-29843	in	_	
141-124	29844-29852	economic	_	
141-125	29853-29858	games	_	
141-126	29859-29866	Imaging	_	
141-127	29867-29875	dopamine	_	
141-128	29876-29885	receptors	_	
141-129	29886-29888	in	_	
141-130	29889-29895	humans	_	
141-131	29896-29900	with	_	
141-132	29901-29902	[	_	
141-133	29902-29905	11C	_	
141-134	29905-29906	]	_	
141-135	29906-29907	-	_	
141-136	29907-29908	(	_	
141-137	29908-29909	+	_	
141-138	29909-29910	)	_	
141-139	29910-29911	-	_	
141-140	29911-29915	PHNO	_	
141-141	29915-29916	:	_	
141-142	29917-29927	dissection	_	
141-143	29928-29930	of	_	
141-144	29931-29933	D3	_	
141-145	29934-29940	signal	_	
141-146	29941-29944	and	_	
141-147	29945-29952	anatomy	_	
141-148	29953-29958	DPABI	_	
141-149	29958-29959	:	_	
141-150	29960-29964	Data	_	
141-151	29965-29975	Processing	_	
141-152	29976-29977	&	_	
141-153	29978-29986	Analysis	_	
141-154	29987-29990	for	_	
141-155	29991-29992	(	_	
141-156	29992-30005	Resting-State	_	
141-157	30005-30006	)	_	
141-158	30007-30012	Brain	_	
141-159	30013-30020	Imaging	_	
141-160	30021-30035	Correspondence	_	
141-161	30036-30038	of	_	
141-162	30039-30042	the	_	
141-163	30043-30048	brain	_	
141-164	30048-30049	’	_	
141-165	30049-30050	s	_	
141-166	30051-30061	functional	_	
141-167	30062-30074	architecture	_	
141-168	30075-30081	during	_	
141-169	30082-30092	activation	_	
141-170	30093-30096	and	_	
141-171	30097-30101	rest	_	
